SERFF Tracking #: MILL-132822823 State Tracking #: MILL-132822823

Company Tracking #: CICA - MEDAMERICA

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Filing at a Glance

Company: MedAmerica Insurance Company

Product Name: Long-Term Care State: Pennsylvania

TOI: LTC03I Individual Long Term Care

Sub-TOI: LTC03I.001 Qualified

Filing Type: Rate - Other (Not M.U. or G.I. Product)

Date Submitted: 07/29/2021

SERFF Tr Num: MILL-132822823

SERFF Status: Assigned

State Tr Num: MILL-132822823

State Status: Received Review in Progress

Co Tr Num: CICA - MEDAMERICA

Effective On Approval

Date Requested:

Author(s): Courtney Williamson, Joe Neary, Cassi Noel, Derek Lesniak, Matt Mickolichek, Lola Heimlich,

Casey Gustina

Reviewer(s): Jim Laverty (primary)

Disposition Date:
Disposition Status:
Effective Date:

State Filing Description:

Proposed aggregate 12.1% increase on 222 policyholders of MedAmerica's individual LTC forms 14515-PA (the 515 Series) and 14785-PA (the 780 Series).

Company Tracking #: CICA - MEDAMERICA

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

General Information

Project Name: CICA LTC Rate Increase Filing Status of Filing in Domicile: Pending

Project Number: 145MAI01-40.05 Date Approved in Domicile:

Requested Filing Mode: Review & Approval Domicile Status Comments: Pennsylvania is the state of

domicile.

Explanation for Combination/Other: Market Type: Individual Submission Type: New Submission Individual Market Type:

Overall Rate Impact: 12.1% Filing Status Changed: 07/31/2021

State Status Changed: 07/31/2021

Deemer Date: Created By: Derek Lesniak

Submitted By: Joe Neary Corresponding Filing Tracking Number:

State TOI: LTC03I Individual Long Term Care

Filing Description:

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

On behalf of the company, we are submitting the referenced rate filing for your review. This is an existing policy form(s) that provides long-term care coverage. This policy form(s) was written by Combined Insurance Company of America (CICA) and issued in Pennsylvania from February 18, 1999 through June 1, 2008 and is no longer marketed in any jurisdiction.

In 2008, MedAmerica acquired the long-term care block of business issued by CICA from Ace Ltd. and subsequently submitted a certificate of assumption filing. As a result, most of the nationwide policies are now on MedAmerica paper; however, approximately 16% of the in-force policyholders nationwide objected to the assumption filing and remain on CICA paper. In Pennsylvania, all of the in-force policies are on MedAmerica paper. MedAmerica has 100% of the risk on this form(s), including policies on CICA paper, and administers and manages the entire block.

The company is requesting a premium rate increase on the form(s), including all associated riders. The need for a premium rate increase is due to emerging and projected experience running more adverse than originally expected.

This rate increase request is a follow-up to two prior nationwide requests for the 515 Series and one prior nationwide request for the 780 Series. However, because this jurisdiction did not allow full implementation of the prior requested increase(s), the rate level being requested in this follow-up filing was determined to be actuarially equivalent as described in Appendix B to the enclosed actuarial memorandum. As with the prior request, the requested rate increase varies by series and inflation protection option. The enclosed cover letter provides the average prior, requested, and cumulative rate increases for the form(s) by series and inflation protection option.

For the 780 Series policies, the prior requested rate increase was approved in full. The company is not requesting a rate increase on these policies at this time as shown in the cover letter.

The cumulative prior increase reflects the four prior increases filed for use on the 515 Series policies in May 2014, June 2015, August 2019, and August 2020 and one prior increase phased in over a 2-year period filed for use on the 780 Series policies in August 2019. The company is seeking this current rate increase request to help alleviate the adverse performance on this block of business.

As stated in the enclosed actuarial memorandum, a larger rate increase is justified on this block of business. If it is the Department's position to only allow future rate increases if experience deteriorates from the current most-likely projections used in this filing, the company respectfully requests that the Department notify them and allow the company to revise the current rate increase request.

Similar to the prior increase(s), the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

Company and Contact

Filing Contact Information

Courtney Williamson, Associate Actuary 8500 Normandale Lake Blvd.

courtney.williamson@milliman.com 952-820-2413 [Phone]

Suite 1850

Minneapolis, MN 55437

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Filing Company Information

(This filing was made by a third party - millimaninc)

MedAmerica Insurance Company CoCode: 69515 State of Domicile: 165 Court Street Group Code: 1186 Pennsylvania

Rochester, NY 14647 Group Name: Lifetime HealthCare Company Type:

(800) 544-0327 ext. [Phone] Group Life/Accident/Health

FEIN Number: 34-0977231 State ID Number:

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Filing Fees

State Fees

Fee Required? No Retaliatory? No

Fee Explanation:

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Rate Information

Rate data applies to filing.

Filing Method: Review and Approval

Rate Change Type: Increase

Overall Percentage of Last Rate Revision: 10.500%

Effective Date of Last Rate Revision: 08/21/2020

Filing Method of Last Filing: Review and Approval SERFF Tracking Number of Last Filing: MILL-132344370

Company Rate Information

Company	Overall %	Overall % Rate	Written Premium Change for	Number of Policy Holders Affected	Written Premium for	Maximum % Change	Minimum %
Name:	Change:	Impact:	this Program:	for this Program:	this Program:	(where req'd):	(where req'd):
MedAmerica Insurance Company	12.100%	12.100%	\$38,512	222	\$319,208	21.500%	0.000%

 State:
 Pennsylvania
 Filing Company:
 MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Rate/Rule Schedule

Item No.	Schedule Item Status	Document Name	Affected Form Numbers (Separated with commas)	Rate Action	Rate Action Information	Attachments
1		515 Series Rate Tables	14515-PA	Revised	Previous State Filing Number: MILL-132344370 Percent Rate Change Request: 15.9	PA_CICA_Proposed Rate Tables_515 Series_20210728.pdf, PA_CICA_Current Rate Tables_515 Series_20210728.pdf,
2		780 Series Rate Tables	14785-PA	Revised	Previous State Filing Number: MILL-132344370 Percent Rate Change Request:	PA_CICA_Proposed Rate Tables_780 Series_20210728.pdf, PA_CICA_Current Rate Tables_780 Series_20210728.pdf,

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR POLICY FORM 14515 WITH NO INFLATION PROTECTION

BASE PLAN ANNUAL PREMIUMS (Per \$10 of Benefit) WITH 0% RATE INCREASE

	Lifetime Multiplier = 400 Lifetime Multiplier = 80		-= 800	Lifetii	ne Multiplier	= 1200	Lifetin	ne Multiplier	= 1600	Lifetime Multiplier = Unlimited						
Issue	El	imination Peri	iod	El	imination Peri	od	El	imination Peri	iod	Eli	imination Peri	iod	Elimination Period			
Age	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	
18-44	\$17	\$15	\$14	\$22	\$19	\$18	\$25	\$22	\$21	\$26	\$23	\$22	\$36	\$32	\$29	
45-49	\$23	\$21	\$19	\$32	\$28	\$26	\$36	\$32	\$29	\$40	\$35	\$32	\$58	\$50	\$46	
50	\$26	\$23	\$22	\$36	\$32	\$29	\$43	\$37	\$35	\$48	\$41	\$39	\$69	\$59	\$55	
51	\$28	\$25	\$22	\$37	\$33	\$30	\$46	\$40	\$36	\$51	\$44	\$40	\$73	\$63	\$58	
52	\$29	\$25	\$23	\$40	\$35	\$32	\$48	\$41	\$37	\$54	\$47	\$43	\$77	\$68	\$61	
53	\$30	\$26	\$25	\$43	\$36	\$33	\$51	\$44	\$40	\$58	\$50	\$46	\$81	\$72	\$65	
54	\$32	\$28	\$25	\$44	\$39	\$35	\$54	\$47	\$43	\$61	\$52	\$48	\$87	\$75	\$69	
55	\$33	\$29	\$26	\$47	\$41	\$37	\$58	\$50	\$44	\$65	\$55	\$51	\$91	\$80	\$72	
56	\$35	\$30	\$28	\$51	\$43	\$39	\$62	\$52	\$48	\$69	\$59	\$54	\$98	\$84	\$77	
57	\$36	\$32	\$29	\$55	\$47	\$41	\$66	\$57	\$51	\$75	\$63	\$58	\$105	\$91	\$83	
58	\$40	\$35	\$30	\$59	\$51	\$46	\$72	\$62	\$57	\$81	\$69	\$63	\$113	\$98	\$90	
59	\$43	\$36	\$33	\$65	\$55	\$50	\$79	\$68	\$61	\$88	\$76	\$69	\$123	\$106	\$97	
60	\$47	\$40	\$36	\$70	\$61	\$54	\$86	\$73	\$66	\$97	\$83	\$75	\$134	\$116	\$105	
61	\$50	\$43	\$39	\$76	\$65	\$59	\$92	\$80	\$72	\$105	\$90	\$81	\$145	\$126	\$115	
62	\$54	\$46	\$41	\$83	\$70	\$63	\$101	\$87	\$77	\$112	\$97	\$88	\$156	\$135	\$123	
63	\$58	\$50	\$44	\$88	\$75	\$68	\$106	\$92	\$83	\$120	\$104	\$94	\$166	\$144	\$130	
64	\$62	\$52	\$48	\$92	\$79	\$70	\$112	\$97	\$87	\$126	\$109	\$98	\$174	\$150	\$137	
65	\$66	\$57	\$51	\$97	\$83	\$75	\$119	\$102	\$92	\$132	\$115	\$104	\$182	\$159	\$144	
66	\$70	\$61	\$55	\$104	\$90	\$80	\$127	\$109	\$98	\$142	\$123	\$112	\$195	\$168	\$153	
67	\$77	\$68	\$61	\$113	\$97	\$87	\$138	\$119	\$108	\$156	\$134	\$121	\$213	\$184	\$167	
68	\$86	\$73	\$68	\$126	\$108	\$97	\$153	\$132	\$119	\$173	\$149	\$134	\$235	\$203	\$184	
69	\$94	\$81	\$73	\$139	\$120	\$108	\$171	\$148	\$132	\$192	\$166	\$149	\$259	\$225	\$204	
70	\$104	\$90	\$81	\$156	\$134	\$120	\$190	\$164	\$148	\$214	\$185	\$167	\$290	\$250	\$226	
71	\$115	\$99	\$90	\$174	\$149	\$134	\$213	\$184	\$166	\$239	\$206	\$186	\$323	\$279	\$253	
72	\$128	\$110	\$99	\$195	\$167	\$150	\$239	\$206	\$185	\$268	\$230	\$208	\$360	\$312	\$282	
73	\$144	\$124	\$112	\$218	\$186	\$167	\$266	\$230	\$207	\$299	\$258	\$233	\$402	\$348	\$315	
74	\$160	\$138	\$126	\$243	\$208	\$186	\$297	\$257	\$230	\$334	\$288	\$261	\$449	\$388	\$351	
75	\$179	\$155	\$139	\$269	\$230	\$207	\$331	\$286	\$257	\$373	\$320	\$290	\$498	\$431	\$389	
76	\$200	\$173	\$156	\$299	\$257	\$230	\$367	\$317	\$286	\$413	\$356	\$322	\$552	\$477	\$432	
77	\$222	\$192	\$174	\$331	\$284	\$257	\$407	\$352	\$316	\$458	\$395	\$357	\$611	\$529	\$477	
78	\$247	\$213	\$192	\$368	\$316	\$286	\$451	\$391	\$351	\$508	\$439	\$396	\$676	\$585	\$529	
79	\$275	\$236	\$214	\$408	\$352	\$317	\$501	\$432	\$388	\$564	\$487	\$440	\$751	\$649	\$585	
80	\$304	\$261	\$236	\$450	\$389	\$352	\$552	\$476	\$428	\$622	\$537	\$484	\$827	\$715	\$644	
81	\$333	\$286	\$258	\$493	\$426	\$386	\$603	\$522	\$468	\$680	\$587	\$530	\$901	\$778	\$702	
82	\$360	\$309	\$279	\$534	\$462	\$418	\$653	\$563	\$505	\$734	\$633	\$571	\$969	\$836	\$755	
83	\$388	\$333	\$299	\$574	\$498	\$450	\$700	\$603	\$542	\$785	\$678	\$611	\$1,032	\$891	\$802	
84	\$415	\$356	\$320	\$615	\$533	\$480	\$745	\$644	\$580	\$835	\$720	\$650	\$1,093	\$943	\$849	
85+	\$563	\$477	\$424	\$822	\$704	\$627	\$976	\$838	\$749	\$1,076	\$925	\$829	\$1,341	\$1,145	\$1,024	

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR POLICY FORM 14515 WITH INFLATION PROTECTION

BASE PLAN ANNUAL PREMIUMS (Per \$10 of Benefit) WITH 21.5% RATE INCREASE

	Lifetime Multiplier = 400 Lifetime Multiplier		r = 800	Lifeti	me Multiplier	= 1200	Lifetin	ne Multiplier	= 1600	Lifetime Multiplier = Unlimited					
Issue	E	limination Peri	od	El	imination Peri	iod	Elimination Period			Eli	imination Peri	od	Elimination Period		
Age	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days	20 Days	90 Days	180 Days
18-44	\$29	\$27	\$24	\$39	\$34	\$31	\$43	\$39	\$36	\$46	\$41	\$39	\$63	\$56	\$51
45-49	\$41	\$36	\$34	\$56	\$48	\$46	\$63	\$56	\$51	\$70	\$60	\$56	\$101	\$87	\$80
50	\$46	\$41	\$39	\$63	\$56	\$51	\$75	\$65	\$60	\$85	\$72	\$68	\$121	\$104	\$97
51	\$48	\$43	\$39	\$65	\$58	\$53	\$80	\$70	\$63	\$89	\$77	\$70	\$128	\$111	\$101
52	\$51	\$43	\$41	\$70	\$60	\$56	\$85	\$72	\$65	\$94	\$82	\$75	\$135	\$118	\$106
53	\$53	\$46	\$43	\$75	\$63	\$58	\$89	\$77	\$70	\$101	\$87	\$80	\$142	\$126	\$114
54	\$56	\$48	\$43	\$77	\$68	\$60	\$94	\$82	\$75	\$106	\$92	\$85	\$152	\$130	\$121
55	\$58	\$51	\$46	\$82	\$72	\$65	\$101	\$87	\$77	\$114	\$97	\$89	\$159	\$140	\$126
56	\$60	\$53	\$48	\$89	\$75	\$68	\$109	\$92	\$85	\$121	\$104	\$94	\$171	\$147	\$135
57	\$63	\$56	\$51	\$97	\$82	\$72	\$116	\$99	\$89	\$130	\$111	\$101	\$184	\$159	\$145
58	\$70	\$60	\$53	\$104	\$89	\$80	\$126	\$109	\$99	\$142	\$121	\$111	\$198	\$171	\$157
59	\$75	\$63	\$58	\$114	\$97	\$87	\$138	\$118	\$106	\$155	\$133	\$121	\$215	\$186	\$169
60	\$82	\$70	\$63	\$123	\$106	\$94	\$150	\$128	\$116	\$169	\$145	\$130	\$234	\$203	\$184
61	\$87	\$75	\$68	\$133	\$114	\$104	\$162	\$140	\$126	\$184	\$157	\$142	\$254	\$220	\$200
62	\$94	\$80	\$72	\$145	\$123	\$111	\$176	\$152	\$135	\$196	\$169	\$155	\$273	\$237	\$215
63	\$101	\$87	\$77	\$155	\$130	\$118	\$186	\$162	\$145	\$210	\$181	\$164	\$290	\$251	\$227
64	\$109	\$92	\$85	\$162	\$138	\$123	\$196	\$169	\$152	\$220	\$191	\$171	\$304	\$263	\$239
65	\$116	\$99	\$89	\$169	\$145	\$130	\$208	\$179	\$162	\$232	\$200	\$181	\$319	\$278	\$251
66	\$123	\$106	\$97	\$181	\$157	\$140	\$222	\$191	\$171	\$249	\$215	\$196	\$341	\$295	\$268
67	\$135	\$118	\$106	\$198	\$169	\$152	\$242	\$208	\$188	\$273	\$234	\$213	\$372	\$321	\$292
68	\$150	\$128	\$118	\$220	\$188	\$169	\$268	\$232	\$208	\$302	\$261	\$234	\$411	\$355	\$321
69	\$164	\$142	\$128	\$244	\$210	\$188	\$299	\$258	\$232	\$336	\$290	\$261	\$454	\$394	\$357
70	\$181	\$157	\$142	\$273	\$234	\$210	\$333	\$287	\$258	\$374	\$324	\$292	\$507	\$437	\$396
71	\$200	\$174	\$157	\$304	\$261	\$234	\$372	\$321	\$290	\$418	\$360	\$326	\$565	\$488	\$442
72	\$225	\$193	\$174	\$341	\$292	\$263	\$418	\$360	\$324	\$469	\$403	\$365	\$630	\$546	\$493
73	\$251	\$217	\$196	\$382	\$326	\$292	\$466	\$403	\$362	\$524	\$452	\$408	\$703	\$609	\$551
74	\$280	\$242	\$220	\$425	\$365	\$326	\$519	\$449	\$403	\$584	\$505	\$456	\$785	\$679	\$613
75	\$314	\$270	\$244	\$471	\$403	\$362	\$580	\$500	\$449	\$652	\$560	\$507	\$872	\$753	\$681
76	\$350	\$302	\$273	\$524	\$449	\$403	\$642	\$555	\$500	\$722	\$623	\$563	\$966	\$836	\$756
77	\$389	\$336	\$304	\$580	\$497	\$449	\$712	\$616	\$553	\$802	\$691	\$625	\$1,070	\$925	\$836
78	\$432	\$372	\$336	\$645	\$553	\$500	\$790	\$683	\$613	\$889	\$768	\$693	\$1,183	\$1,024	\$925
79	\$481	\$413	\$374	\$715	\$616	\$555	\$877	\$756	\$679	\$988	\$852	\$770	\$1,314	\$1,135	\$1,024
80	\$531	\$456	\$413	\$787	\$681	\$616	\$966	\$833	\$749	\$1,089	\$939	\$848	\$1,447	\$1,251	\$1,128
81	\$582	\$500	\$452	\$862	\$746	\$676	\$1,055	\$913	\$819	\$1,191	\$1,026	\$927	\$1,577	\$1,362	\$1,229
82	\$630	\$541	\$488	\$935	\$809	\$732	\$1,142	\$985	\$884	\$1,285	\$1,108	\$1,000	\$1,695	\$1,463	\$1,321
83	\$679	\$582	\$524	\$1,005	\$872	\$787	\$1,224	\$1,055	\$949	\$1,374	\$1,186	\$1,070	\$1,806	\$1,560	\$1,403
84	\$727	\$623	\$560	\$1,077	\$932	\$840	\$1,304	\$1,128	\$1,014	\$1,461	\$1,261	\$1,137	\$1,913	\$1,649	\$1,485
85+	\$985	\$836	\$741	\$1,439	\$1,232	\$1,096	\$1,707	\$1,466	\$1,311	\$1,884	\$1,618	\$1,451	\$2,347	\$2,004	\$1,792

	Optional R	ider Premi	um Factors
Issue	Home Health	Inflation	Non-Forfeiture
Age	Care Increase	<u>Protection</u>	<u>Benefit</u>
18-44	1.15	2.08	1.25
45-49	1.15	2.00	1.20
50	1.15	1.94	1.15
51	1.15	1.92	1.14
52	1.15	1.90	1.14
53	1.15	1.89	1.14
54	1.15	1.88	1.14
55	1.15	1.87	1.14
56	1.15	1.86	1.14
57	1.15	1.85	1.14
58	1.15	1.84	1.14
59	1.15	1.83	1.14
60	1.15	1.82	1.14
61	1.15	1.81	1.14
62	1.15	1.80	1.13
63	1.15	1.78	1.13
64	1.15	1.76	1.13
65	1.15	1.74	1.13
66	1.15	1.72	1.12
67	1.15	1.70	1.12
68	1.15	1.68	1.12
69	1.15	1.66	1.12
70	1.15	1.64	1.11
71	1.15	1.62	1.11
72	1.15	1.60	1.11
73	1.15	1.58	1.10
74	1.15	1.56	1.10
75	1.15	1.54	1.09
76	1.15	1.52	1.09
77	1.15	1.50	1.08
78	1.15	1.48	1.08
79	1.15	1.46	1.07
80	1.15	1.44	1.07
81	1.15	1.42	1.07
82	1.15	1.40	1.06
83	1.15	1.39	1.06
84	1.15	1.38	1.06
85+	1.15	1.36	1.06

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR POLICY FORM 14515 WITH NO INFLATION PROTECTION

CURRENT BASE PLAN ANNUAL PREMIUMS (Per \$10 of Benefit)

	Lifetime Multiplier = 400		Lifetime Multiplier = 800			Lifetii	ne Multiplier	= 1200	Lifetin	ne Multiplier	= 1600	Lifetime Multiplier = Unlimited				
Issue	El	imination Peri	od	Eli	mination Peri	iod	El	imination Peri	od	Eli	mination Peri	iod	Elimination Period			
Age	<u> 20 Days</u>	<u>90 Days</u>	180 Days	<u> 20 Days</u>	<u>90 Days</u>	180 Days	<u> 20 Days</u>	<u>90 Days</u>	<u>180 Days</u>	<u>20 Days</u>	90 Days	180 Days	20 Days	<u>90 Days</u>	<u>180 Days</u>	
18-44	\$17	\$15	\$14	\$22	\$19	\$18	\$25	\$22	\$21	\$26	\$23	\$22	\$36	\$32	\$29	
45-49	\$23	\$21	\$19	\$32	\$28	\$26	\$36	\$32	\$29	\$40	\$35	\$32	\$58	\$50	\$46	
50	\$26	\$23	\$22	\$36	\$32	\$29	\$43	\$37	\$35	\$48	\$41	\$39	\$69	\$59	\$55	
51	\$28	\$25	\$22	\$37	\$33	\$30	\$46	\$40	\$36	\$51	\$44	\$40	\$73	\$63	\$58	
52	\$29	\$25	\$23	\$40	\$35	\$32	\$48	\$41	\$37	\$54	\$47	\$43	\$77	\$68	\$61	
53	\$30	\$26	\$25	\$43	\$36	\$33	\$51	\$44	\$40	\$58	\$50	\$46	\$81	\$72	\$65	
54	\$32	\$28	\$25	\$44	\$39	\$35	\$54	\$47	\$43	\$61	\$52	\$48	\$87	\$75	\$69	
55	\$33	\$29	\$26	\$47	\$41	\$37	\$58	\$50	\$44	\$65	\$55	\$51	\$91	\$80	\$72	
56	\$35	\$30	\$28	\$51	\$43	\$39	\$62	\$52	\$48	\$69	\$59	\$54	\$98	\$84	\$77	
57	\$36	\$32	\$29	\$55	\$47	\$41	\$66	\$57	\$51	\$75	\$63	\$58	\$105	\$91	\$83	
58	\$40	\$35	\$30	\$59	\$51	\$46	\$72	\$62	\$57	\$81	\$69	\$63	\$113	\$98	\$90	
59	\$43	\$36	\$33	\$65	\$55	\$50	\$79	\$68	\$61	\$88	\$76	\$69	\$123	\$106	\$97	
60	\$47	\$40	\$36	\$70	\$61	\$54	\$86	\$73	\$66	\$97	\$83	\$75	\$134	\$116	\$105	
61	\$50	\$43	\$39	\$76	\$65	\$59	\$92	\$80	\$72	\$105	\$90	\$81	\$145	\$126	\$115	
62	\$54	\$46	\$41	\$83	\$70	\$63	\$101	\$87	\$77	\$112	\$97	\$88	\$156	\$135	\$123	
63	\$58	\$50	\$44	\$88	\$75	\$68	\$106	\$92	\$83	\$120	\$104	\$94	\$166	\$144	\$130	
64	\$62	\$52	\$48	\$92	\$79	\$70	\$112	\$97	\$87	\$126	\$109	\$98	\$174	\$150	\$137	
65	\$66	\$57	\$51	\$97	\$83	\$75	\$119	\$102	\$92	\$132	\$115	\$104	\$182	\$159	\$144	
66	\$70	\$61	\$55	\$104	\$90	\$80	\$127	\$109	\$98	\$142	\$123	\$112	\$195	\$168	\$153	
67	\$77	\$68	\$61	\$113	\$97	\$87	\$138	\$119	\$108	\$156	\$134	\$121	\$213	\$184	\$167	
68	\$86	\$73	\$68	\$126	\$108	\$97	\$153	\$132	\$119	\$173	\$149	\$134	\$235	\$203	\$184	
69	\$94	\$81	\$73	\$139	\$120	\$108	\$171	\$148	\$132	\$192	\$166	\$149	\$259	\$225	\$204	
70	\$104	\$90	\$81	\$156	\$134	\$120	\$190	\$164	\$148	\$214	\$185	\$167	\$290	\$250	\$226	
71	\$115	\$99	\$90	\$174	\$149	\$134	\$213	\$184	\$166	\$239	\$206	\$186	\$323	\$279	\$253	
72	\$128	\$110	\$99	\$195	\$167	\$150	\$239	\$206	\$185	\$268	\$230	\$208	\$360	\$312	\$282	
73	\$144	\$124	\$112	\$218	\$186	\$167	\$266	\$230	\$207	\$299	\$258	\$233	\$402	\$348	\$315	
74	\$160	\$138	\$126	\$243	\$208	\$186	\$297	\$257	\$230	\$334	\$288	\$261	\$449	\$388	\$351	
75 75	\$179	\$155	\$139	\$269	\$230	\$207	\$331	\$286	\$257	\$373	\$320	\$290	\$498	\$431	\$389	
76	\$200	\$173	\$156	\$299	\$257	\$230	\$367	\$317	\$286	\$413	\$356	\$322	\$552	\$477	\$432	
77	\$222	\$192	\$174	\$331	\$284	\$257	\$407	\$352	\$316	\$458	\$395	\$357	\$611	\$529	\$477	
78	\$247	\$213	\$192	\$368	\$316	\$286	\$451	\$391	\$351	\$508	\$439	\$396	\$676	\$585	\$529	
79	\$275	\$236	\$214	\$408	\$352	\$317	\$501	\$432	\$388	\$564	\$487	\$440	\$751	\$649	\$585	
80	\$304	\$261	\$236	\$450	\$389	\$352	\$552	\$476	\$428	\$622	\$537	\$484	\$827	\$715	\$644	
81	\$333	\$286	\$258	\$493	\$426	\$386	\$603	\$522	\$468	\$680	\$587	\$530	\$901	\$778	\$702	
82	\$360	\$309	\$279	\$534	\$462	\$418	\$653	\$563	\$505	\$734	\$633	\$571	\$969	\$836	\$755	
83	\$388	\$333	\$299	\$574	\$498	\$450	\$700	\$603	\$542	\$785	\$678	\$611	\$1,032	\$891	\$802	
84	\$415	\$356	\$320	\$615	\$533	\$480	\$745	\$644	\$580	\$835	\$720	\$650	\$1,093	\$943	\$849	
85+	\$563	\$477	\$424	\$822	\$704	\$627	\$976	\$838	\$749	\$1,076	\$925	\$829	\$1,341	\$1,145	\$1,024	

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR POLICY FORM 14515 WITH INFLATION PROTECTION

CURRENT BASE PLAN ANNUAL PREMIUMS (Per \$10 of Benefit)

	Lifetime Multiplier = 400		Lifetii	Lifetime Multiplier = 800			ne Multiplier	= 1200	Lifetin	ne Multiplier	= 1600	Lifetime Multiplier = Unlimited				
Issue	Eli	imination Peri	iod	Eli	imination Peri	od	El	imination Peri	od	Eli	imination Peri	od	Elimination Period			
<u>Age</u>	<u> 20 Days</u>	<u>90 Days</u>	<u> 180 Days</u>	20 Days	90 Days	<u> 180 Days</u>	20 Days	90 Days	180 Days	<u> 20 Days</u>	90 Days	<u> 180 Days</u>	<u> 20 Days</u>	90 Days	180 Days	
18-44	\$24	\$22	\$20	\$32	\$28	\$26	\$36	\$32	\$30	\$38	\$34	\$32	\$52	\$46	\$42	
45-49	\$34	\$30	\$28	\$46	\$40	\$38	\$52	\$46	\$42	\$58	\$50	\$46	\$83	\$72	\$66	
50	\$38	\$34	\$32	\$52	\$46	\$42	\$62	\$54	\$50	\$70	\$60	\$56	\$99	\$85	\$79	
51	\$40	\$36	\$32	\$54	\$48	\$44	\$66	\$58	\$52	\$74	\$64	\$58	\$105	\$91	\$83	
52	\$42	\$36	\$34	\$58	\$50	\$46	\$70	\$60	\$54	\$78	\$68	\$62	\$111	\$97	\$87	
53	\$44	\$38	\$36	\$62	\$52	\$48	\$74	\$64	\$58	\$83	\$72	\$66	\$117	\$103	\$93	
54	\$46	\$40	\$36	\$64	\$56	\$50	\$78	\$68	\$62	\$87	\$76	\$70	\$125	\$107	\$99	
55	\$48	\$42	\$38	\$68	\$60	\$54	\$83	\$72	\$64	\$93	\$79	\$74	\$131	\$115	\$103	
56	\$50	\$44	\$40	\$74	\$62	\$56	\$89	\$76	\$70	\$99	\$85	\$78	\$141	\$121	\$111	
57	\$52	\$46	\$42	\$79	\$68	\$60	\$95	\$81	\$74	\$107	\$91	\$83	\$151	\$131	\$119	
58	\$58	\$50	\$44	\$85	\$74	\$66	\$103	\$89	\$81	\$117	\$99	\$91	\$163	\$141	\$129	
59	\$62	\$52	\$48	\$93	\$79	\$72	\$113	\$97	\$87	\$127	\$109	\$99	\$177	\$153	\$139	
60	\$68	\$58	\$52	\$101	\$87	\$78	\$123	\$105	\$95	\$139	\$119	\$107	\$193	\$167	\$151	
61	\$72	\$62	\$56	\$109	\$93	\$85	\$133	\$115	\$103	\$151	\$129	\$117	\$209	\$181	\$165	
62	\$78	\$66	\$60	\$119	\$101	\$91	\$145	\$125	\$111	\$161	\$139	\$127	\$225	\$195	\$177	
63	\$83	\$72	\$64	\$127	\$107	\$97	\$153	\$133	\$119	\$173	\$149	\$135	\$238	\$207	\$187	
64	\$89	\$76	\$70	\$133	\$113	\$101	\$161	\$139	\$125	\$181	\$157	\$141	\$250	\$217	\$197	
65	\$95	\$81	\$74	\$139	\$119	\$107	\$171	\$147	\$133	\$191	\$165	\$149	\$262	\$229	\$207	
66	\$101	\$87	\$79	\$149	\$129	\$115	\$183	\$157	\$141	\$205	\$177	\$161	\$280	\$242	\$221	
67	\$111	\$97	\$87	\$163	\$139	\$125	\$199	\$171	\$155	\$225	\$193	\$175	\$306	\$264	\$240	
68	\$123	\$105	\$97	\$181	\$155	\$139	\$221	\$191	\$171	\$248	\$215	\$193	\$338	\$292	\$264	
69	\$135	\$117	\$105	\$201	\$173	\$155	\$246	\$213	\$191	\$276	\$238	\$215	\$374	\$324	\$294	
70	\$149	\$129	\$117	\$225	\$193	\$173	\$274	\$236	\$213	\$308	\$266	\$240	\$417	\$360	\$326	
71	\$165	\$143	\$129	\$250	\$215	\$193	\$306	\$264	\$238	\$344	\$296	\$268	\$465	\$401	\$364	
72	\$185	\$159	\$143	\$280	\$240	\$217	\$344	\$296	\$266	\$386	\$332	\$300	\$519	\$449	\$405	
73	\$207	\$179	\$161	\$314	\$268	\$240	\$384	\$332	\$298	\$431	\$372	\$336	\$578	\$501	\$453	
74	\$231	\$199	\$181	\$350	\$300	\$268	\$427	\$370	\$332	\$481	\$415	\$376	\$646	\$558	\$505	
75	\$258	\$223	\$201	\$388	\$332	\$298	\$477	\$411	\$370	\$537	\$461	\$417	\$717	\$620	\$560	
76	\$288	\$248	\$225	\$431	\$370	\$332	\$529	\$457	\$411	\$594	\$513	\$463	\$795	\$688	\$622	
77	\$320	\$276	\$250	\$477	\$409	\$370	\$586	\$507	\$455	\$660	\$568	\$515	\$880	\$761	\$688	
78	\$356	\$306	\$276	\$531	\$455	\$411	\$650	\$562	\$505	\$731	\$632	\$570	\$974	\$843	\$761	
79	\$395	\$340	\$308	\$588	\$507	\$457	\$721	\$622	\$558	\$813	\$701	\$634	\$1,081	\$934	\$843	
80	\$437	\$376	\$340	\$648	\$560	\$507	\$795	\$686	\$616	\$896	\$773	\$698	\$1,190	\$1,029	\$928	
81	\$479	\$411	\$372	\$709	\$614	\$556	\$868	\$751	\$674	\$980	\$845	\$763	\$1,298	\$1,121	\$1,011	
82	\$519	\$445	\$401	\$769	\$666	\$602	\$940	\$811	\$727	\$1,057	\$912	\$823	\$1,395	\$1,204	\$1,087	
83	\$558	\$479	\$431	\$827	\$717	\$648	\$1,008	\$868	\$781	\$1,131	\$976	\$880	\$1,486	\$1,284	\$1,155	
84	\$598	\$513	\$461	\$886	\$767	\$692	\$1,073	\$928	\$835	\$1,202	\$1,037	\$936	\$1,574	\$1,357	\$1,222	
85+	\$811	\$688	\$610	\$1,184	\$1,013	\$902	\$1,405	\$1,206	\$1,079	\$1,550	\$1,331	\$1,194	\$1,932	\$1,649	\$1,475	

	Optional R	ider Premi	um Factors
Issue	Home Health	Inflation	Non-Forfeiture
Age	Care Increase	<u>Protection</u>	Benefit
18-44	1.15	2.08	1.25
45-49	1.15	2.00	1.20
50	1.15	1.94	1.15
51	1.15	1.92	1.14
52	1.15	1.90	1.14
53	1.15	1.89	1.14
54	1.15	1.88	1.14
55	1.15	1.87	1.14
56	1.15	1.86	1.14
57	1.15	1.85	1.14
58	1.15	1.84	1.14
59	1.15	1.83	1.14
60	1.15	1.82	1.14
61	1.15	1.81	1.14
62	1.15	1.80	1.13
63	1.15	1.78	1.13
64	1.15	1.76	1.13
65	1.15	1.74	1.13
66	1.15	1.72	1.12
67	1.15	1.70	1.12
68	1.15	1.68	1.12
69	1.15	1.66	1.12
70	1.15	1.64	1.11
71	1.15	1.62	1.11
72	1.15	1.60	1.11
73	1.15	1.58	1.10
74	1.15	1.56	1.10
75	1.15	1.54	1.09
76	1.15	1.52	1.09
77	1.15	1.50	1.08
78	1.15	1.48	1.08
79	1.15	1.46	1.07
80	1.15	1.44	1.07
81	1.15	1.42	1.07
82	1.15	1.40	1.06
83	1.15	1.39	1.06
84	1.15	1.38	1.06
85+	1.15	1.36	1.06

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR LONG TERM CARE POLICY FORM 14785 WITH NO INFLATION PROTECTION

	Base		nual Pro			Optional Rider Premium Percentages					
		(Per \$10	of Benefi	t)							
	V	Vith 0% I	Rate Incre	ease		Inflation	Non-	Home Care	ROP		
	90	Day Elim	ination P	eriod		Increase	Forfeiture	Increase	at Death		
Issue			Period Mi			Rider#	Rider#	Rider#	Rider#		
Age	400	800	1200	1600	Lifetime	<u>14532</u>	<u>14628</u>	<u>14625</u>	<u>14622</u>		
18-44	\$14	\$18	\$20	\$21	\$29	255%	125%	115%	#N/A		
45-49	\$19	\$25	\$29	\$32	\$45	245%	120%	115%	#N/A		
50	\$21	\$29	\$34	\$37	\$54	243%	115%	115%	#N/A		
51	\$22	\$30	\$36	\$39	\$57	241%	114%	115%	#N/A		
52	\$23	\$32	\$38	\$41	\$60	239%	114%	115%	#N/A		
53	\$24	\$33	\$40	\$43	\$63	237%	114%	115%	#N/A		
54	\$25	\$35	\$42	\$46	\$67	235%	114%	115%	#N/A		
55	\$26	\$37	\$45	\$49	\$71	232%	114%	115%	#N/A		
56	\$27	\$39	\$48	\$53	\$77	229%	114%	115%	#N/A		
57	\$29	\$42	\$51	\$57	\$82	226%	114%	115%	#N/A		
58	\$32	\$45	\$56	\$61	\$88	222%	114%	115%	#N/A		
59	\$34	\$49	\$60	\$66	\$96	218%	114%	115%	#N/A		
60	\$36	\$54	\$65	\$72	\$104	214%	114%	115%	#N/A		
61	\$38	\$58	\$71	\$80	\$113	210%	114%	115%	#N/A		
62	\$41	\$63	\$78	\$87	\$123	205%	113%	115%	#N/A		
63	\$44	\$68	\$85	\$96	\$133	200%	113%	115%	#N/A		
64	\$48	\$75	\$92	\$104	\$145	195%	113%	115%	#N/A		
65	\$53	\$82	\$101	\$113	\$156	190%	113%	115%	#N/A		
66	\$58	\$89	\$110	\$124	\$169	185%	112%	115%	#N/A		
67	\$64	\$98	\$121	\$135	\$183	180%	112%	115%	#N/A		
68	\$69	\$108	\$133	\$149	\$198	176%	112%	115%	#N/A		
69	\$76	\$120	\$148	\$165	\$217	172%	112%	115%	#N/A		
70	\$83	\$132	\$165	\$183	\$240	168%	111%	115%	#N/A		
71	\$91	\$146	\$184	\$204	\$269	165%	111%	115%	#N/A		
72	\$102	\$161	\$205	\$228	\$302	162%	111%	115%	#N/A		
73	\$114	\$179	\$229	\$255	\$340	159%	110%	115%	#N/A		
74	\$129	\$200	\$256	\$286	\$382	156%	110%	115%	#N/A		
75	\$146	\$224	\$286	\$319	\$427	154%	109%	115%	#N/A		
76	\$165	\$251	\$317	\$358	\$476	152%	109%	115%	#N/A		
77	\$186	\$281	\$351	\$399	\$526	150%	108%	115%	#N/A		
78	\$208	\$315	\$386	\$442	\$579	148%	108%	115%	#N/A		
79	\$231	\$351	\$424	\$486	\$633	146%	107%	115%	#N/A		
80	\$255	\$386	\$464	\$531	\$690	144%	107%	115%	#N/A		
81	\$279	\$422	\$506	\$576	\$749	142%	107%	115%	#N/A		
82	\$303	\$458	\$549	\$622	\$810	140%	106%	115%	#N/A		
83	\$328	\$494	\$593	\$667	\$870	139%	106%	115%	#N/A		
84	\$352	\$530	\$637	\$713	\$932	138%	106%	115%	#N/A		
85+	\$418	\$616	\$733	\$810	\$1,003	136%	106%	115%	#N/A		

Elimination Period Factors (Applied to 90 Day EP rates)

30 Day EP 1.14 60 Day EP 1.06 180 Day EP 0.91

165 COURT STREET, ROCHESTER, NEW YORK 14647 RATE SHEET FOR LONG TERM CARE POLICY FORM 14785 WITH INFLATION PROTECTION

Base Plan Annual Premiums Optional Rider Premium Percentages (Per \$10 of Benefit) With 0% Rate Increase Inflation Non-Home Care ROP 90 Day Elimination Period Increase Forfeiture Increase at Death Benefit Period Multiplier Rider# Rider# Rider# Rider# Issue <u>Age</u> 400 1200 1600 Lifetime 14532 14628 14625 14622 18-44 \$19 \$24 \$27 255% 125% 115% #N/A \$28 \$39 45-49 \$26 \$34 \$39 \$43 \$61 245% 120% 115% #N/A \$39 \$50 243% 115% 50 \$28 \$46 \$73 115% #N/A\$30 \$41 \$49 \$53 241% 114% 115% 51 \$77 #N/A \$31 \$43 \$51 \$55 239% 114% 115% 52 \$81 #N/A 237% 115% 53 \$32 \$45 \$54 \$58 \$85 114% #N/A 54 \$34 \$47 \$57 \$62 \$90 235% 114% 115% #N/A 55 \$35 \$50 \$61 \$66 \$96 232% 114% 115% #N/A 56 \$36 \$53 \$65 \$72 \$104 229% 114% 115% #N/A 57 \$39 \$57 \$69 \$77 \$111 226% 114% 115% #N/A 58 \$43 \$61 \$76 \$82 \$119 222% 114% 115% #N/A 59 \$46 \$66 \$81 \$89 \$130 218% 114% 115% #N/A 60 \$49 \$73 \$88 \$97 \$140 214% 114% 115% #N/A 61 \$51 \$78 \$96 \$108 \$153 210% 114% 115% #N/A \$55 \$85 \$105 \$117 205% 113% 115% #N/A62 \$166 \$59 \$92 \$130 200% 113% 115% #N/A 63 \$115 \$180 64 \$65 \$101 \$124 \$140 \$196 195% 113% 115% #N/A 65 \$72 \$111 \$136 \$153 \$211 190% 113% 115% #N/A 66 \$78 \$120 \$149 \$167 \$228 185% 112% 115% #N/A 67 \$86 \$132 \$163 \$182 \$247 180% 112% 115% #N/A \$93 176% 112% 68 \$146 \$180 \$201 \$267 115% #N/A 69 \$103 \$162 \$200 \$223 \$293 172% 112% 115% #N/A 70 \$112 \$178 \$223 \$247 \$324 168% 111% 115% #N/A 71 \$123 \$197 \$248 \$275 \$363 165% 111% 115% #N/A 72 \$138 \$217 \$277 \$308 \$408 162% 111% 115% #N/A 73 \$154 \$242 \$309 \$344 \$459 159% 110% 115% #N/A 74 \$174 \$270 \$346 \$386 156% 110% 115% #N/A \$516 75 154% 115% \$197 \$302 \$386 \$431 \$576 109% #N/A 76 \$223 \$339 \$428 \$483 \$643 152% 109% 115% #N/A 77 \$251 \$379 \$474 \$539 \$710 150% 108% 115% #N/A 78 \$281 \$425 \$521 \$597 \$782 148% 108% 115% #N/A 79 \$312 \$474 \$572 \$656 \$855 146% 107% 115% #N/A 80 \$344 \$521 \$626 \$717 \$932 144% 107% 115% #N/A 81 \$377 \$570 \$683 \$778 \$1,011 142% 107% 115% #N/A 82 \$409 \$618 \$741 \$840 \$1,094 140% 106% 115% #N/A 83 \$443 \$667 \$801 \$900 \$1,175 139% 106% 115% #N/A

Elimination Period Factors (Applied to 90 Day EP rates)

\$716

\$832

\$963

\$1,094

\$860

\$990

\$1,258

\$1,354

138%

136%

106%

106%

115%

115%

#N/A

#N/A

30 Day EP 1.14 60 Day EP 1.06 180 Day EP 0.91

\$475

\$564

84

85+

165 COURT STREET, ROCHESTER, NEW YORK 14647

RATE SHEET FOR LONG TERM CARE POLICY FORM 14785 WITH NO INFLATION PROTECTION

Current Base Plan Annual Premiums							Optional Rider Premium Percentages					
		(Per \$10	of Benefi	t)								
							Inflation	Non-	Home Care	ROP		
	90	Day Elim	ination P	eriod			Increase	Forfeiture	Increase	at Death		
Issue			Period Mi				Rider#	Rider#	Rider#	Rider#		
Age	400	800	1200	1600	Lifetime		<u>14532</u>	<u>14628</u>	<u>14625</u>	<u>14622</u>		
18-44	\$14	\$18	\$20	\$21	\$29		255%	125%	115%	#N/A		
45-49	\$19	\$25	\$29	\$32	\$45		245%	120%	115%	#N/A		
50	\$21	\$29	\$34	\$37	\$54		243%	115%	115%	#N/A		
51	\$22	\$30	\$36	\$39	\$57		241%	114%	115%	#N/A		
52	\$23	\$32	\$38	\$41	\$60		239%	114%	115%	#N/A		
53	\$24	\$33	\$40	\$43	\$63		237%	114%	115%	#N/A		
54	\$25	\$35	\$42	\$46	\$67		235%	114%	115%	#N/A		
55	\$26	\$37	\$45	\$49	\$71		232%	114%	115%	#N/A		
56	\$27	\$39	\$48	\$53	\$77		229%	114%	115%	#N/A		
57	\$29	\$42	\$51	\$57	\$82		226%	114%	115%	#N/A		
58	\$32	\$45	\$56	\$61	\$88		222%	114%	115%	#N/A		
59	\$34	\$49	\$60	\$66	\$96		218%	114%	115%	#N/A		
60	\$36	\$54	\$65	\$72	\$104		214%	114%	115%	#N/A		
61	\$38	\$58	\$71	\$80	\$113		210%	114%	115%	#N/A		
62	\$41	\$63	\$78	\$87	\$123		205%	113%	115%	#N/A		
63	\$44	\$68	\$85	\$96	\$133		200%	113%	115%	#N/A		
64	\$48	\$75	\$92	\$104	\$145		195%	113%	115%	#N/A		
65	\$53	\$82	\$101	\$113	\$156		190%	113%	115%	#N/A		
66	\$58	\$89	\$110	\$124	\$169		185%	112%	115%	#N/A		
67	\$64	\$98	\$121	\$135	\$183		180%	112%	115%	#N/A		
68	\$69	\$108	\$133	\$149	\$198		176%	112%	115%	#N/A		
69	\$76	\$120	\$148	\$165	\$217		172%	112%	115%	#N/A		
70	\$83	\$132	\$165	\$183	\$240		168%	111%	115%	#N/A		
71	\$91	\$146	\$184	\$204	\$269		165%	111%	115%	#N/A		
72	\$102	\$161	\$205	\$228	\$302		162%	111%	115%	#N/A		
73	\$114	\$179	\$229	\$255	\$340		159%	110%	115%	#N/A		
74	\$129	\$200	\$256	\$286	\$382		156%	110%	115%	#N/A		
75	\$146	\$224	\$286	\$319	\$427		154%	109%	115%	#N/A		
76	\$165	\$251	\$317	\$358	\$476		152%	109%	115%	#N/A		
77	\$186	\$281	\$351	\$399	\$526		150%	108%	115%	#N/A		
78	\$208	\$315	\$386	\$442	\$579		148%	108%	115%	#N/A		
79	\$231	\$351	\$424	\$486	\$633		146%	107%	115%	#N/A		
80	\$255	\$386	\$464	\$531	\$690		144%	107%	115%	#N/A		
81	\$279	\$422	\$506	\$576	\$749		142%	107%	115%	#N/A		
82	\$303	\$458	\$549	\$622	\$810		140%	106%	115%	#N/A		
83	\$328	\$494	\$593	\$667	\$870		139%	106%	115%	#N/A		
84	\$352	\$530	\$637	\$713	\$932		138%	106%	115%	#N/A		
85+	\$418	\$616	\$733	\$810	\$1,003		136%	106%	115%	#N/A		

Elimination Period Factors (Applied to 90 Day EP rates)

30 Day EP 1.14 60 Day EP 1.06 180 Day EP 0.91

165 COURT STREET, ROCHESTER, NEW YORK 14647 RATE SHEET FOR LONG TERM CARE POLICY FORM 14785 WITH INFLATION PROTECTION

C	urrent l	Base Plai	n Annua	l Premi	ıms	Option	al Rider Pr	emium Perce	ntages
		(Per \$10	of Benefi	it)		•			O
				,		Inflation	Non-	Home Care	ROP
	90	Day Elim	ination P	ariad		Increase	Forfeiture	Increase	at Death
,	70								
Issue			Period Mi			Rider #	Rider #	Rider #	Rider #
<u>Age</u>	<u>400</u>	<u>800</u>	<u>1200</u>	<u>1600</u>	<u>Lifetime</u>	<u>14532</u>	<u>14628</u>	<u>14625</u>	<u>14622</u>
18-44	\$19	\$24	\$27	\$28	\$39	255%	125%	115%	#N/A
45-49	\$26	\$34	\$39	\$43	\$61	245%	120%	115%	#N/A
50	\$28	\$39	\$46	\$50	\$73	243%	115%	115%	#N/A
51	\$30	\$41	\$49	\$53	\$77	241%	114%	115%	#N/A
52	\$31	\$43	\$51	\$55	\$81	239%	114%	115%	#N/A
53	\$32	\$45	\$54	\$58	\$85	237%	114%	115%	#N/A
54	\$34	\$47	\$57	\$62	\$90	235%	114%	115%	#N/A
55	\$35	\$50	\$61	\$66	\$96	232%	114%	115%	#N/A
56	\$36	\$53	\$65	\$72	\$104	229%	114%	115%	#N/A
57	\$39	\$57	\$69	\$77	\$111	226%	114%	115%	#N/A
58	\$43	\$61	\$76	\$82	\$119	222%	114%	115%	#N/A
59	\$46	\$66	\$81	\$89	\$130	218%	114%	115%	#N/A
60	\$49	\$73	\$88	\$97	\$140	214%	114%	115%	#N/A
61	\$51	\$78	\$96	\$108	\$153	210%	114%	115%	#N/A
62	\$55	\$85	\$105	\$117	\$166	205%	113%	115%	#N/A
63	\$59	\$92	\$115	\$130	\$180	200%	113%	115%	#N/A
64	\$65	\$101	\$124	\$140	\$196	195%	113%	115%	#N/A
65	\$72	\$111	\$136	\$153	\$211	190%	113%	115%	#N/A
66	\$78	\$120	\$149	\$167	\$228	185%	112%	115%	#N/A
67	\$86	\$132	\$163	\$182	\$247	180%	112%	115%	#N/A
68	\$93	\$146	\$180	\$201	\$267	176%	112%	115%	#N/A
69	\$103	\$162	\$200	\$223	\$293	172%	112%	115%	#N/A
70	\$112	\$178	\$223	\$247	\$324	168%	111%	115%	#N/A
71	\$123	\$197	\$248	\$275	\$363	165%	111%	115%	#N/A
72	\$138	\$217	\$277	\$308	\$408	162%	111%	115%	#N/A
73	\$154	\$242	\$309	\$344	\$459	159%	110%	115%	#N/A
74	\$174	\$270	\$346	\$386	\$516	156%	110%	115%	#N/A
75	\$197	\$302	\$386	\$431	\$576	154%	109%	115%	#N/A
76	\$223	\$339	\$428	\$483	\$643	152%	109%	115%	#N/A
77	\$251	\$379	\$474	\$539	\$710	150%	108%	115%	#N/A
78	\$281	\$425	\$521	\$597	\$782	148%	108%	115%	#N/A
79	\$312	\$474	\$572	\$656	\$855	146%	107%	115%	#N/A
80	\$344	\$521	\$626	\$717	\$932	144%	107%	115%	#N/A
81	\$377	\$570	\$683	\$778	\$1,011	142%	107%	115%	#N/A
82	\$409	\$618	\$741	\$840	\$1,094	140%	106%	115%	#N/A
83	\$443	\$667	\$801	\$900	\$1,175	139%	106%	115%	#N/A
84	\$475	\$716	\$860	\$963	\$1,258	138%	106%	115%	#N/A
85+	\$564	\$832	\$990	\$1,094	\$1,354	136%	106%	115%	#N/A

Elimination Period Factors (Applied to 90 Day EP rates)

30 Day EP 1.14 60 Day EP 1.06 180 Day EP 0.91

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Supporting Document Schedules

Satisfied - Item:	Transmittal Letter (A&H)
Comments:	
Attachment(s):	PA_Cover Letter_CICA_LRRS_20210728.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Actuarial Certification (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Actuarial Memorandum and Explanatory Information (A&H)
Comments:	
Attachment(s):	PA_ActMemo_CICA_LRRS_20210728.pdf PA_Supplement_CICA_LRRS_20210728.pdf PA_Exhibits and Supplement Attachments_CICA_20210728.xlsb
Item Status:	
Status Date:	
Bypassed - Item:	Advertisements (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Authorization to File (A&H)
Comments:	
Attachment(s):	Authorization to file MedAmerica 20210119.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Insert Page Explanation (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	

State: Pennsylvania Filing Company: MedAmerica Insuran TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified Product Name: Long-Term Care Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05	ce Company
Item Status:	
Status Date:	
Satisfied - Item: Rate Table (A&H)	
Comments: Rate Tables are attached on the Rate/Rule Schedule tab.	
Attachment(s):	
Item Status:	
Status Date:	
Bypassed - Item: Replacement Form with Highlighted Changes (A&H)	
Bypass Reason: Not applicable as this is not a form filing.	
Attachment(s):	
Item Status:	
Status Date:	
Bypassed - Item: Advertisement Compliance Certification	
Bypass Reason: Not applicable as this is not an advertisement filing.	
Attachment(s):	
Item Status:	
Status Date:	
Bypassed - Item: Reserve Calculation (A&H)	
Bypass Reason: Not applicable as this is not a form filing.	
Attachment(s):	
Item Status:	
Status Date:	
Bypassed - Item: Variability Explanation (A&H)	
Bypass Reason: Not applicable as this is not a form filing.	
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item: Sample Policyholder Notification Letter	
Comments:	
Attachment(s): TEMPLATE MAPA Legacy-Assumed PH Letter 9.30.19.pdf TEMPLATE MAPA Legacy-Assumed CNF 9.30.19.pdf	
Item Status:	

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Status Date:

State: Pennsylvania Filing Company: MedAmerica Insurance Company

TOI/Sub-TOI: LTC03I Individual Long Term Care/LTC03I.001 Qualified

Product Name: Long-Term Care

Project Name/Number: CICA LTC Rate Increase Filing/145MAI01-40.05

Attachment PA_Exhibits and Supplement Attachments_CICA_20210728.xlsb is not a PDF document and cannot be reproduced here.



8500 Normandale Lake Blvd. Suite 1850 Minneapolis, MN 55437-3830

Tel +1 952 897 5300

milliman com

July 28, 2021

Honorable Jessica K. Altman Insurance Commissioner Pennsylvania Insurance Department (Department)

Via SERFF

Re: MedAmerica Insurance Company (MedAmerica)

Company NAIC # 69515

SERFF Tracking # MILL- 132822823

515 Series

Tax-Qualified Long-Term Care Policy Form 14515-PA

780 Series

Tax-Qualified Long-Term Care Policy Form 14785-PA

Dear Commissioner Altman:

On behalf of the company, we are submitting the referenced rate filing for your review. This is an existing policy form(s) that provides long-term care coverage. This policy form(s) was written by Combined Insurance Company of America (CICA) and issued in Pennsylvania from February 18, 1999 through June 1, 2008 and is no longer marketed in any jurisdiction.

In 2008, MedAmerica acquired the long-term care block of business issued by CICA from Ace Ltd. and subsequently submitted a certificate of assumption filing. As a result, most of the nationwide policies are now on MedAmerica paper; however, approximately 16% of the in-force policyholders nationwide objected to the assumption filing and remain on CICA paper. In Pennsylvania, all of the in-force policies are on MedAmerica paper. MedAmerica has 100% of the risk on this form(s), including policies on CICA paper, and administers and manages the entire block.

The company is requesting a premium rate increase on the above-listed form(s), including all associated riders. The need for a premium rate increase is due to emerging and projected experience running more adverse than originally expected.

This rate increase request is a follow-up to two prior nationwide requests for the 515 Series and one prior nationwide request for the 780 Series. However, because this jurisdiction did not allow full implementation of the prior requested increase(s), the rate level being requested in this follow-up filing was determined to be actuarially equivalent as described in Appendix B to the enclosed actuarial memorandum. As with the prior request, the requested rate increase varies by series and inflation protection option. The following table provides the average prior, requested, and cumulative rate increases for the above-listed form(s) by series and inflation protection option.

For the 780 Series policies, the prior requested rate increase was approved in full. The company is not requesting a rate increase on these policies at this time as shown in the following table.

Offices in Principal Cities Worldwide

This work product was prepared solely to provide assistance to MedAmerica. Milliman does not intend to benefit and assumes no duty or liability to other parties who receive this work. Milliman recommends recipient be aided by its own actuary or other qualified professional when reviewing the Milliman work product.



Pennsylvania -Specific	Rate	Increase	Request
------------------------	------	----------	---------

	Inflation			
	Protection	Cumulative	Requested	Cumulative
Series	Option	Prior Increase	Increase	Increase
E1E	Non-Auto	38.0%	0.0%	38%
515	Auto	98.7	21.5	142
780 ^[1]	Non-Auto	0.0	0.0	0
1001.1	Auto	35.0	0.0	35
Average ^[2]		58.4	12.1	77

^[1] No rate increase is being requested on the 780 Series policies as the Department fully approved the prior request.

The cumulative prior increase reflects the four prior increases filed for use on the 515 Series policies in May 2014, June 2015, August 2019, and August 2020 and one prior increase phased in over a 2-year period filed for use on the 780 Series policies in August 2019. The company is seeking this current rate increase request to help alleviate the adverse performance on this block of business.

As stated in the enclosed actuarial memorandum, a larger rate increase is justified on this block of business. If it is the Department's position to only allow future rate increases if experience deteriorates from the current most-likely projections used in this filing, the company respectfully requests that the Department notify them and allow the company to revise the current rate increase request.

Similar to the prior increase(s), the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

The following electronic items are included with this submission:

- cover letter
- letter from MedAmerica authorizing submission of this filing on its behalf
- actuarial memorandum
- supplement to the actuarial memorandum
- numerical data in Excel
- current and proposed premium rate schedules
- sample policyholder notification letter*

No filing fee is required for this submission.

^[2] As of December 31, 2019.

^{*}Please note that in the future slight variations in language may occur that do not materially change the information being provided to the policyholder. It is our understanding that such variations do not need to be filed with the Department.



The contact person for this filing is:

Courtney Williamson, ASA, MAAA Associate Actuary Milliman, Inc. 8500 Normandale Lake Blvd., Suite 1850 Minneapolis, MN 55437 (952) 820-2413 courtney.williamson@milliman.com

Thank you for your assistance in reviewing this filing.

Respectfully,

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

MAG/dpl

Enclosures

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

Product Sumber 515 Series Tax-Qualified Long-Term Care Policy Form 14515-PA 780 Series Tax-Qualified Long-Term Care Policy Form 14785-PA

The company is requesting a rate increase on the above-listed long-term care policy form(s). Combined Insurance Company of America (CICA) wrote and issued this policy form(s) in Pennsylvania from February 1999 through June 2008 and is no longer marketing it in any jurisdiction.

In 2008, MedAmerica Insurance Company (MedAmerica) acquired the long-term care block of business issued by CICA from Ace Ltd. and subsequently submitted a certificate of assumption filing. As a result, most of the nationwide policies are now on MedAmerica paper; however, approximately 16% of the in-force policyholders nationwide objected to the assumption filing and remain on CICA paper. In Pennsylvania, all of the in-force policies are on MedAmerica paper. MedAmerica has 100% of the risk on this form(s), including policies on CICA paper, and administers and manages the entire block.

Nationwide, the company is requesting a premium rate increase that varies by series and inflation protection option, except where limited by regulatory restrictions or the limited amount of in-force business. This actuarial memorandum captures the pooled experience of the policy form(s) listed above as well as similar nationwide policy forms of the 515, 700, and 780 Series.

As indicated in the enclosed cover letter for the 780 Series policies, the prior requested rate increase was approved in full. The company is not requesting a rate increase on these policies at this time.

1. Purpose of Filing

This actuarial memorandum has been prepared for the purpose of demonstrating that the requested rate increase discussed in Section 2 meets the minimum requirements of the applicable sections of the 2014 National Association of Insurance Commissioners (NAIC) Long-Term Care Insurance Model Regulation (Model Regulation). The enclosed supplement to the actuarial memorandum demonstrates compliance with the applicable regulatory requirements of this jurisdiction, to the extent they differ from the Model Regulation, and includes other commonly requested information of this jurisdiction. It may not be suitable for other purposes.

2. Requested Rate Increase

The company is requesting a rate increase that varies by series and inflation protection option. The rate increase levels were determined to vary by series and inflation protection option to better align the rate increase with the adverse experience. Appendix A to this memorandum provides a description of the development of and justification for the assumptions used in this filling, which were used to analyze the adverse experience.

This rate increase request is a follow-up to two prior nationwide requests for the 515 Series and one prior nationwide request for the 700 and 780 Series. In jurisdictions that did not allow full implementation of the prior requested increase(s), the company is requesting a follow-up increase to achieve an actuarially equivalent lifetime loss ratio to the prior request(s). Appendix B to this memorandum provides additional details on the development of and justification for the requested rate increase, including a detailed description of how actuarial equivalence was determined and a demonstration that the requested rate increase does not recoup past losses.

The table below provides the average prior, requested, and cumulative rate increases by series and inflation protection option based on the nationwide distribution of business. The enclosed cover letter provides similar information based on the jurisdiction-specific distribution and discloses the requested rate increase in this jurisdiction.

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

Nationwide Average^[1] Rate Increase Request

	Inflation			
	Protection	Prior	Requested	Cumulative
Series	Option	Increase	Increase	Increase
515	Non-Auto	24.4%	0.0%	24%
313	Auto	58.6	49.4	137
700	Non-Auto	13.4	0.0	13
700	Auto	36.6	52.2	108
780	Non-Auto	4.1	0.0	4
700	Auto	13.1	20.5	36
Average		34.3	28.3	72

^[1] As of December 31, 2019.

While emerging experience supports a larger rate increase, the company is limiting the increase to be an actuarially equivalent follow-up to the prior request(s) in order to improve equity across jurisdictions. The company plans to continue to monitor experience and request additional rate increases in the future, to the extent justified. However, if it is the Department's position to only allow future rate increases if experience deteriorates from the current most-likely projections used in this filing, the company respectfully requests that the Department notify them and allow the company to revise the current rate increase request.

Corresponding rate tables reflecting the current and proposed rate increases are enclosed with this filing. Please note that the actual rates implemented may vary slightly from those in the enclosed rate tables due to implementation rounding algorithms.

As the company is not currently marketing new business, the required statement that the renewal premium rate schedules are not greater than the new business premium rate schedules is not applicable.

3. Description of Benefits

These are individually underwritten policy forms that provide comprehensive coverage on a reimbursement basis. These forms have benefit eligibility requirements that involve activities of daily living (ADL) deficiencies or cognitive impairment. Waiver of premium is provided after the policyholder has been receiving covered care for 90 days and as long as the person continues to receive covered benefits. A daily benefit, benefit period, and elimination period were selected at issue. All policies have a lifetime premium payment term.

At issue, the insured may have been offered the option to elect an inflation protection rider that provides for benefit levels that increase on each anniversary date by 5% compounded annually for the life of the insured. The increasing benefits apply even when the insured is in claim status.

The available choices for benefit period and elimination period are shown in Section 21 below.

At issue, the insured may have been offered the option of selecting riders that provide the following types of coverage: non-forfeiture benefit, return of premium benefit, or additional community care benefit.

A contingent benefit upon lapse (CBUL) will be available to all insureds at the time of the rate increase.

4. Renewability

These policies are guaranteed renewable for life.

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

5. Applicability

This rate increase applies to all policies issued on the above-listed form(s) in this jurisdiction. The rate changes will apply to the premium of the base form and all applicable options and riders associated with the base form.

6. Actuarial Assumptions

The following assumptions are used to project the experience shown in this filing.

- a. Morbidity reflects claim costs developed using the 2017 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for underwriting selection, an all-lives exposure basis, and two years of retrospective improvement to bring the Guidelines forward to 2019. The claim costs were further adjusted based on historical claim experience by series, attained age, coverage type, benefit period (non-lifetime vs. lifetime), and payment type, to the extent credible. These adjustment factors can be found in Exhibit A-5a of Appendix A to this memorandum.
- b. Mortality Rates reflect the 2012 Individual Annuitant Mortality (IAM) Basic table. These mortality rates were then adjusted based on historical mortality experience by gender, marital status, attained age, and duration. The adjusted 2012IAM table was then brought forward to 2019 using the 2012IAM attained age mortality improvement scale (i.e., G2 projection scale). The mortality adjustment factors can be found in Exhibit A-1a and A-1c of Appendix A to this memorandum.
- c. <u>Voluntary Lapse Rates</u> vary by policy duration (ultimate for 11+), attained age (ultimate for 65+), benefit period (lifetime or non-lifetime), inflation protection (auto or non-auto), marital status, and series. The table below summarizes the ultimate lapse rates by key characteristics.

Ultimate Lapse Rates

		Mar	ried		Single			
	Life	time	Non-L	ifetime	Lifetime		Non-Lifetime	
	Benefit	Period	Benefit	Benefit Period Benefit		Period	Benefit	Period
	Auto	Non-Auto	Auto	Non-Auto	Auto	Non-Auto	Auto	Non-Auto
Series	Inflation	Inflation	Inflation	Inflation	Inflation	Inflation	Inflation	Inflation
515	0.9%	1.0%	1.0%	1.4%	1.1%	1.3%	1.3%	1.8%
700	8.0	0.9	0.9	1.2	1.0	1.1	1.2	1.6
780	8.0	0.9	0.9	1.2	1.0	1.1	1.2	1.5

d. <u>Benefit Expiry Rates</u> reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the 2017 *Guidelines* with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age as shown in the following table.

	Benefit		Attained Age ^[1]									
Gender	Period in Days	<65	65	70	75	80	85	90	95	100	105	110+
Female	400	0.0%	0.1%	0.2%	0.3%	0.8%	2.3%	5.4%	9.7%	11.3%	19.3%	20.7%
	800	0.0	0.0	0.1	0.2	0.5	1.6	4.4	8.2	10.7	19.0	20.7
	1200	0.0	0.0	0.1	0.2	0.5	1.3	3.4	6.7	9.3	19.0	20.7
	1600	0.0	0.0	0.1	0.1	0.3	0.9	2.5	4.8	7.1	17.0	20.7
	Lifetime	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Male	400	0.0	0.1	0.1	0.2	0.5	1.6	4.0	6.9	7.8	11.3	20.7
	800	0.0	0.0	0.1	0.2	0.4	1.1	2.8	5.1	6.0	10.2	20.7
	1200	0.0	0.0	0.1	0.1	0.3	8.0	1.9	3.8	4.8	9.1	20.7
	1600	0.0	0.0	0.0	0.1	0.2	0.4	1.3	2.4	3.4	7.9	20.7
	Lifetime	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

[1] The assumption varies by attained age, but is shown every five years for display purposes.

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

e. <u>Policyholder Behavior Due to the Rate Increase.</u> At the time of a rate increase, insureds have the option to elect a CBUL or reduced benefit option (RBO). An increase in morbidity for adverse selection due to the rate increase is assumed based on the percentage of policies that elect CBUL and RBO.

Insureds who elect a CBUL are modeled as a lapse (i.e., the CBUL benefit is not modeled), which results in a slightly lower lifetime loss ratio than if the CBUL benefit had been modeled. The following table provides the CBUL and RBO election rates, reduction to premiums and benefits due to the impact of RBO elections, and increase in morbidity by rate increase band.

Policyholder Behavior Assumptions

Rate Increase Band	CBUL Election Rate	RBO Election Rate	Approximate Reduction for RBO ^[1]	Morbidity Increase for Adverse Selection
1.0 - 9.9%	1%	1%	0.0%	0.4%
10.0 – 19.9	3	2	0.3	1.0
20.0 – 49.9	6	6	1.7	2.3
50.0 - 79.9	9	14	6.1	4.2
80.0 – 99.9	12	18	9.7	5.5
100.0 – 199.9	14	25	17.4	7.1
200.0 - 299.9	16	35	29.8	9.1

[1] For display purposes, the approximate reduction for RBO values reflect the midpoint of the requested increase within each range. A detailed description of the calculation can be found in Appendix A. For example, the 20.0% – 49.9% range was calculated using the formula in Appendix A and a rate increase of 35%.

- f. <u>Interest Rate</u> consistent with the maximum valuation interest rate applicable to the year of issue (ranges from 4.0% to 4.5% and averages 4.4%) is used to demonstrate compliance with the minimum loss ratio requirements.
- g. Annual Improvement in the mortality and morbidity assumptions is assumed for 10 years starting in 2020. Annual improvement factors vary by attained age and gender based on the G2 improvement scale from the 2012IAM table.
- h. <u>Expenses</u> have not been explicitly projected for the purpose of demonstrating compliance with minimum loss ratio requirements. Originally filed expense assumptions are assumed to remain appropriate, except that reductions are made to the renewal commission rates so that the total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

The above assumptions are based on the experience of policies issued by CICA and its sister company Combined Life Insurance Company of New York (CLICNY) that issued the same products, other similar business issued by MedAmerica (including its affinity partners and acquired blocks of business), industry experience, and actuarial judgment. The above assumptions are deemed reasonable for the particular policy form(s) in this filing and are considered "most likely" (without explicit margin).

In establishing the assumptions described in this section, the policy design, underwriting, and claims adjudication practices for the above-referenced policy forms were taken into consideration. Appendix A to this memorandum provides a description of the development of and justification for the assumptions used in this filing.

The company is not currently marketing long-term care products. As a result, the requirement to reflect on any assumptions that deviate from those used for pricing other forms currently available for sale is not applicable.

Address: 165 Court Street, Rochester, New York 14647

Actuarial Memorandum

July 28, 2021

7. Marketing Method

These policy forms were marketed by agents of CICA and by estate-planning consultants.

8. Underwriting Description

These policies were individually underwritten with the use of various underwriting tools in addition to the application, which may have included medical records, cognitive screening, telephone interview and/or face-to-face assessment.

9. Premiums

Premiums are unisex and payable for life. The premiums may vary by policy form, issue age, elimination period, benefit period, initial daily benefit, inflation protection option, marital status at issue, and the selection of any riders.

10. Issue Age Range

Issue ages are from 18 to 84.

11. Area Factors

Area factors are not used for these products.

12. Premium Modalization Rules

The following modal factors and percent distributions (based on the nationwide in-force count as of December 31, 2019) are applied to the annual premium (AP):

Premium Mode	Modal Factors	Percent Distribution
Annual	1.000*AP	19%
Semi-Annual	0.520*AP	4
Quarterly	0.265*AP	3
Monthly	0.090*AP	74

13. Reserves

Active life reserves and reserves for the election of a CBUL have not been used in the experience exhibits for this rate increase analysis for the purpose of demonstrating compliance with minimum loss ratio requirements, except as described in the supplement to the actuarial memorandum. Claim reserves as of December 31, 2019 have been discounted to the incurral date of each respective claim and included in historical incurred claims. An incurred but not reported (IBNR) reserve balance as of December 31, 2019 has been allocated to the 2019 calendar year and included in historical incurred claims.

14. Trend Assumptions

As this is not medical insurance, an explicit medical cost trend is not included in the projections.

15. Demonstration of Satisfaction of Loss Ratio Requirements

This filing uses the nationwide pooled experience of the 515, 700, and 780 Series. The pooled experience is appropriate as the forms have similar benefits, it is consistent with how MedAmerica manages the business, and combining experience increases credibility.

Address: 165 Court Street, Rochester, New York 14647

Actuarial Memorandum

July 28, 2021

Exhibit I provides actual and projected experience using current assumptions. Actual experience is provided from inception through 2019 and then projected on a seriatim basis for 50 years using the current assumptions described above in Section 6. The actual and projected experience is based on nationwide premiums that reflect prior rate increases filed for use between January 2014 and April 2020, which average 34% across all jurisdictions and series. The after increase projected experience reflects the additional increase needed to achieve the cumulative increase by series and inflation protection option (shown in Section 2) on a seriatim basis.

Values in Exhibit I are shown (a) before and (b) after the nationwide requested rate increase. Included are calendar year earned premiums, incurred claims, end of year lives, and annual loss ratios. As shown in Exhibit I-b, the anticipated lifetime loss ratio with the nationwide requested rate increase exceeds the minimum loss ratio required by pre-rate stability regulation.

For cohorts where a rate increase is being requested (i.e., auto inflation) and in aggregate, the following table demonstrates that the nationwide lifetime loss ratios by series and inflation protection option also exceed the minimum loss ratio required by pre-rate stability regulation. The 'All' row corresponds to that shown in Exhibit I.

Nationwide Lifetime Loss Ratios at the Maximum Valuation Interest Rate

by Series and initiation Protection Option							
Series	Inflation Protection Option	Before Increase	After Increase				
	Non-Auto	60%	60%				
All	Auto	113	102				
	All	90	84				
	Non-Auto	60	60				
515	Auto	115	104				
	All	92	86				
	Non-Auto	81	81				
700	Auto	93	80				
	All	88	80				
	Non-Auto	58	58				
780	Auto	108	102				
	All	81	79				

Exhibit II provides a demonstration that the nationwide requested rate increase meets the 58%/85% test required by post-rate stability regulation. This exhibit shows that the sum of the accumulated value of incurred claims without the inclusion of active life reserves, and the present value of projected incurred claims, without the inclusion of active life reserves, will not be less than the sum of the following:

- 1. Accumulated value of the initial earned premium times 58%,
- 2. 85% of the accumulated value of prior premium rate schedule increases,
- 3. Present value of projected initial earned premium times 58%, and
- 4. 85% of the present value of projected premium in excess of the projected initial earned premium.

The projected incurred claims in Exhibit II were increased by 15% from the current assumptions described in Section 6 to reflect assumptions that include moderately adverse conditions.

The following table demonstrates that the 58%/85% test is passed by series and inflation protection option. The 'All' row corresponds to that shown in Exhibit II. Dollar values in the table are shown in millions.

Address: 165 Court Street, Rochester, New York 14647

Actuarial Memorandum

July 28, 2021

Nationwide 58%/85% Test by Series and Inflation Protection Option

	y consecuted inflation i rottottion option						
Series	Inflation Protection Option	Item 5 ^[1]	Item 7 ^[2]	Result ^[3]			
	Non-Auto	\$91.1	\$99.6	Pass			
All	Auto	124.9	230.3	Pass			
	All	216.0	329.8	Pass			
	Non-Auto	69.0	73.7	Pass			
515	Auto	101.8	188.8	Pass			
	All	170.8	262.5	Pass			
	Non-Auto	3.2	4.7	Pass			
700	Auto	6.2	9.1	Pass			
	All	9.5	13.8	Pass			
	Non-Auto	18.9	21.1	Pass			
780	Auto	16.9	32.4	Pass			
	All	35.8	53.5	Pass			

- [1] Item 5 is the Lifetime Earned Premium Times Prescribed Factor.
- [2] Item 7 is Lifetime Incurred Claims with Rate Increase.
- [3] Test of whether Item 7 is not less than Item 5.

16. Actual-to-Expected Experience

The following table provides a comparison of actual and projected nationwide experience using current assumptions to that expected using original pricing assumptions. Values in the following table are shown (a) before and (b) after the nationwide requested rate increase.

Nationwide Actual and Expected Loss Ratios by Series and Inflation Protection Option

by defies and inflation i folection option							
	Inflation	Li	fetime Loss R	Actual-to-Expected			
	Protection	Before	After		Before	After	
Series	Option	Increase	Increase	Expected	Increase	Increase	
	Non-Auto	58%	58%	59%	0.98	0.98	
All	Auto	107	98	60	1.78	1.62	
	All	85	80	59	1.43	1.35	
	Non-Auto	57	57	60	0.95	0.95	
515	Auto	110	100	61	1.79	1.62	
	All	87	82	61	1.44	1.35	
	Non-Auto	79	79	54	1.45	1.45	
700	Auto	88	76	55	1.59	1.37	
	All	85	77	55	1.54	1.40	
	Non-Auto	55	55	53	1.04	1.04	
780	Auto	100	94	56	1.78	1.67	
	All	75	73	54	1.39	1.35	

Actual and projected experience in the above table is identical to that described in Exhibit I, except historical experience is accumulated at MedAmerica's actual historical earned interest rates, which average 5.2% for this block, and projected experience is discounted at MedAmerica's current most-likely interest rate assumption of 4.5%. This 4.5% rate represents MedAmerica's expectation of its long-term investment earnings rate based on the average net investment earnings rate projected for MedAmerica's 2019 cash flow testing.

Expected experience uses the actual policies sold and projects from issue on a seriatim basis using the original pricing assumptions for each series or, if not available, the original pricing assumptions from another policy form that was priced during a similar era.

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

Exhibit III provides a comparison of the current and original pricing assumptions that underlie the actual and expected experience described above.

17. History of Previous Rate Revisions

Please see the enclosed cover letter, which provides the jurisdiction-specific average prior rate increase history for the above-listed form(s). Section 2 above describes the nationwide average prior rate increase across the pooled experience.

18. Analysis Performed to Consider a Rate Increase

For cohorts where a rate increase is being requested (i.e., auto inflation) and in aggregate, the experience table in Section 16 above demonstrates that experience has been more adverse from that expected using original pricing assumptions as the A:E loss ratios exceed 1.0. The adverse experience is due to a combination of higher persistency and lower interest.

The following table provides a comparison of actual and projected nationwide experience to that expected in pricing with respect to morbidity, mortality, lapse (combination of voluntary lapse and benefit expiry), interest, and improvement. The current and original pricing assumptions are provided in Exhibit III.

Impact of Changing from Pricing to Current Assumptions

impact of entanging from thomas to earterity toothing to						
	Lifetime Loss Ratio	Incremental Impact on the	Increase			
Scenario	(LLR)	LLR ^[1]	Needed ^[2]			
Original pricing assumptions	59%	N/A	N/A			
Historical experience through 2019 & projections with pricing assumptions ^[3]	65	10%	113%			
Historical experience through 2019 & projections w	vith pricing assum	ptions, except for	current:			
Interest	69	5	55			
Interest, lapse	76	10	98			
Interest, lapse, mortality	89	18	145			
Interest, lapse, mortality, morbidity	87	-3	-22			
Interest, lapse, mortality, morbidity, improvement	85	-2	-14			
Historical experience through 2019 & projections with all current most-likely assumptions ^[4]	85	43	338			

^[1] Calculated as the ratio of the lifetime loss ratio in a given row to that in the row immediately above it less one.

For the 515 Series, in 2013, a nationwide requested increase was determined such that the company was able to certify that rates would remain stable under moderately adverse experience (MAE). The company's threshold for MAE was defined as a lifetime loss ratio of 85%. To determine whether experience has deteriorated beyond this threshold, experience was restated to reflect the timing and rate level of the 2013 requested increase and projected using current most-likely assumptions. As the resulting lifetime loss ratio was 88%, the MAE threshold was crossed and additional rate increases could be considered. A comparison of the current assumptions used in this filing and the assumptions used in the 2013 nationwide request is provided in Exhibit IV.

For the 700 and 780 Series, an analysis of the projected loss ratio compared to that assumed at the time of original pricing revealed that experience has unfolded more than moderately adverse and crossed the original pricing threshold for which the company could consider a rate increase.

Documentation of the original pricing definition for moderately adverse experience is not explicitly stated for the 700 and 780 Series. However, the original pricing documentation for the 700 and 780 Series

^[2] Shows the rate increase needed to reproduce the lifetime loss ratio in the row immediately above it. Calculated without regard to CBUL, RBO, adverse selection, and higher waiver claims due to the needed rate increase.

^[3] This row reflects actual historical experience and pricing assumptions projected from the valuation date, reflecting prior rate increases filed for use between January 2014 and April 2020.

^[4] This row is calculated in regards to the pricing lifetime loss ratio of 59%.

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

states that margin of 10% was included in determining statutory contract reserves. This definition of margin is consistent with the MAE definition used by MedAmerica for similar products priced around the same time. Therefore, the assumed original pricing threshold before which a rate increase may be considered is a 10% increase in the original pricing lifetime loss ratio. Section 16 demonstrates that the lifetime loss ratios for cohorts where a rate increase is being requested (i.e., auto inflation), and in aggregate, are well in excess of this assumed original pricing threshold (i.e., before increase A:E exceeds 1.10).

19. Average Annual Premium in Pennsylvania (Based on December 31, 2019 In-Force)

The number of insureds and the corresponding average annual premium that will be affected by this rate increase filing in this jurisdiction are shown in the table(s) below by series and inflation protection option.

Pennsylvania - MedAmerica

1 omioyivama moazmonoa				
Series	Inflation Protection Option	Number of Insureds	Before Increase Premium ^[1]	After Requested Increase Premium ^[1]
	Non-Auto	75	\$851	\$851
515	Auto	93	1,924	2,338
	All	168	1,445	1,674
	Non-Auto	33	1,006	1,006
780	Auto	21	2,061	2,061
	All	54	1,416	1,416
	Non-Auto	108	898	898
Total	Auto	114	1,949	2,287
	All	222	1,438	1,611

^[1] Premium reflects all prior rate increases filed for use, including the most recent increase filed on August 21, 2020.

20. Proposed Effective Date

This rate increase will apply to policies on their next premium payment date following at least a 60-day policyholder notification period after being filed for use by the department of insurance, but no sooner than 12 months after the prior increase was effective.

21. Distribution of Business as of December 31, 2019 (Based on Nationwide In-Force Insured Count)

	Percent
Issue Ages	Distribution
<40	1%
40-44	2
45-49	4
50-54	12
55-59	17
60-64	33
65-69	25
70-74	6
75+	1

Address: 165 Court Street, Rochester, New York 14647

Actuarial Memorandum

July 28, 2021

	Percent
Elimination Period	Distribution
20-Day	15%
30-Day	9
60-Day	3
90-Day	70
180-Day	3

	Percent
Benefit Period	Distribution
400 Days	9%
800 Days	21
1200 Days	31
1600 Days	20
Lifetime	20

Inflation	Percent	
Protection Option	Distribution	
None	49%	
5% Compound for Life	51	

	Percent
Coverage Type	Distribution
Facility Only	<1%
Comprehensive	99
Home Health Only	1

22. Number of Insureds and Annualized Premium (Based on December 31, 2019 In-Force)

The number of insureds and annualized premium that will be affected by this rate increase filing in this jurisdiction and nationwide are shown in the tables below by series and inflation protection option.

Pennsylvania – MedAmerica

Series	Inflation Protection Option	Number of Insureds	Annualized Premium ^[1]
	Non-Auto	75	\$63,847
515	Auto	93	178,894
	All	168	242,741
	Non-Auto	33	33,188
780	Auto	21	43,279
	All	54	76,466
	Non-Auto	108	97,035
Total	Auto	114	222,173
	All	222	319,208

^[1] Premium reflects all prior rate increases filed for use, including the most recent increase filed on August 21, 2020.

Address: 165 Court Street, Rochester, New York 14647

Actuarial Memorandum

July 28, 2021

Nationwide - MedAmerica, CICA, and CLICNY

Series	Inflation Protection Option	Number of Insureds	Annualized Premium
	Non-Auto	1,528	\$1,764,856
515	Auto	2,038	3,779,244
	All	3,566	5,544,099
	Non-Auto	115	130,777
700	Auto	139	257,429
	All	254	388,205
	Non-Auto	924	924,427
780	Auto	474	803,589
	All	1,398	1,728,016
	Non-Auto	2,567	2,820,059
Total	Auto	2,651	4,840,262
	All	5,218	7,660,321

Address: 165 Court Street. Rochester. New York 14647

Actuarial Memorandum

July 28, 2021

23. Actuarial Certification

I am a Principal and Consulting Actuary for Milliman, Inc. and retained by MedAmerica to render an opinion with regard to long-term care insurance rates. I am a member of the American Academy of Actuaries. I meet the Academy's qualification standards to render this actuarial opinion and am familiar with the requirements for filing long-term care insurance premiums and rate increases.

This memorandum has been prepared in conformity with all applicable Actuarial Standards of Practice, including Actuarial Standards of Practice No. 8, "Regulatory Filings for Health Benefits, Accident and Health Insurance, and Entities Providing Health Benefits" and 18, "Long-Term Care Insurance".

I hereby certify that, to the best of my knowledge and judgment, this rate submission is in compliance with the applicable laws and regulations of this jurisdiction and the rules of this department of insurance.

In my opinion, the rates are not excessive or unfairly discriminatory, and bear reasonable relationship to the benefits based on the loss ratio standards of this jurisdiction.

This filing will enhance premium adequacy, but may not be sufficient to prevent future rate action. Additional rate increases are needed to certify that rates will remain stable under moderately adverse conditions.

In forming my opinion, I have used actuarial assumptions and actuarial methods (which gave consideration to policy design, underwriting, and claim adjudication) and such tests of the actuarial calculations as I considered necessary. Based on these assumptions, or statutory requirements where necessary, the premium rate filing is in compliance with the loss ratio standards of this jurisdiction. Certain models were developed to estimate future experience, which I have reviewed for consistency, reasonableness, and appropriateness to the intended purpose.

I have relied on data and information provided by MedAmerica to develop this memorandum, including but not limited to management's view of when a rate change may be considered, policy design, underwriting and claim adjudication process, seriatim in-force data, claim data, and the company's long-term earnings rate. I have not audited or independently verified the data and information provided, but have reviewed it for reasonableness.

The basis for contract reserves has been previously filed and there is no anticipation of any changes.

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

Date: July 28, 2021

Exhibit I-a MedAmerica, CICA, and CLICNY

Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Before Requested Rate Increase 515, 700, and 780 Series

			Without Interest			<u> </u>	With Max. Val. Intere	st
		A		C = B / A	D	E	F	G = F / E
	Calendar	Earned	Incurred	Incurred	End of Year	Earned	Incurred	Incurred
	Year	Premium	Claims	Loss Ratio	Lives	Premium	Claims	Loss Ratio
	1997 1998	1,404 365,019	0	0% 0%	23 789	3,781 940,408	0	0%
	1998	1,714,718	43,198	3%	789 2,811	4,227,432	106,500	0% 3%
	2000	3,840,098	190,025	5%	4,181	9,059,620	448,311	5%
	2001	5,786,651	263,180	5%	6,197	13,064,074	594,161	5%
	2002	8,213,556	587,804	7%	8,017	17,744,604	1,269,894	7%
	2003	9,337,136	266,048	3%	8,572	19,303,340	550,021	3%
	2004	9,694,462	1,042,726	11%	8,787	19,179,012	2,062,873	11%
Historical	2005	10,104,171	3,021,107	30%	9,506	19,128,763	5,719,424	30%
Experience	2006	11,387,255	2,720,509	24%	10,611	20,500,746	4,928,561	24%
	2007	12,244,848	1,713,599	14%	10,739	20,972,409	2,960,391	14%
	2008 2009	12,052,895 11,306,015	2,416,335 4,304,209	20% 38%	10,226 9,441	19,747,891 17,749,874	4,003,251 6,786,527	20% 38%
	2010	10,575,892	3,171,158	30%	8,931	15,908,766	4,817,510	30%
	2011	10,015,916	5,732,652	57%	8,507	14,432,945	8,328,009	58%
	2012	9,547,964	4,077,497	43%	8,133	13,179,271	5,663,557	43%
	2013	9,065,895	5,684,574	63%	7,792	11,987,391	7,548,949	63%
	2014	8,562,633	5,600,353	65%	7,110	10,845,051	7,115,112	66%
	2015	8,387,584	5,775,336	69%	6,644	10,176,424	7,021,172	69%
	2016	8,278,673	8,185,005	99%	6,272	9,621,867	9,542,664	99%
	2017	7,919,269	8,918,678	113%	5,963	8,816,543	9,944,552	113%
	2018 2019	7,507,743 7,146,613	9,056,385 8,884,266	121% 124%	5,592 5,218	8,006,847 7,301,553	9,668,759 9,080,612	121% 124%
	2020	6,977,166	9,254,664	133%	4,894	6,829,203	9,060,012	133%
	2021	6,764,897	9,927,055	147%	4,623	6,343,777	9,299,633	147%
	2022	6,417,962		166%	4,358	5,766,347	9,545,784	166%
	2023	6,002,414	11,340,106	189%	4,091	5,167,475	9,739,649	188%
	2024	5,587,385	11,997,014	215%	3,825	4,609,375	9,867,026	214%
	2025	5,176,757	12,586,651	243%	3,561	4,092,674	9,913,858	242%
	2026	4,772,774	13,091,902	274%	3,300	3,616,383	9,876,301	273%
	2027 2028	4,378,018	13,496,452	308%	3,044	3,179,628	9,752,559	307%
	2028	3,994,798 3,625,381	13,803,855 14,010,449	346% 386%	2,794 2,552	2,781,201 2,419,776	9,555,621 9,292,415	344% 384%
	2030	3,271,760	14,160,191	433%	2,319	2,093,788	8,999,652	430%
	2031	2,935,373	14,239,913	485%	2,095	1,801,320	8,673,386	482%
Projected	2032	2,617,910	14,200,275	542%	1,884	1,540,647	8,289,732	538%
Future	2033	2,321,129	14,064,547	606%	1,685	1,310,120	7,869,749	601%
Experience	2034	2,046,241	13,846,714	677%	1,499	1,107,829	7,426,567	670%
(50 Years)	2035	1,793,960	13,545,960	755%	1,327	931,690	6,964,280	747%
	2036	1,564,494	13,166,734	842%	1,170	779,490	6,488,878	832%
	2037 2038	1,357,542		938%	1,027 897	648,937	6,013,142 5,545,795	927%
	2039	1,172,302 1,007,679	12,244,106 11,710,034	1,044% 1,162%	781	537,693 443,500	5,085,159	1,031% 1,147%
	2040	862,278	11,119,843	1,290%	677	364,186	4,630,308	1,271%
	2041	734,653	10,490,685	1,428%	584	297,774	4,189,040	1,407%
	2042	623,290	9,833,324	1,578%	502	242,466	3,765,722	1,553%
	2043	526,615	9,160,588	1,740%	430	196,621	3,364,929	1,711%
	2044	443,091	8,493,978	1,917%	367	158,791	2,993,044	1,885%
	2045	371,271	7,835,507	2,110%	312		2,648,965	2,074%
	2046	309,819	7,194,366	2,322%	264	102,305	2,333,638	2,281%
	2047	257,539	6,574,400	2,553%	223	81,637	2,046,386	2,507%
	2048 2049	213,306 176,086	5,988,347 5,439,560	2,807% 3,089%	188 158	64,913 51,446	1,789,033 1,560,121	2,756% 3,033%
	2050	144,936	4,921,908	3,396%	132	40,657	1,355,867	3,335%
	2051	119,003	4,455,299	3,744%	110		1,179,338	3,679%
	2052	97,509	4,025,526	4,128%	92	25,222	1,024,372	4,061%
	2053	79,774	3,624,331	4,543%	77	19,817	886,918	4,475%
	2054	65,188	3,257,380	4,997%	64	15,554	766,994	4,931%
	2055	53,226	2,915,707	5,478%	53	12,200	660,720	5,416%
	2056	43,425	2,583,687	5,950%	44	9,562	563,163	5,890%
	2057	35,390	2,264,993	6,400%	36	7,486	474,602	6,340%
	2058 2059	28,805 23,412	1,971,449 1,702,242	6,844% 7,271%	30 24	5,854 4,570	396,750 328,795	6,778% 7,194%
	2059	64,182		8,412%	69	11,305	933,312	7,194% 8,256%
	2065-2069	19,428	2,076,263	10,687%	21	2,781	290,940	10,461%
		11,120	_,,_00	, 7 70				,.5170
His	tory	183,056,412	81,654,645	45%	160,062	291,898,613	108,160,812	37%
Fut	1	79,078,168	375,385,522	475%	56,185	57,875,770	205,437,458	355%
ı Lifot	time	262,134,581	457,040,167	174%	216,247	349,774,383	313,598,270	90%

Actuarial Memorandum **Exhibits**

Exhibit I-b

MedAmerica, CICA, and CLICNY

Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience After Requested Rate Increase 515, 700, and 780 Series

		Without Interest				With Max. Val. Interest				
		Α	В	C = B / A	D	Е		G = F / E		
	Calendar	Earned	Incurred	Incurred	End of Year	Earned		Incurred		
-	Year 1997	Premium 1,404	Claims 0	Loss Ratio 0%	Lives 23	Premium 3,781	Claims 0	Loss Ratio 0%		
	1998	365,019	0	0%	789	940,408	0			
	1999	1,714,718	43,198	3%	2,811	4,227,432		3%		
	2000	3,840,098	190,025	5%	4,181	9,059,620		5%		
	2001	5,786,651	263,180	5%	6,197	13,064,074	594,161	5%		
	2002	8,213,556	587,804	7%	8,017	17,744,604	1,269,894	7%		
	2003	9,337,136	266,048	3%	8,572	19,303,340	550,021	3%		
	2004	9,694,462	1,042,726	11%	8,787	19,179,012		11%		
Historical	2005	10,104,171	3,021,107	30%	9,506	19,128,763	5,719,424	30%		
Experience	2006 2007	11,387,255	2,720,509	24% 14%	10,611 10,739	20,500,746 20,972,409	,,	24% 14%		
	2007	12,244,848 12,052,895	1,713,599 2,416,335	20%	10,739	19,747,891	2,960,391 4,003,251	20%		
	2009	11,306,015	4,304,209	38%	9,441	17,749,874	6,786,527	38%		
	2010	10,575,892	3,171,158	30%	8,931	15,908,766	4,817,510	30%		
	2011	10,015,916	5,732,652	57%	8,507	14,432,945		58%		
	2012	9,547,964	4,077,497	43%	8,133	13,179,271	5,663,557	43%		
	2013	9,065,895	5,684,574	63%	7,792	11,987,391	7,548,949	63%		
	2014	8,562,633	5,600,353	65%	7,110	10,845,051	7,115,112			
	2015	8,387,584	5,775,336	69%	6,644	10,176,424	7,021,172			
	2016	8,278,673	8,185,005	99%	6,272	9,621,867	9,542,664	99%		
	2017	7,919,269	8,918,678	113%	5,963	8,816,543	9,944,552			
	2018	7,507,743	9,056,385	121%	5,592	8,006,847	9,668,759 9.080.612	121%		
	2019 2020	7,146,613 6,977,166	8,884,266 9,254,664	124% 133%	5,218 4,894	7,301,553 6,829,203	9,080,612	124% 133%		
	2020	6,909,184	9,849,447	143%	4,694 4,546	6,479,000	9,055,314			
	2022	7,361,442	10,091,113	137%	4,198	6,613,054	9,051,649	137%		
	2023	7,056,560	10,637,623	151%	3,939	6,073,437	9,136,952			
	2024	6,574,005	11,236,779	171%	3,682	5,421,463	9,242,661	170%		
	2025	6,095,176	11,772,845	193%	3,427	4,816,714	9,274,038	193%		
	2026	5,623,055	12,229,953	217%	3,175	4,258,449	9,227,530	217%		
	2027	5,160,768	12,594,132	244%	2,927	3,745,823	9,102,315			
	2028	4,711,122	12,868,837	273%	2,686	3,277,578	8,910,440	272%		
	2029	4,276,928	13,050,074	305%	2,453	2,852,334	8,657,818	304%		
	2030	3,860,716	13,179,075	341%	2,228	2,468,430	8,378,759	339%		
Drainatad	2031	3,464,342	13,244,633	382%	2,013	2,123,750	8,070,112			
Projected Future	2032 2033	3,089,924 2,739,675	13,201,105 13,068,688	427% 477%	1,809 1,617	1,816,369 1,544,440	7,709,616 7,315,882			
Experience	2034	2,415,140	12,860,091	532%	1,439	1,305,782		528%		
(50 Years)	2035	2,117,220	12,575,465	594%	1,274	1,097,966		589%		
,	2036	1,846,195	12,218,557	662%	1,123	918,397	6,025,265			
	2037	1,601,745	11,807,555	737%	985	764,384	5,582,056			
	2038	1,382,961	11,355,796	821%	860	633,178	5,147,153	813%		
	2039	1,188,542	10,857,726	914%	748	522,106	4,718,722	904%		
	2040	1,016,846	10,309,616	1,014%	648	428,604	4,296,563	1,002%		
	2041	866,175	9,726,704	1,123%	560	350,340	3,887,537	1,110%		
	2042	734,737	9,118,703	1,241%	481	285,183	3,495,506	1,226%		
	2043	620,667	8,497,161	1,369%	412	231,197	3,124,544	1,351%		
	2044 2045	522,147 437,464	7,882,078 7,274,586	1,510% 1,663%	352 299	186,667 150,103	2,780,566 2,462,278	1,490% 1,640%		
	2046	365,029	6,682,183	1,831%	299 253	120,218				
	2047	303,417	6,109,506	2,014%	214	95,918		1,985%		
	2048	251,297	5,568,840	2,216%	180	76,259	1,665,957	2,185%		
	2049	207,444	5,062,725	2,441%	151	60,432		2,406%		
	2050	170,747	4,585,302	2,685%	126	47,755		2,649%		
	2051	140,195	4,154,399	2,963%	106	37,647	1,101,326	2,925%		
	2052	114,869	3,757,297	3,271%	88	29,620		3,233%		
	2053	93,971	3,386,812	3,604%	73	23,270				
	2054	76,779	3,047,468	3,969%	61	18,261	718,778	3,936%		
	2055	62,674	2,730,603	4,357%	50	14,318		4,329%		
	2056	51,111	2,421,726	4,738%	42	11,216		4,715%		
	2057	41,623 33,844	2,124,447 1,849,942	5,104% 5,466%	34 28	8,774 6,853	446,025 373,074	5,083% 5,444%		
	2058 2059	27,473	1,597,570	5,466% 5,815%	28	6,853 5,343	373,074 309,266	5,444% 5,788%		
	2060-2064	74,972	5,071,137	6,764%	66	13,154	878,890	6,681%		
	2065-2069	22,436	1,958,505	8,729%	20	3,197		8,611%		
		22,100	.,555,500	5,. 2570	20	3,107	2. 3,201	0,0.170		
	tory	183,056,412	81,654,645	45%	160,062	291,898,613				
	ure	90,687,780	350,871,471	387%	54,291	65,766,185				
Life:	time	273,744,192	432,526,115	158%	214,353	357,664,798	300,909,334	84%		

Actuarial Memorandum **Exhibits**

Exhibit II Demonstration that the Requested Cumulative Rate Increase Passes the 58%/85% Loss Ratio Minimum MedAmerica, CICA, and CLICNY Nationwide Experience with Prior Approved Increases 515, 700, and 780 Series

1 Accumulated value of initial earned premium	286,353,220 x	58%	=	166,084,867
2a Accumulated value of earned premium 2b Accumulated value of prior premium rate schedule increases (2a - 1)	291,898,613 5,545,393 x	85%	=	4,713,584
3 Present value of future projected initial earned premium	39,547,147 x	58%	=	22,937,345
4a Present value of future projected premium 4b Present value of future projected premium in excess of the projected initial earned premiums (4a - 3)	65,766,185 26,219,038 x	85%	=	22,286,182
5 Lifetime Earned Premium Times Prescribed Factor: Sum of 1, 2b, 3, and 4b				216,021,979
6a Accumulated value of incurred claims without the inclusion of active life reserves 6b Present value of future projected incurred claims without the inclusion of active life reserves				108,160,812 221,660,800
7 Lifetime Incurred Claims with Rate Increase: Sum 6a and 6b				329,821,612
8 Test: 7 is not less than 5				Pass
All values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue, which ranges from 4.0% to 4.5%. Future projected initial earned premium schedule (i.e., without the requested rate increase) reflects the assumed impact of CBUL and RBO. The future projected incurred claims (item 6b) were increased by 15% to reflect assumptions with moderately adverse experience.				

Actuarial Memorandum Exhibits

Exhibit III

MedAmerica, CICA, and CLICNY

Comparison of Current and Original Pricing Assumptions

		Morbidity
Current Assumptions	All CICA	Expected claim costs are developed using the 2017 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for underwriting selection, an all-lives exposure basis, and two years of retrospective improvement to bring the Guidelines forward to 2019. The claim costs were further adjusted based on historical claim experience by series, attained age, coverage type, benefit period (non-lifetime vs. lifetime), and payment type, to the extent credible. These adjustment factors can be found in Exhibit A-5a of Appendix A of the actuarial memorandum.
Original Assumptions	All CICA	The pricing claim costs were developed from the 1997 Guidelines. All values were adjusted to reflect the effects of the nature of the benefits, the elimination periods, policy maximums, and the eligibility standards. The claim costs include factors to adjust them to an all-lives exposure base. These claim costs do not necessarily represent the original pricing claim costs because MedAmerica did not receive the original pricing claim costs at the time of acquisition. These claim costs are a reasonable proxy of the original pricing claim costs based on a reproduction of the original pricing lifetime loss ratio.
		Mortality
Current Assumptions	All CICA	Mortality rates reflect the 2012 Individual Annuitant Mortality (IAM) Basic table. The mortality rates were adjusted based on historical mortality experience by gender, marital status, attained age, and duration. The adjusted 2012IAM table was then brought forward to 2019 using the 2012IAM attained age mortality improvement scale (i.e., G2 projection scale). These adjustment factors can be found in Exhibit A-1a and A-1c of Appendix A of the actuarial memorandum.
Original	515 Series and 700 Series Not Issued in Florida	Ultimate mortality level of 95% of U.S. Life Mortality (79-81). While the original pricing selection factors were not available, selection factors grading from 50% to 95% over the first 10 durations were assumed.
Assumptions	700 Series Issued in Florida and 780 Series	1983 GAM Table without selection.
		Lapse Rates
Current Assumptions	All CICA	Voluntary lapse rates (excludes benefit expiry) vary by policy duration (ultimate for 11+), attained age (ultimate for 65+), benefit period (lifetime or non-lifetime), inflation protection (auto or non-auto inflation), marital status, and series. A summary of the ultimate lapse rates by key characteristics can be found in Section 6 of the actuarial memorandum.

Exhibit III MedAmerica, CICA, and CLICNY Comparison of Current and Original Pricing Assumptions

								Lapse	Rates							
		Lapse rates vary by policy for	orm series, dur	ation, and issue	age.			· ·								
ļ					E Caris - /h' '	Incured to NI.	Vauls					E1E 0 '	(leaved in At	w Verl-\		
l				51		Issued in New sue Age	YORK)			515 Series (Issued in New York) Issue Age						
ļ		Duration	<55	55-59	60-64	65-69	70-74	75-79	80+	<55	55-59	60-64	65-69	70-74	75-79	80+
ļ		1	20.00%	18.00%	18.00%	18.00%	14.00%	12.00%	10.00%	20.00%	18.00%	16.00%	14.00%	12.00%	10.00%	10.00%
ļ		2	16.00%	15.00%	15.00%	15.00%	12.00%	10.00%	8.00%	15.00%	14.00%	12.00%	10.00%	8.00%	6.00%	6.00%
ļ		3	13.00%	12.00%	12.00%	12.00%	10.00%	9.00%	7.00%	10.00%	10.00%	9.00%	6.00%	6.00%	4.00%	4.00%
ļ		4	11.00%	10.00%	10.00%	10.00%	9.00%	8.00%	7.00%	8.00%	8.00%	6.00%	5.00%	4.00%	3.00%	3.00%
ļ		5	10.00%	9.00%	9.00%	9.00%	8.00%	7.00%	6.00%	6.00%	6.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		6	10.00%	9.00%	8.00%	8.00%	7.00%	7.00%	6.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		7	10.00%	9.00%	8.00%	7.00%	6.00%	6.00%	5.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ	515 Series	8 9	9.00%	8.00% 8.00%	8.00% 7.00%	7.00% 7.00%	6.00% 5.00%	6.00% 5.00%	5.00% 4.00%	5.00% 5.00%	5.00% 5.00%	4.00% 4.00%	4.00% 4.00%	3.00%	3.00% 3.00%	3.00% 3.00%
ļ		10	9.00%	8.00%	7.00%	6.00%	5.00%	5.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		11	8.00%	8.00%	7.00%	6.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		12	8.00%	7.00%	6.00%	6.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		13	8.00%	7.00%	6.00%	5.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		14	7.00%	7.00%	6.00%	5.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		15	7.00%	6.00%	6.00%	5.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		16	6.00%	6.00%	6.00%	4.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		17	6.00%	6.00%	5.00%	4.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		18	5.00%	5.00%	5.00%	4.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		19	5.00%	5.00%	5.00%	4.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		20+	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	5.00%	5.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ				-	OO Cariaa /N	ot Issued in Flor	rida\					700 Carias	/leased in F	larida\		
ļ						sue Age	iua)			700 Series (Issued in Florida) Issue Age						
ļ		Duration	<55	55-59	60-64	65-69	70-74	75-79	80+	<55	55-59	60-64	65-69	70-74	75-79	80+
ļ		1	20.00%	18.00%	18.00%	18.00%	14.00%	12.00%	10.00%	20.00%	18.00%	18.00%	18.00%	14.00%	12.00%	10.00%
ļ		2	16.00%	15.00%	15.00%	15.00%	12.00%	10.00%	8.00%	16.00%	15.00%	15.00%	15.00%	12.00%	10.00%	8.00%
jinal		3	13.00%	12.00%	12.00%	12.00%	10.00%	9.00%	7.00%	13.00%	12.00%	12.00%	12.00%	10.00%	9.00%	7.00%
umptions		4	11.00%	10.00%	10.00%	10.00%	9.00%	8.00%	7.00%	11.00%	10.00%	10.00%	10.00%	9.00%	8.00%	7.00%
l		5	10.00%	9.00%	9.00%	9.00%	8.00%	7.00%	6.00%	10.00%	9.00%	9.00%	9.00%	8.00%	7.00%	6.00%
ļ		6	10.00%	9.00%	8.00%	8.00%	7.00%	7.00%	6.00%	10.00%	9.00%	8.00%	8.00%	7.00%	7.00%	6.00%
l	700 Series	7	10.00%	9.00%	8.00%	7.00%	6.00%	6.00%	5.00%	10.00%	9.00%	8.00%	7.00%	6.00%	6.00%	5.00%
l		8	9.00%	8.00%	8.00%	7.00%	6.00%	6.00%	5.00%	9.00%	8.00%	8.00%	7.00%	6.00%	6.00%	5.00%
ļ		9	9.00%	8.00%	7.00%	7.00%	5.00%	5.00%	4.00%	9.00%	8.00%	7.00%	7.00%	5.00%	5.00%	4.00%
ļ		10	9.00%	8.00%	7.00%	6.00%	5.00%	5.00%	4.00%	9.00%	8.00%	7.00%	6.00%	5.00%	5.00%	4.00%
ļ		11 12	8.00% 7.00%	8.00%	7.00% 6.00%	6.00%	4.00% 4.00%	4.00% 4.00%	4.00% 4.00%	8.00%	8.00% 7.00%	7.00%	6.00%	4.00% 4.00%	4.00% 4.00%	4.00% 4.00%
ļ		13	6.00%	7.00% 6.00%	6.00%	6.00% 5.00%	4.00%	4.00%	4.00%	7.00% 6.00%	6.00%	6.00%	5.00%	4.00%	4.00%	4.00%
ļ		13	5.00%	5.00%	5.00%	5.00%	4.00%	4.00%	4.00%	5.00%	5.00%	5.00%	5.00%	4.00%	4.00%	4.00%
ļ		15+	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	3.00%	3.00%	3.00%
ļ		10.1														
ļ					780	0 Series										
ļ		1 1				sue Age										
ļ		I				65-69	70-74	75-79	+08							
		Duration	<55	55-59	60-64											
Ì		1	17.00%	15.00%	15.00%	15.00%	12.00%	10.00%	8.00%							
		1 2	17.00% 13.00%	15.00% 12.00%	15.00% 12.00%	15.00% 12.00%	12.00% 10.00%	8.00%	6.00%							
		1	17.00% 13.00% 11.00%	15.00% 12.00% 10.00%	15.00% 12.00% 10.00%	15.00% 12.00% 10.00%	12.00% 10.00% 8.00%	8.00% 8.00%	6.00% 6.00%							
		1 2	17.00% 13.00% 11.00% 10.00%	15.00% 12.00% 10.00% 9.00%	15.00% 12.00% 10.00% 9.00%	15.00% 12.00% 10.00% 9.00%	12.00% 10.00% 8.00% 8.00%	8.00% 8.00% 7.00%	6.00% 6.00% 6.00%							
		1 2 3 4	17.00% 13.00% 11.00% 10.00% 9.00%	15.00% 12.00% 10.00% 9.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00%	12.00% 10.00% 8.00% 8.00% 7.00%	8.00% 8.00% 7.00% 6.00%	6.00% 6.00% 6.00% 5.00%							
	780 Series	1 2 3 4 5	17.00% 13.00% 11.00% 10.00%	15.00% 12.00% 10.00% 9.00%	15.00% 12.00% 10.00% 9.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00%	12.00% 10.00% 8.00% 8.00%	8.00% 8.00% 7.00%	6.00% 6.00% 6.00%							
	780 Series	1 2 3 4 5 6	17.00% 13.00% 11.00% 10.00% 9.00% 10.00%	15.00% 12.00% 10.00% 9.00% 8.00% 9.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00%	8.00% 8.00% 7.00% 6.00% 7.00%	6.00% 6.00% 6.00% 5.00% 6.00%							
	780 Series	1 2 3 4 5 6	17.00% 13.00% 11.00% 10.00% 9.00% 10.00%	15.00% 12.00% 10.00% 9.00% 8.00% 9.00% 9.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 7.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00% 6.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00%							
	780 Series	1 2 3 4 5 6 7	17.00% 13.00% 11.00% 10.00% 9.00% 10.00% 10.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00% 9.00% 9.00% 7.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 8.00% 7.00%	15.00% 12.00% 10.00% 9.00% 8.00% 7.00% 6.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00% 6.00% 5.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00% 4.00%							
	780 Series	1 2 3 4 5 6 7 8 9 10 11	17.00% 13.00% 11.00% 10.00% 9.00% 10.00% 40.00% 8.00% 9.00% 9.00% 7.00%	15.00% 12.00% 10.00% 9.00% 8.00% 9.00% 9.00% 7.00% 8.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 8.00% 7.00% 7.00% 6.00%	15.00% 12.00% 10.00% 9.00% 8.00% 7.00% 6.00% 7.00%	12.00% 10.00% 8.00% 8.00% 7.00% 6.00% 5.00% 5.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00% 5.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00% 4.00% 4.00%							
	780 Series	1 2 3 4 5 6 7 8 9 10 11 11 12	17.00% 13.00% 11.00% 10.00% 9.00% 10.00% 8.00% 9.00% 9.00% 7.00%	15.00% 12.00% 10.00% 9.00% 9.00% 9.00% 7.00% 8.00% 8.00% 7.00% 7.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 8.00% 7.00% 7.00% 6.00%	15.00% 12.00% 10.00% 9.00% 8.00% 7.00% 6.00% 7.00% 6.00% 6.00% 6.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00% 5.00% 5.00% 5.00% 4.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00% 5.00% 5.00% 4.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00% 4.00% 4.00% 4.00% 4.00%							
	780 Series	1 2 3 4 5 6 7 8 9 10 11 12 12	17.00% 13.00% 11.00% 10.00% 9.00% 10.00% 8.00% 9.00% 9.00% 7.00% 5.00%	15.00% 12.00% 10.00% 9.00% 8.00% 9.00% 7.00% 8.00% 8.00% 7.00% 7.00% 5.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 7.00% 7.00% 7.00% 6.00% 6.00% 5.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00% 6.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00% 6.00% 5.00% 5.00% 3.00% 4.00% 3.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00% 5.00% 5.00% 3.00% 4.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00% 4.00% 4.00% 4.00% 3.00% 3.00%							
	780 Series	1 2 3 4 5 6 7 8 9 10 11 11 12	17.00% 13.00% 11.00% 10.00% 9.00% 10.00% 8.00% 9.00% 9.00% 7.00%	15.00% 12.00% 10.00% 9.00% 9.00% 9.00% 7.00% 8.00% 8.00% 7.00% 7.00%	15.00% 12.00% 10.00% 9.00% 8.00% 8.00% 8.00% 7.00% 7.00% 6.00%	15.00% 12.00% 10.00% 9.00% 8.00% 7.00% 6.00% 7.00% 6.00% 6.00% 6.00%	12.00% 10.00% 8.00% 8.00% 7.00% 7.00% 5.00% 5.00% 5.00% 4.00%	8.00% 8.00% 7.00% 6.00% 7.00% 6.00% 5.00% 5.00% 5.00% 4.00%	6.00% 6.00% 6.00% 5.00% 6.00% 5.00% 4.00% 4.00% 4.00% 4.00%							

Actuarial Memorandum Exhibits

Exhibit III

MedAmerica, CICA, and CLICNY

Comparison of Current and Original Pricing Assumptions

		Benefit Expiry Rates
Current Assumptions	All CICA	Benefit expiry rates reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the 2017 Guidelines with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age. A table containing the benefit expiry rates is provided in Section 6 of the actuarial memorandum.
Original Assumptions	All CICA	Benefit expiry was not separated from the lapse assumption.
		Interest Rate
Current Assumptions	All CICA	The current most-likely earnings rate assumption is 4.5%. This rate represents MedAmerica's expectation of its long-term investment earnings rate based on the average net investment earnings rate projected for MedAmerica's 2019 cash flow testing. The maximum valuation interest rate applicable to the year of issue ranges from 4.0% to 4.5% and averages 4.4%.
Original	515 Series and 700 Series	An original pricing earnings rate assumption of 6.00% was assumed.
Assumptions	780 Series	An original pricing earnings rate assumption of 5.50% was assumed.
		Improvement
Current Assumptions	All CICA	Annual improvement in the mortality and morbidity assumptions is assumed for 10 years starting in 2020. Annual improvement factors vary by attained age and gender based on the G2 improvement scale from the 2012IAM table.
Original Assumptions	All CICA	No mortality or morbidity improvement was assumed.

Exhibit IV

MedAmerica, CICA, and CLICNY

Comparison of Current and 2013 Nationwide Filing Assumptions for the 515 Series

Current Assumptions

Morbidity

Expected claim costs are developed using the 2017 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for underwriting selection, an all-lives exposure basis, and two years of retrospective improvement to bring the Guidelines forward to 2019. The claim costs were further adjusted based on historical claim experience by series, attained age, coverage type, benefit period (non-lifetime vs. lifetime), and payment type, to the extent credible. These adjustment factors can be found in Exhibit A-5a of Appendix A of the actuarial memorandum.

Expected claim costs were the pricing claim costs adjusted with attained age and durational adjustment factors. These factors were developed based on a comparison of actual and expected historical incurred claims for 515 Series policies issued by Combined Insurance Company of America (CICA) and Combined Life Insurance Company of New York (CLICNY) from inception through December 31, 2012. To develop the attained age adjustment factors, the experience for the 515 Series policies was combined with experience for other similar policies issued by CICA and CLICNY.

2013 Nationwide Filing Assumptions

Allaineu	1
Age	Factor
<75	0.85
75-79	0.98
80+	1.25

Attained

Duration	Factor
1	0.30
2	0.30
3	0.30
4	0.55
5	0.55
6	0.55
7	0.55
8	0.55
9	0.60
10	0.65
11	0.70
12+	0.75

Mortality

Current Assumptions

2013 Nationwide Filing Assumptions Mortality rates reflect the 2012 Individual Annuitant Mortality (IAM) Basic table. The mortality rates were adjusted based on historical mortality experience by gender, marital status, attained age, and duration. The adjusted 2012IAM table was then brought forward to 2019 using the 2012IAM attained age mortality improvement scale (i.e., G2 projection scale). These adjustment factors can be found in Exhibit A-1a and A-1c of Appendix A of the actuarial memorandum.

Levels of 86% and 93% of the 1994 Group Annuitant Mortality (GAM) Static table were assumed for males and females, respectively, in all durations. These levels captured the impact of mortality improvement.

Exhibit IV

MedAmerica, CICA, and CLICNY

Comparison of Current and 2013 Nationwide Filing Assumptions for the 515 Series

Lapse Rates

Current Assumptions

Voluntary lapse rates (excludes benefit expiry) vary by policy duration (ultimate for 11+), attained age (ultimate for 65+), benefit period (lifetime or non-lifetime), inflation protection (auto or non-auto inflation), marital status, and series. A summary of the ultimate lapse rates by key characteristics can be found in Section 6 of the actuarial memorandum.

2013 Nationwide Filing Assumptions Lapse rates were developed using the mortality assumption described above and actual policy termination experience for 515 Series policies issued by CICA and CLICNY from inception through December 31, 2012. Lapse rates varied by duration and are provided in the table below.

	Lapse
Duration	Rate
1	20.0%
2	10.5%
3	6.5%
4	4.5%
5	4.0%
6	3.0%
7	3.0%
8	2.5%
9+	2.0%

Benefit Expiry Rates

Current Assumptions

2013 Nationwide Filing Assumptions Benefit expiry rates reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the 2017 *Guidelines* with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age. A table containing the benefit expiry rates is provided in Section 6 of the actuarial memorandum.

Benefit expiry was not separated from the lapse assumption.

Current Assumptions

.

2013 Nationwide Filing Assumptions

Interest Rate

The current most-likely earnings rate assumption is 4.5%. This rate represents MedAmerica's expectation of its long-term investment earnings rate based on the average net investment earnings rate projected for MedAmerica's 2019 cash flow testing.

The maximum valuation interest rate applicable to the year of issue ranges from 4.0% to 4.5% and averages 4.4%.

The prior earnings rate assumption was 5.25%.

Current Assumptions

2013 Nationwide Filing Assumptions

Improvement

Annual improvement in the mortality and morbidity assumptions is assumed for 10 years starting in 2020. Annual improvement factors vary by attained age and gender based on the G2 improvement scale from the 2012IAM table.

No mortality or morbidity improvement was assumed.

This appendix describes the development of and justification for the current actuarial assumptions used in this filing.

The persistency and morbidity assumptions were developed using historical experience and predictive analytics. Where actual experience was limited or did not exist, industry experience and actuarial judgment was also used. The experience used to develop these assumptions includes historical experience of the policies originally issued by Combined Insurance Company of America and Combined Life Insurance Company of New York (collectively, CICA), which MedAmerica Insurance Company (MedAmerica) acquired from Ace Ltd. in 2008. Additionally, experience on other series originally issued by CICA, MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business is also used. For persistency, policy termination experience from January 2008 through December 2017, with runout through March 2018, was used. For morbidity, claim experience from January 2008 through December 2017 was used, with runout through December 2018.

Improvement assumptions for mortality and morbidity were developed based on individual annuitant or industry experience, along with actuarial judgment. The rate increase dependent assumptions were developed using historical experience, and actuarial judgment where experience was limited or did not exist.

The sections that follow provide more detail on the development of and justification for the current assumptions that are material to the projections in this filing.

Persistency

The policy persistency assumptions were developed based on detailed historical experience from January 2008 through December 2017, with runout through March 2018, for MedAmerica's organic (including affinity partners) and acquired business. Experience adjustment factors were developed using predictive analytics as described in the Predictive Analytics section below.

Mortality

The mortality assumption utilizes the 2012 Individual Annuitant Mortality (IAM) Basic table with experience adjustments.

Exhibit A-1 supports the mortality assumption and provides the following information by marital status, gender, policy duration, and attained age.

- Exhibit A-1a Provides the adjustment factors that are to be applied to the 2012IAM hazard rates; the adjusted
 hazard rates are converted back into mortality probabilities to create the mortality assumption produced by the
 predictive model. Attained age adjustment factors are applicable to only policy durations 7 and later.
- Exhibit A-1b Provides a summary of actual-to-modeled (A:M) mortality experience for all products of MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business.
 - Policy year exposure [A] reflects the length of time a covered life is exposed to the risk of death (i.e., exact exposure basis).
 - Actual deaths [B]
 - Mortality probabilities underlying actual experience [C], 2012IAM [D], and the modeled assumption [E]. The modeled mortality probabilities capture the adjustment factors from Exhibit A-1a that were produced by the predictive model. Mortality probabilities were calculated by first calculating the hazard rate of mortality, then transforming into a probability. For example, the actual mortality probability [C] = 1 EXP(-([B] / [A])).
 - A:M ratios are calculated as actual mortality probabilities to the 2012IAM mortality probabilities [F] and to the
 modeled assumption [G]. The modeled A:M [G] provides an indication of fit. This fit will not be perfect (i.e.,
 ratios deviate from 1.0) because the main goal is to develop an assumption that generalizes well to new
 data by balancing assumption complexity and fit on the historical experience.
- Exhibit A-1c Provides an additional attained age adjustment that was developed to better align the composite termination (i.e., mortality and voluntary lapse combined) assumption with actual experience. Similar to the attained age adjustment factors in Exhibit A-1a, the additional adjustments are applicable to only policy durations 7 and later. The adjustment from Exhibit A-1c is excluded from Exhibit A-1b, but it is included with the composite termination assumptions in Exhibit A-3 described below.

For projection purposes, the adjusted 2012IAM table is brought forward to 2019 using the G2 improvement scale.

Lifetime-Pay Voluntary Lapse Assumption

The voluntary lapse assumption reflects the 2017 cash flow testing voluntary lapse assumption with experience adjustments for attained age, benefit period (lifetime or non-lifetime), inflation protection option (auto or non-auto), marital status, and product cohort.

The attained age adjustment factors developed from the predictive model produced a U-shaped pattern (i.e., decreased and then increased) by attained age. However, the attained age adjustment factors are held constant for ages 65 and older to produce an ultimate voluntary lapse assumption that is constant rather than increasing by attained age. The adjustments are held constant after this point because an increasing attained age lapse trend is not widely used in the industry, and this increasing lapse trend may be due to miscoding a death or underreporting of deaths in the Social Security Death Master File. An additional attained age adjustment to mortality was developed (Exhibit A-1c) in order to capture these terminations (i.e., higher lapses at older attained ages) such that the combined mortality and voluntary lapse assumption better aligns with actual experience as described in Exhibit A-3 below.

The ultimate voluntary lapse probabilities are shown in Section 6 of the actuarial memorandum. These ultimate voluntary lapse probabilities are applicable for attained ages 65 and older at policy durations 11 and later. Only these ultimate voluntary lapse probabilities are material to the projections given the age of this cohort.

Exhibit A-2 supports the voluntary lapse assumption. It provides a comparison of A:M voluntary lapse experience for all products of MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business, and includes the following:

- Policy year exposure [A] reflects the length of time a covered life is exposed to the risk of lapse (i.e., exact exposure basis).
- Actual lapses [B]
- Lapse probabilities underlying actual experience [C], unadjusted [D], and the modeled assumption [E]. The modeled voluntary lapse probabilities capture the assumptions produced by the predictive model (i.e., include the U-shaped attained age adjustments) to demonstrate the fit of the predictive model. The attained age cap is captured with the composite termination assumptions in Exhibit A-3 as described below. Lapse probabilities were calculated by first calculating the hazard rate of lapse, then transforming into a probability. For example, the actual lapse probability [C] = 1 EXP(-([B] / [A])).
- A:M ratios are calculated as actual lapse probabilities to the unadjusted lapse probabilities [F] and the
 modeled assumption [G]. The modeled A:M [G] provides an indication of fit. This fit will not be perfect (i.e.,
 ratios deviate from 1.0) because the main goal is to develop an assumption that generalizes well to new
 data by balancing assumption complexity and fit on the historical experience.

The experience underlying Exhibit A-2 reflects lifetime-pay policies for policy durations 10 and later to focus on the fit of the ultimate voluntary lapse assumption and excludes "shock" lapses. For certain policies there have been prior rate increases and thus the option to lapse with a contingent benefit (i.e., shock lapse). Additionally, some policy forms offered an optional shortened non-forfeiture benefit. Policies that elected one of these options were not counted as a voluntary lapse; however, their annual policy exposure was valued up to the date of election.

Limited-Pay Voluntary Lapse Assumption

All policies in this filing have a lifetime premium payment term. Therefore, limited-pay voluntary lapse probabilities are not applicable to this filing.

Composite Termination

Exhibit A-3 supports the composite termination (i.e., mortality and voluntary lapse combined) assumption. It provides a comparison of actual-to-expected (A:E) composite termination experience for all products of MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business, and includes the following:

 Policy year exposure [A] reflects the length of time a covered life is exposed to the risk of termination (i.e., exact exposure basis).

- Actual composite terminations [B]
- Composite termination probabilities underlying actual experience [C] and the expected assumption [D]. The expected composite termination probabilities capture all of the experience adjustments for mortality (i.e., Exhibits A-1a and A-1c) and voluntary lapse (i.e., attained age cap). Termination probabilities were calculated by first calculating the hazard rate of termination, then transforming into a probability. For example, the actual termination probability [C] = 1 EXP(-([B] / [A])).
- A:E ratios are calculated as actual termination probabilities to the expected composite termination probabilities [E]. The A:E [E] provides an indication of fit. This fit will not be perfect (i.e., ratios deviate from 1.0) because the main goal is to develop an assumption that generalizes well to new data by balancing assumption complexity and fit on the historical experience.

The experience underlying Exhibit A-3 reflects lifetime-pay policies for policy durations 10 and later to focus on the fit of the ultimate composite termination assumption. It also excludes "shock" lapses as described above for Exhibit A-2.

Benefit Expiry

Benefit expiry probabilities reflect assumed policy lapses due to exhaustion of benefits based on the 2017 Milliman *Long-Term Care Guidelines (Guidelines)* with experience adjustments and vary by attained age, gender, and benefit period. Insureds with lifetime benefits do not have an expiry assumption (i.e., probability of 0%). The final benefit expiry assumptions are provided in Section 6 of the actuarial memorandum.

Exhibit A-4 supports the benefit expiry assumption. It provides a comparison of A:E benefit expiry experience for all products of MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business, and includes the following:

- Policy year exposure [A] reflects the length of time a covered life is exposed to the risk of benefit expiry (i.e., exact exposure basis).
- o Actual benefit expiries [B]
- Benefit expiry probabilities underlying actual experience [C], 2017 Guidelines [D], and the expected assumption [E]. The expected benefit expiry probabilities capture the assumptions from Section 6 of the actuarial memorandum. Benefit expiry probabilities were calculated by first calculating the hazard rate of benefit expiry, then transforming into a probability. For example, the actual benefit expiry probability [C] = 1 EXP(-([B] / [A])).
- A:E ratios are calculated as actual benefit expiry probabilities to the 2017 *Guidelines* probabilities [F] and the expected assumption [G]. The expected A:E [G] provides an indication of fit. This fit will not be perfect (i.e., ratios deviate from 1.0) because the main goal is to develop an assumption that generalizes well to new data by balancing assumption complexity and fit on the historical experience.

The experience underlying Exhibit A-4 excludes lifetime benefit periods because benefit expiry is not applicable. It also excludes ages less than 65 because the assumed benefit expiry assumption is 0% and actual experience reflects less than 2% of actual expiries. The experience underlying Exhibit A-4 reflects policy durations 7 and later.

Morbidity

The claim costs were developed using the 2017 *Guidelines* with experience adjustment factors based on all products of MedAmerica, its affinity partners, and any acquired business from January 2008 through December 2017, with runout through December 2018. The experience adjustment factors were developed using predictive analytics as described in the Predictive Analytics section below.

- Exhibit A-5a provides the adjustment factors that are to be applied to the 2017 *Guidelines* claim costs for the 515 Series, 700 Series, and 780 Series.
- Exhibit A-5b provides a summary of A:E experience for the 515 Series, 700 Series, and 780 Series. The
 experience underlying this exhibit is for policy durations 7 and later only.
 - Exposure [A] reflects the length of time a covered life is in force (i.e., an exact exposure basis).

- Actual incurred claim counts [B] and dollars [C] are based on historical claim experience from inception through December 2017, with runout through December 2018. Actual incurred claim dollars were valued as paid claims plus claim reserves. Paid claims and claim reserves were discounted to the year of incurral.
- 2017 Guidelines incurred claims [D] are valued as the 2017 Guidelines claim costs multiplied by actual all-lives exposure. The claim costs vary by gender, attained age, policy duration, benefit period, elimination period, payment type, level of home care coverage, level of assisted living facility coverage, inflation type, and coverage type (comprehensive/facility only/home health care only). Policy design, claims adjudication, and degree of underwriting were considered in developing the claim costs.
- Expected incurred claims [E] are calculated by applying each applicable adjustment from Exhibit A-5a to the 2017 Guidelines incurred claims [D].
- A:E ratios are calculated as actual incurred claims to the 2017 *Guidelines* incurred claims [F] and expected incurred claims [G]. The expected A:E [G] provides an indication of fit. This fit will not be perfect (i.e., ratios deviate from 1.0) because the main goal is to develop an assumption that generalizes well to new data by balancing assumption complexity and fit on the historical experience.
- Exhibit A-5c provides information similar to Exhibit A-5b, except provides the experience for all products of MedAmerica and its affinity partners, and MedAmerica's other acquired blocks of business. Like Exhibit A-5b, this exhibit includes only experience for policy durations 7 and later.

For projection purposes, the 2017 Guidelines are brought forward to 2019 using the G2 improvement scale.

Prospective Improvement

For projected mortality and morbidity improvement, the G2 improvement scale from the 2012IAM mortality table was used. The G2 improvement scale varies by attained age and gender. It is applied beginning in the first projection year and continues for 10 projection years.

Rate Increase Dependent Assumptions

At the time of a rate increase, insureds have options to elect a contingent benefit upon lapse (CBUL) or reduced benefit options (RBO). Adverse selection is assumed relative to CBUL and RBO elections. These insured behavior assumptions are provided in Section 6 of the actuarial memorandum. These assumptions are based on MedAmerica and its affinity partners, and MedAmerica's acquired business's combined actual CBUL and RBO election rate experience and actuarial judgment—particularly at the higher rate increase magnitudes where limited experience exists.

Contingent Benefit Upon Lapse Election

The assumed CBUL election rate is based on the requested rate increase and is applied on a seriatim basis.

Reduced Benefit Options

We assume that those electing RBO will reduce their benefits so that premiums after the increase are closer to those before the increase. We assume that the percent reduction in premium corresponds to an equivalent percent reduction in claims. We assume an RBO election rate based on the requested rate increase and it is applied on a seriatim basis.

The reduction to premium and claims then varies based on the level of the rate increase and can then be determined as follows:

Reduction to premium and claims due to the election of RBO

= 1 – (Average premium level after the rate increase with RBO election / Premium level after the full rate increase without any RBO election), where

Average premium level after the rate increase with RBO election

= weighted average premium level of those assumed to elect RBO with those assumed to accept the full rate increase

Adverse Selection

The adverse selection assumption is a function of the CBUL and RBO election rates, such that the relative increase to morbidity due to adverse selection varies by the rate increase's magnitude. The increase to morbidity due to adverse selection was developed from the following formula and actuarial judgment. We assume that at the time of the rate increase, insureds that elect a CBUL will be selective in that their relative morbidity is 25% lower than that of the remaining pool. Similarly, we assume that at the time of the rate increase, insureds that elect an RBO will be selective in that their relative morbidity is 12.5% lower than that of the remaining pool.

PoolMorb = AdvSelMorb x (1 - CBUL - RBO) + [(1 - 25%) x AdvSelMorb] x CBUL + [(1 - 12.5%) x AdvSelMorb] x RBO, where

PoolMorb = morbidity of the pool before the rate increase = 1.0

AdvSelMorb = adverse morbidity of the remaining pool after the rate increase due to selective lapses

CBUL = percentage of insureds that elect CBUL RBO = percentage of insureds that elect RBO

Solving the above for the adverse selection component results in the following formula:

Adverse Selection = $1 / (1 - 25\% \times CBUL - 12.5\% \times RBO)$

Predictive Analytics

In developing the persistency and morbidity experience adjustment factors, predictive analytics was employed in the form of a penalized generalized linear model (GLM).

A penalized GLM is similar to a traditional GLM. The only difference is that it adds an additional constraint that penalizes the size of the model's coefficients in order to control overfitting the model to the historical data. This penalty placed on the coefficients can be seen as a credibility lever, which controls how much weight is given to the company's actual experience. A high penalty would give no weight to the data, leaving the benchmark assumption (i.e., the 2017 *Guidelines* for morbidity) unadjusted. No penalty would give full weight to the company's actual data potentially making large adjustments to the benchmark, which could be overfitting the actual experience. When using a penalized GLM, it is important to choose a penalty that gives the right amount of weight to the actual data to avoid underfitting or overfitting the experience.

A standard approach for choosing such a penalty is to use a k-fold cross-validation to test a series of penalty values. A k-fold cross-validation splits the data into k subsets and iteratively trains and tests the model independently on each subset of the data. This process gives an estimation of how well a model will generalize to new data that was not used to develop the assumption. Through the k-fold cross-validation we evaluated the impact the penalty had on the model's generalizability by testing a range of 100 penalties. We selected a penalty to balance minimizing the k-fold cross-validation prediction error with the generalizability of the model. This allows for a statistically robust and automated process to determine the amount of weight to give actual experience versus the benchmark assumption.

Exhibit A-1a Mortality Hazard Rate Adjustment Factors All Products

Attained	Ger	nder	1 [Marital	Status
Age	Male	Female		Married	Single
<55	0.99	1.00	1	0.99	1.01
55	0.97	0.99	1 [0.97	1.01
56	0.97	0.98		0.95	1.01
57	0.95	0.97		0.93	1.02
58	0.93	0.96		0.91	1.02
59	0.91	0.93		0.89	1.02
60	0.89	0.89	l l	0.88	1.01
61	0.85	0.86		0.85	1.00
62	0.85	0.86		0.84	1.00
63	0.84	0.85		0.82	1.00
64	0.84	0.84		0.81	1.01
65	0.87	0.84	!	0.81	1.01
66	0.88	0.85		0.81	1.01
67	0.87	0.82		0.81	1.00
68	0.91	0.82		0.82	1.01
69	0.95	0.85		0.84	1.02
70	0.97	0.85		0.85	1.02
71	0.99	0.84		0.86	1.03
72	1.02	0.85		0.87	1.04
73	1.03	0.85		0.89	1.03
74	1.04	0.85		0.90	1.04
75	1.05	0.86	 	0.91	1.04
76	1.08	0.87		0.92	1.04
77	1.11	0.92		0.94	1.07
78	1.09	0.94		0.95	1.05
79	1.08	0.94		0.95	1.02
80	1.09	0.93	 	0.96	1.04
81	1.10	0.95		0.97	1.04
82	1.08	0.93		0.96	1.04
83	1.08	0.91		0.95	1.04
84	1.03	0.89		0.96	1.02
85	1.06	0.92	ŀ	0.99	1.02
86	1.04	0.93		0.99	1.01
87	1.04	0.90		1.00	0.99
88	1.07	0.90		1.00	0.99
89	1.13	0.94		0.99	1.01
90	1.09	0.95		0.99	1.02
91	1.07	0.96		1.00	1.02
92	1.09	1.00	$ \ $	1.01	1.03
93	1.06	1.01	$ \ $	1.02	1.03
94	1.03	1.00		1.01	1.03
95	1.01	1.00		0.99	1.04
96	1.01	1.01		0.99	1.05
97	1.00	1.02		0.99	1.05
98	1.00	1.04		0.99	1.05
99	0.99	1.04		1.00	1.04
100	0.99	1.03		1.00	1.03
101	0.99	1.02		1.00	1.02
102	0.98	1.01		0.99	1.01
103	0.99	1.01		0.99	1.00
104+	0.99	1.00		1.00	1.01

Duration	Factor
1	0.81
2	0.70
3	0.63
4	0.59
5	0.56
6	0.66
7	0.00
8	0.81
9	0.84
10	0.86
11	0.90
12	0.92
13	0.93
14	0.96
15	0.98
16	0.98
17	0.98
18	0.98
19	0.98
20+	0.98

Exhibit A-1b
Actual-to-Modeled Mortality Experience 2008-2017
Policy Durations 7+
All Products

	Policy Year	Actua	al	Mortality P	robability	Actual-to-Modeled N	Nortality Probability
Product or Insured	Exposure	Deaths	Probability	2012IAM	Modeled	2012IAM	Modeled
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
	-				-		-
Marital Status							
Married	386,931	5,992	1.5%	1.8%	1.6%	0.86	0.99
Single	392,172	9,243	2.3%	2.4%	2.3%	0.97	1.00
Gender							
Female	452,361	7,931	1.7%	2.0%	1.7%	0.88	0.99
Male	326,742	7,304	2.2%	2.3%	2.2%	0.98	1.00
Policy Duration							
7-9	204,938	1,429	0.7%	1.0%	0.7%	0.70	0.97
10-14	315,361	4,614	1.5%	1.7%	1.5%	0.87	0.99
15-19	172,971	5,090	2.9%	2.9%	2.9%	1.00	1.01
20-24	69,899	3,138	4.4%	4.3%	4.4%	1.03	1.00
25+	15,933	964	5.9%	5.7%	5.9%	1.03	0.99
Attained Age	-		-		-		
<65	278,751	776	0.3%	0.4%	0.3%	0.71	0.95
65-69	121,892	789	0.6%	0.9%	0.7%	0.70	0.98
70-74	121,461	1,396	1.1%	1.4%	1.2%	0.80	0.99
75-79	111,354	2,505	2.2%	2.4%	2.2%	0.93	1.00
80-84	84,877	3,624	4.2%	4.3%	4.2%	0.97	1.00
85+	60,768	6,145	9.6%	9.5%	9.6%	1.01	1.00
Total	779,103	15,235	1.9%	2.1%	1.9%	0.93	1.00

Exhibit A-1c Composite Termination Attained Age Mortality Adjustment For Policy Durations 7+ All Products

Attained	
Age	Adjustment
<55	1.00
55	1.00
56	1.00
57	1.00
58	1.00
59	1.00
60	1.00
61	1.00
62	1.00
63	1.00
64	1.00
65	1.00
66	1.00
67	1.00
68	1.00
69	1.00
70	1.00
71	1.01
72	1.01
73	1.01
74	1.01

Attained	
Age	Adjustment
75	1.02
76	1.02
77	1.03
78	1.03
79	1.03
80	1.03
81	1.04
82	1.04
83	1.04
84	1.04
85	1.05
86	1.05
87	1.06
88	1.06
89	1.06
90	1.06
91	1.07
92	1.07
93	1.07
94	1.07
95+	1.07

Exhibit A-2
Actual-to-Modeled Voluntary Lapse Experience 2008-2017
Lifetime-Pay for Policy Durations 10+
All Products

	Policy Year	Actual		Lapse Probabilit	у	Actual-to-Modeled Lapse	e Probability
Product or Insured	Exposure	Lapses	Probability	Unadjusted	Modeled	Unadjusted	Modeled
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
Marital Status	<u> </u>						
Married	226,840	1,757	0.8%	1.0%	0.8%	0.76	0.98
Single	252,968	2,338	0.9%	0.9%	0.9%	1.02	1.01
Benefit Period							
Non-Lifetime	343,952	3,341	1.0%	1.0%	1.0%	0.95	1.01
Lifetime	135,856	754	0.6%	0.8%	0.6%	0.68	0.95
Inflation			•				
Non-Auto	177,263	2,052	1.2%	1.0%	1.1%	1.13	1.01
Auto	302,544	2,043	0.7%	0.9%	0.7%	0.73	0.98
Cohort ^[1]			•				
515 Series	38,207	617	1.6%	2.2%	1.7%	0.74	0.97
700 Series	1,489	29	1.9%	1.5%	1.2%	1.29	1.54
780 Series	4,512	64	1.4%	1.5%	1.3%	0.94	1.13
Attained Age	•		•		•		
<65	113,757	1,078	0.9%	0.9%	0.8%	1.01	1.14
65-69	67,892	376	0.6%	0.9%	0.6%	0.59	0.91
70-74	79,255	523	0.7%	1.0%	0.7%	0.68	0.92
75-79	88,328	649	0.7%	1.0%	0.8%	0.74	0.93
80-84	74,228	677	0.9%	1.0%	0.9%	0.94	0.96
85+	56,348	792	1.4%	1.0%	1.4%	1.45	1.01
Total	479,808	4,095	0.8%	1.0%	0.9%	0.89	1.00

^[1] Series characteristic captures the experience of 515 Series, 700 Series, and 780 Series policies only, while other characteristics capture the pooled experience of products of MedAmerica, its affinity partners, and MedAmerica's acquired blocks of business.

Exhibit A-3 Actual-to-Expected Composite^[1] Termination Experience 2008-2017 Lifetime-Pay for Policy Durations 10+ All Products

	Policy Year	Actual		Expected Termination	Actual-to-Expected
Product or Insured	Exposure	Terminations	Probability	Probability ^[1]	Termination Probability ^[1]
Characteristic	[A]	[B]	[C]	[D]	[E] = [C] / [D]
Marital Status					
Married	226,840	6,737	2.9%	2.9%	1.00
Single	252,968	10,430	4.0%	3.9%	1.03
Gender	•	·			
Female	291,631	9,451	3.2%	3.2%	1.01
Male	188,176	7,716	4.0%	3.9%	1.03
Benefit Period	•	·	·		
Non-Lifetime	343,952	13,461	3.8%	3.8%	1.02
Lifetime	135,856	3,706	2.7%	2.6%	1.03
Inflation	•		•		
Non-Auto	177,263	9,333	5.1%	4.9%	1.05
Auto	302,544	7,834	2.6%	2.6%	0.99
Cohort ^[2]					
515 Series	38,207	1,693	4.3%	3.8%	1.13
700 Series	1,489	52	3.4%	2.9%	1.20
780 Series	4,512	120	2.6%	2.5%	1.05
Policy Duration			•		
10-14	256,833	6,828	2.6%	2.5%	1.07
15-19	145,062	5,757	3.9%	3.9%	0.99
20-24	62,763	3,496	5.4%	5.4%	1.00
25+	15,150	1,086	6.9%	7.1%	0.98
Attained Age			•		
<65	113,757	1,466	1.3%	1.2%	1.11
65-69	67,892	883	1.3%	1.3%	0.99
70-74	79,255	1,488	1.9%	1.9%	1.00
75-79	88,328	2,733	3.0%	3.0%	1.01
80-84	74,228	3,966	5.2%	5.1%	1.02
85+	56,348	6,631	11.1%	10.9%	1.01
Total	479,808	17,167	3.5%	3.4%	1.02

^[1] Combination of mortality and voluntary lapse

^[2] Series characteristic captures the experience of 515 Series, 700 Series, and 780 Series policies only, while other characteristics capture the pooled experience of products of MedAmerica, its affinity partners, and MedAmerica's acquired blocks of business.

Exhibit A-4
Actual-to-Expected Benefit Expiry Experience 2008-2017
Policy Durations 7+
All Products

	Policy Year	Actual		Benefit Expiry Pr		Actual-to-Expected	
Product or Insured	Exposure ^[1]	Benefit Expiry	Probability	2017 Guidelines	Expected ^[2]	2017 Guidelines	Expected ^[2]
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
<u> </u>							
Gender							
Female	226,513	1,317	0.6%	0.5%	0.6%	1.07	1.02
Male	162,541	445	0.3%	0.3%	0.3%	0.99	0.97
Benefit Period							
1 Year	21,879	139	0.6%	0.7%	0.7%	0.91	0.88
2 Year	59,932	533	0.9%	0.7%	0.8%	1.20	1.13
3 Year	181,848	722	0.4%	0.4%	0.4%	0.96	0.93
4 Year	52,938	188	0.4%	0.3%	0.4%	1.05	0.99
5 Year	66,951	175	0.3%	0.2%	0.2%	1.19	1.12
6 Year	4,677	5	0.1%	0.0%	0.0%	2.92	2.80
10 Year	830	0	0.0%	0.0%	0.0%	0.00	0.00
Attained Age	•		•		•		
<75	186,976	86	0.0%	0.1%	0.1%	0.64	0.83
75-79	85,088	145	0.2%	0.2%	0.2%	0.73	0.90
80-84	66,442	376	0.6%	0.6%	0.6%	1.01	1.01
85-89	36,785	544	1.5%	1.3%	1.5%	1.10	0.99
90-94	11,698	466	3.9%	3.0%	3.7%	1.30	1.06
95+	2,066	145	6.8%	5.6%	6.3%	1.22	1.07
Total	389,054	1,762	0.5%	0.4%	0.5%	1.05	1.00

^[1] Experience excludes lifetime benefit periods and ages less than 65

^[2] Expected = Rates in Section 6 of the actuarial memorandum

Exhibit A-5a MedAmerica and CICA **Morbidity Adjustment Factors**

CICA 515 Series, 700 Series, and 780 Series Policy Forms

	Product-Sne	cific Adjustment F	actors
Attained			
Age	515 Series	700 Series	780 Series
<55	1.00	1.00	1.00
55	1.00	1.00	1.00
56	1.00	1.00	1.00
57	1.00	1.00	1.00
58	1.00	1.00	1.00
59	1.00	1.00	1.00
60	0.99	1.00	1.00
61	0.99	1.00	1.00
62	0.99	1.00	1.00
63	0.99	1.00	1.00
64	0.99	1.00	1.00
65	1.00	1.00	1.00
66	1.00	1.00	1.00
67	1.00	1.00	1.00
68	1.00	1.00	1.00
69	1.00	1.00	1.00
70	1.00	1.00	1.00
71	1.01	1.00	1.00
72	1.01	1.00	1.00
73	1.01	1.01	1.01
74	1.01	1.01	1.01
75	1.01	1.01	1.01
76	1.00	1.01	1.01
77	1.00	1.01	1.01
78	1.00	1.01	1.01
79	1.00	1.00	1.00
80	1.01	1.00	1.00
81	1.01	1.00	1.00
82	1.00	1.00	1.00
83	1.00	1.00	1.00
84	1.00	1.00	1.00
85	1.00	1.00	1.00
86	1.00	1.00	1.00
87	1.00	1.00	1.00
88	1.00	1.00	1.00
89	1.00	1.00	1.00
90	1.00	1.00	1.00
91	1.00	1.00	1.00
92	1.00	1.00	1.00
93	1.00	1.00	1.00
93	1.00	1.00	1.00
95	1.00	1.00	1.00
95 96			
96	1.00	1.00	1.00
-	1.00	1.00	1.00
98	1.00	1.00	1.00
99	1.00	1.00	1.00
100	1.00	1.00	1.00
101+	1.00	1.00	1.00

Allameu	Aujustinent	
Age	Factor	
<55	1.00	
55	1.00	
56	1.00	
	0.99	
57		
58	0.99	
59	0.98	
60	0.98	
61	0.97	
62	0.96	
63	0.95	
64	0.95	
65	0.95	
66	0.95	
67	0.96	
68	0.97	
69	0.99	
70	0.99	
71	1.00	
72	1.01	
73	1.01	
74	1.01	
75	1.01	
76	1.02	
77	1.02	
78	1.04	
79	1.06	
80	1.09	
81	1.09	
82	1.09	
83	1.08	
84	1.07	
85	1.06	
86	1.06	
87	1.07	
88	1.07	
89	1.07	
90	1.07	
91	1.07	
92	1.05	
93	1.03	
94	1.02	
95	1.01	
96	1.01	
97	1.01	
98	1.01	
99	1.01	
100	1.01	
101+	1.01	
1017	1.01	l

Payment Type

Attained

Adjustment

I	Attained	Adjustment	Attained		
I	Age	Factor	Age	Non-Lifetime	
I	<55	1.00	<55	1.00	L
I	55	1.00	55	1.00	l
I	56	1.00	56	1.00	l
I	57	0.99	57	1.00	l
I	58	0.99	58	1.00	
I	59	0.98	59	1.00	
I	60	0.98	60	1.00	
I	61	0.98	61	1.00	
I	62	0.97	62	1.00	
I	63	0.97	63	1.00	
I	64	0.97	64	1.00	
I	65	0.97	65	1.00	
I	66	0.96	66	1.00	
I	67	0.96	67	1.00	
I	68	0.95	68	1.00	
I	69	0.95	69	1.00	
I	70	0.95	70	1.00	Г
I	71	0.96	71	1.00	
I	72	0.97	72	1.00	
I	73	0.99	73	1.00	
I	74	1.01	74	1.00	
I	75	1.01	75	1.00	Г
I	76	1.00	76	1.00	
I	77	1.00	77	1.00	
I	78	1.00	78	1.00	
I	79	1.00	79	1.00	
ı	80	1.02	80	1.00	Т
I	81	1.03	81	1.00	
I	82	1.02	82	1.00	
I	83	1.03	83	1.00	
I	84	1.03	84	1.00	
I	85	1.03	85	1.00	Т
I	86	1.03	86	1.00	
I	87	1.04	87	1.00	
I	88	1.04	88	1.00	
I	89	1.05	89	1.00	
ı	90	1.05	90	1.00	Т
I	91	1.04	91	1.00	
I	92	1.03	92	1.00	
I	93	1.02	93	1.00	
I	94	1.02	94	1.00	
I	95	1.02	95	1.00	Т
I	96	1.01	96	1.00	
I	97	1.01	97	1.00	
I	98	1.01	98	1.00	
I	99	1.01	99	1.00	
I	100	1.01	100	1.00	H
I	100	1.01	100	1.00	ı

Benefit Period Adjustment Factors

Lifetime

1.01 1.01 1.01 1.02 1.02 1.02 1.00 0.99 0.97 0.95 0.94 0.94 0.95 0.96 0.98 0.99 0.99 0.99 0.99 0.99 0.99 0.98 0.97 0.97 0.97 0.97 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.01 1.01 1.01 1.01 1.00 1.00 0.99 0.99 0.99 0.99 1.00 1.00 1.00 1.00

Coverage	Adjustment
Туре	Factor
Comprehensive	1.00
Facility Only	1.04
Home Care Only	1.01

Appendix A **Exhibits**

101+

1.01

101+

1.00

1.00

Exhibit A-5b

MedAmerica, CICA, and CLICNY

Actual-to-Expected Morbidity Experience through December 31, 2017 with Claim Runout Policy Durations 7+

CICA 515 Series, 700 Series, and 780 Series Policy Forms

		Actual Incur	red Claims	Incurred	Claims	Actual-to-Expecte	d Incurred Claims
Product or Insured	Exposure	Count	Dollars	2017 Guidelines	Expected	2017 Guidelines	Expected
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
Coverage Type							
Comprehensive	57,347	702	46,399,778	43,774,470	46,322,077	1.06	1.00
Home Care Only	521	2	115,305	236,726	250,566	0.49	0.46
Facility Only	83	2	143,260	44,587	49,222	3.21	2.91
Benefit Period							
Non-Lifetime	47,265	605	37,381,333	32,666,109	34,860,994	1.14	1.07
Lifetime	10,687	101	9,277,010	11,389,674	11,760,871	0.81	0.79
Attained Age							
< 60	3,500	1	923	256,117	254,516	0.00	0.00
60 - 69	13,415	24	1,448,900	2,432,707	2,213,824	0.60	0.65
70 - 79	30,179	268	20,360,113	19,437,175	19,816,328	1.05	1.03
80 - 89	10,488	384	23,724,415	20,740,248	23,035,167	1.14	1.03
90 +	369	29	1,123,992	1,189,536	1,302,031	0.94	0.86
Product			_				
515 Series	45,630	624	42,296,800	39,979,249	42,456,401	1.06	1.00
700 Series	2,540	11	778,985	1,270,498	1,318,144	0.61	0.59
780 Series	9,781	71	3,582,557	2,806,036	2,847,320	1.28	1.26
Total	57,951	706	46,658,343	44,055,783	46,621,865	1.06	1.00

Exhibit A-5c MedAmerica, Affinity Partners, and Acquired Business Actual-to-Expected Morbidity Experience through December 31, 2017 with Claim Runout Policy Durations 7+ All Products

		Actual Incur	red Claims	Incurred	Claims	Actual-to-Expected	d Incurred Claims
Product or Insured	Exposure	Count	Dollars	2017 Guidelines	Expected	2017 Guidelines	Expected
Characteristic	[A]	[B]	[C]	[D]	[E]	[F] = [C] / [D]	[G] = [C] / [E]
Coverage Type							
Comprehensive	643,394	8,390	757,618,466	717,849,233	750,690,376	1.06	1.01
Home Care Only	11,130	306	20,267,089	14,966,969	16,470,343	1.35	1.23
Facility Only	68,683	1,917	146,394,944	117,700,603	130,167,135	1.24	1.12
Benefit Period			-				
Non-Lifetime	549,699	8,301	646,978,551	576,027,747	612,898,981	1.12	1.06
Lifetime	173,508	2,312	277,301,948	274,489,057	284,428,874	1.01	0.97
Attained Age		•	-				
< 60	148,383	126	21,838,218	13,797,574	14,458,349	1.58	1.51
60 - 69	212,665	539	65,949,907	67,763,623	66,428,499	0.97	0.99
70 - 79	220,546	2,361	238,658,861	247,144,857	248,921,416	0.97	0.96
80 - 89	125,973	5,886	496,974,001	434,148,631	473,252,884	1.14	1.05
90 +	15,640	1,701	100,859,512	87,662,119	94,266,707	1.15	1.07
Total	723,207	10,613	924,280,499	850,516,804	897,327,854	1.09	1.03

This appendix provides details on the development of the current rate increase requests as well as demonstrations of how the requested rate increases are not recouping past losses.

Actuarial Equivalent Rate Increase Development

This rate increase request is a follow-up to two prior nationwide requests for the 515 Series and one prior nationwide request for the 700 and 780 Series. Table B-1 provides the originally requested rate increase by series for policies with auto inflation. In jurisdictions that did not allow full implementation of the prior requested increase(s), the company is requesting a follow-up increase to achieve an actuarially equivalent lifetime loss ratio to the prior request(s) for policies with auto inflation. No rate increase is being requested on policies without inflation.

Table B-1
Originally Requested Nationwide Rate Increases
Auto Inflation Policies

	2013	2017	Cumulative					
Series	Request	Request	Request					
515	38.0%	66.7%	130%					
700	0.0	100.0	100					
780	0.0	35.0	35					
AII ^[1]	27.6	62.8	108					

[1] Average as of December 31, 2019.

Exhibit B-1 provides the lifetime loss ratio that would have been achieved if all jurisdictions had implemented the originally requested rate increase(s). This exhibit is similar to Exhibit I-b except that it reflects policies with auto inflation only, premiums that have been restated to assume implementation of the originally requested rate increase(s) shown in Table B-1, and is split by series. Table B-2 summarizes the lifetime loss ratios from Exhibit B-1, which are the targets for determining actuarial equivalence.

Table B-2
Target Lifetime Loss Ratio for Actuarial Equivalence
Auto Inflation Polices

	Lifetime					
Series	Loss Ratio					
515	104%					
700	80					
780	102					

The average nationwide requested rate increases shown in Section 2 were developed to produce a lifetime loss ratio that is equivalent to that in Table B-2. This equivalence is demonstrated by comparing the after increase lifetime loss ratios from Section 15 to those in Table B-2.

The requested rate increases in this jurisdiction, shown in the enclosed cover letter, were developed to produce a lifetime loss ratio(s) that is equivalent to that in Table B-2. This equivalence is demonstrated by comparing the lifetime loss ratio(s) from Exhibit B-2 to those in Table B-2. Exhibit B-2 provides similar information as Exhibit B-1 except that premiums have been restated to reflect the actual rate increases implemented in this jurisdiction, the requested rate increase shown in the cover letter, and split by the series available in this jurisdiction.

While emerging experience supports a larger rate increase, the company is limiting the increase to be an actuarially equivalent follow-up to the prior request(s) in order to improve equity across jurisdictions. The company plans to continue to monitor experience and request additional rate increases in the future, to the extent justified. However, if it is the Department's position to only allow future rate increases if experience deteriorates from the current most-likely projections used in this filing, the company respectfully requests that the Department notify them and allow the company to revise the current rate increase request.

Demonstrations that the Requested Increase does not Recoup Past Losses

A number of methods exist to quantify or demonstrate whether an increase may be recouping past losses and offer the following for consideration.

Capped Historical Incurred Claims

The 2014 Long-Term Care Model Regulation (Model Regulation) contemplates recouping past losses in Section 20.1.C for newly issued policies. Specifically, recouping past losses is limited by not allowing past actual claims in excess of expected claims by calendar year in the minimum loss ratio test (Section 20.1.C(2)).

While Section 20.1.C is not applicable to these policies, to demonstrate that the nationwide rate increase request is not recouping past losses we capped actual historical claims by those expected in pricing by calendar year in demonstrating compliance with the applicable minimum loss ratio requirements for these policies. Expected claims are calculated as earned premium multiplied by expected loss ratio for each calendar year.

Tables B-3 and B-4 reflect the capped historical incurred claims. For cohorts where a rate increase is being requested (i.e., auto inflation) and in aggregate, Tables B-3 and B-4 demonstrate compliance with the applicable minimum loss ratio requirements for the pre- and post-rate stability regulation (Model Regulation Sections 19 and 20), respectively. Tables B-3 and B-4 provide similar information as that in Section 15 of the actuarial memorandum, except for capping historical incurred claims at that expected.

Table B-3
Nationwide Lifetime Loss Ratios with Capped Historical Incurred Claims at the Maximum Valuation Interest Rate by Series and Inflation Protection Option

Series	Inflation Protection Option	Before Increase	After Increase
	Non-Auto	60%	60%
All	Auto	112	102
	All	90	84
	Non-Auto	60	60
515	Auto	114	103
	All	91	85
	Non-Auto	53	53
700	Auto	92	79
	All	82	73
	Non-Auto	58	58
780	Auto	107	101
	All	81	78

Table B-4
Nationwide 58%/85% Test with Capped Historical Incurred Claims
by Series and Inflation Protection Option

	Inflation			
Series	Protection Option	Item 5 ^[1]	Item 7 ^{[2][3]}	Result ^[4]
	Non-Auto	\$91.1	\$99.5	Pass
All	Auto	124.9	229.0	Pass
	All	216.0	329.5	Pass
	Non-Auto	69.0	73.7	Pass
515	Auto	101.8	187.3	Pass
	All	170.8	261.7	Pass
	Non-Auto	3.2	3.2	Fail
700	Auto	6.2	9.0	Pass
	All	9.5	12.8	Pass
	Non-Auto	18.9	21.1	Pass
780	Auto	16.9	32.0	Pass
	All	35.8	53.3	Pass

- [1] Item 5 is the Lifetime Earned Premium (in millions) Times Prescribed Factor.
- [2] Item 7 is Lifetime Incurred Claims with Rate Increase (in millions). The historical incurred claims by calendar year reflect the lesser of actual and expected pricing claims. The future projected incurred claims were increased by 15% to reflect assumptions with moderately adverse experience.
- [3] The capped historical incurred claims are calculated for each indicated cohort. The difference results in the sum of the series and/or inflation options not tying to the totals.
- [4] Test of whether Item 7 is not less than Item 5.

HATF Discussion and Lifetime Premium Equivalence

One approach that was considered by the NAIC Health Actuarial Task Force (HATF) during discussions for the development of the Model Regulation was that past losses should be defined as past premium inadequacies given current, updated information. A company would demonstrate this approach by restating premiums to the proposed rate level from inception and demonstrating compliance with minimum loss ratio tests.

This approach was determined by HATF to not be a realistic method to define past losses because in reality there is no opportunity for the company to have perfect knowledge from policy inception and this approach greatly expands the risk on the product. Ultimately, HATF settled on the approach that past losses should be defined as any excess of actual past claims over expected claims, which led to the approach outlined in Section 20.1.C of the Model Regulation and described above. For additional background on HATF's review of methods of defining past losses please see the article 'Recouping Past LTC Losses' in the April 2017 issue of the Society of Actuaries Long-Term Care Section newsletter, Long-Term Care News.

While it is not appropriate to use this restrictive method of restating premiums to the proposed rate level from inception to determine the rate increase, we can use it to confirm that current policyholders are not paying more over their lifetime than what they would have if the company had perfect knowledge.

With perfect knowledge, for all policies combined, the company would have charged 53% higher rates from issue to reproduce the original pricing loss ratio of 59%. To avoid recouping premium on past policies that will not receive the rate increase, we compare lifetime premiums on a present value basis for the subset of policies that are in-force. These policies would have paid \$226 million in the history and \$293 million over the lifetime if the company had perfect knowledge and charged 53% higher premiums from issue. In contrast, the actual premium paid by these policies has been \$153 million in the history and is projected to be \$218 million over the lifetime including the requested rate increase. Therefore, these in-force policies will pay less over their lifetime than what they would have paid if the company had perfect knowledge at issue.

Table B-5 below provides a summary of the present value of lifetime premiums under the scenario discussed above by series and inflation protection option. As seen in Table B-5, the auto inflation cohorts as well as all cohorts in aggregate will pay less over their lifetime than what they would have paid if the company had perfect knowledge at issue.

Table B-5 Lifetime Premium Equivalence **In-force Policies**

			III TOTOC I ONOICO		
				Present Value of Lifetim	e Premium (Millions) with:
	Inflation	Original			Actual History
	Protection	Pricing	Increase Needed	Perfect Knowledge	and Requested
Series	Option	Loss Ratios	from Inception ^[1]	at Issue ^[2]	Increase in Future
	Non-Auto	59%	1%	\$78	\$81
All	Auto	60	95	224	137
	All	59	53	293	218
	Non-Auto	60	0	48	52
515	Auto	61	97	174	107
	All	61	54	211	159
	Non-Auto	54	48	5	4
700	Auto	55	72	11	7
	All	55	63	16	11
	Non-Auto	53	5	26	25
780	Auto	56	85	39	23
	All	54	42	65	48

^[1] An increase of 0% reflects that no increase was justified from inception in order to reproduce the original pricing loss ratio.
[2] The increase needed from inception is calculated for each indicated cohort for all lives while the present value of premium is calculated based on policies currently in force. The difference results in the sum of the series and/or inflation options not tying to the totals.

Exhibit B-1a MedAmerica, CICA, and CLICNY Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Restated to Assume Implementation of the Originally Requested Rate Increases 515 Series with Auto Inflation Protection

		Without Interest			With Max. Val. Interest			
		А	В	C = B / A	D	Е	F	G = F / E
					E 1 ()/			
	Calendar Year	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	Earned Premium	Incurred Claims	Incurred Loss Ratio
	1997	544	0	0%	10	1,466	0	0%
	1998	160,240	0	0%	302	412,829	0	0%
	1999	745,926	0	0%	1,148	1,838,992	0	0%
	2000	1,890,494	166,207	9%	1,996	4,460,082	392,118	9%
	2001	3,088,855	145,833	5%	3,163	6,973,470	329,235	5%
	2002	4,396,309	173,328	4%	4,065	9,497,805	374,459	4%
	2003 2004	4,920,879 4,881,672	185,832 546,341	4% 11%	4,192 4,010	10,173,292 9,657,642	384,183 1,080,853	4% 11%
Historical	2004	4,726,680	1,665,413	35%	3,946	8,948,339	3,152,886	35%
Experience	2006	4,774,621	870,809	18%	3,970	8,630,631	1,577,585	18%
	2007	4,797,776	805,302	17%	3,905	8,278,717	1,386,525	17%
	2008	4,658,541	854,361	18%	3,712	7,692,847	1,417,356	18%
	2009	4,424,872	1,578,764	36%	3,502	6,996,702	2,499,144	36%
	2010	4,205,309	1,504,442	36%	3,358	6,366,103	2,285,494	36%
	2011	4,020,008	2,765,000	69%	3,229	5,825,806	4,019,607	69%
	2012	3,864,486	2,253,737	58%	3,118	5,361,255	3,129,971	58%
	2013 2014	3,721,420 3,539,330	2,610,177 1,976,488	70% 56%	3,013 2,780	4,942,493 4,499,937	3,474,769 2,517,872	70% 56%
1	2014	3,891,756	3,263,645	84%	2,780	4,736,505	3,966,108	84%
1	2016	4,201,199	4,596,452	109%	2,446	4,894,446	5,362,036	110%
1	2017	3,962,695	4,651,432	117%	2,350	4,419,249	5,192,510	117%
1	2018	3,752,917	4,699,027	125%	2,211	4,006,567	5,019,753	125%
	2019	3,729,071	5,515,399	148%	2,038	3,811,242	5,637,999	148%
	2020	4,751,683	5,200,355	109%	1,856	4,649,239	5,087,506	109%
	2021	4,666,057	5,672,403	122%	1,766	4,370,789	5,311,144	122%
	2022	4,394,863	6,208,811	141%	1,674	3,941,310	5,563,995	141%
	2023 2024	4,119,979 3,842,952	6,741,668 7,249,679	164% 189%	1,581 1,486	3,537,429 3,159,139	5,782,465 5,951,725	163% 188%
	2025	3,565,475	7,709,851	216%	1,391	2,806,389	6,058,438	216%
	2026	3,289,528	8,104,955	246%	1,295	2,479,184	6,096,388	246%
	2027	3,017,475	8,419,477	279%	1,200	2,177,629	6,062,278	278%
	2028	2,751,515	8,660,307	315%	1,106	1,901,513	5,969,484	314%
	2029	2,493,909	8,827,783	354%	1,015	1,650,514	5,825,557	353%
	2030	2,246,730	8,950,644	398%	926	1,424,055	5,655,257	397%
5	2031	2,011,467	9,027,698	449%	840	1,221,106	5,461,433	447%
Projected Future	2032 2033	1,789,669	9,031,392	505% 567%	758 681	1,040,651	5,231,657	503% 565%
Experience	2033	1,582,809 1,391,784	8,977,133 8,873,653	638%	608	881,618 742,630	4,979,676 4,713,683	635%
(50 Years)	2035	1,216,980	8,717,123	716%	540	622,103	4,434,497	713%
,	2036	1,058,400	8,507,539	804%	477	518,365	4,144,743	800%
	2037	915,717	8,248,639	901%	420	429,720	3,848,868	896%
	2038	788,293	7,944,054	1,008%	368	354,472	3,550,347	1,002%
	2039	675,280	7,589,974	1,124%	320	290,992	3,249,065	1,117%
	2040	575,667	7,182,596	1,248%	278	237,740	2,945,257	1,239%
	2041	488,417	6,740,383	1,380%	240	193,324	2,647,699	1,370%
	2042 2043	412,414 346,549	6,270,818 5,782,144	1,521% 1,668%	206 176	156,468 126,031	2,359,768 2,084,579	1,508% 1,654%
	2044	289,782	5,299,274	1,829%	150	101,025	1,830,396	1,812%
	2045	241,147	4,831,247	2,003%	127	80,594	1,598,868	1,984%
	2046	199,710	4,385,281	2,196%	108	63,987	1,390,546	2,173%
	2047	164,616	3,954,909	2,403%	91	50,566	1,201,628	2,376%
	2048	135,099	3,551,786	2,629%	76	39,785	1,034,158	2,599%
	2049	110,454	3,176,478	2,876%	64	31,185	886,397	2,842%
	2050	90,032	2,820,059	3,132%	53	24,369	754,291	3,095%
	2051	73,194	2,499,930	3,415%	45	18,994	641,146	3,376%
	2052	59,382	2,206,519	3,716%	37	14,773	542,760	3,674%
1	2053 2054	48,129 38,980	1,942,506 1,706,627	4,036% 4,378%	31 26	11,479 8,913	458,340 386,410	3,993% 4,335%
	2054	38,980	1,496,037	4,378% 4,739%	20	6,920	325,123	4,335% 4,698%
	2056	25,570	1,305,760	5,107%	18	5,374	272,336	5,068%
	2057	20,707	1,133,456	5,474%	15	4,172		5,437%
	2058	16,765	984,926	5,875%	12	3,238	188,996	5,836%
	2059	13,574	852,243	6,279%	10	2,513	156,777	6,238%
	2060-2064	37,268	2,765,994	7,422%	28	6,197	454,971	7,342%
	2065-2069	11,809	1,115,331	9,445%	9	1,589	149,376	9,401%
His	story	82,355,601	40,827,987	50%	65,062	132,426,417	53,200,462	40%
	ture	54,001,396	230,667,445	427%	22,126	39,388,083	125,514,848	319%

Exhibit B-1b MedAmerica, CICA, and CLICNY Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Restated to Assume Implementation of the Originally Requested Rate Increases 700 Series with Auto Inflation Protection

			With Max. Val. Interest					
		Α	Without Interest B	C = B / A	D	Е	F	G = F / E
	0-11	F4	l	l	F1 - f V	F	l	l
	Calendar Year	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	Earned Premium	Incurred Claims	Incurred Loss Ratio
	1997	0	0	0%	0	0		0%
	1998	0	0	0%	0	0	0	0%
	1999	374	0	0%	1	922	0	0%
	2000	942	0	0%	1	2,222	0	0%
	2001	8,900	0	0%	23	20,093	0	0%
	2002	67,785	0	0%	62	146,442 315.505	0	0%
	2003 2004	152,612 198,688	0	0% 0%	120 179	315,505 393,074	0	0% 0%
Historical	2005	260,354	0	0%	210	492,891	0	0%
Experience	2006	326,833	0	0%	250	586,075	0	0%
	2007	378,642	27,559	7%	268	644,148	47,777	7%
	2008	369,837	30,280	8%	249	602,755	50,234	8%
	2009	332,597	58,076	17%	227	519,691	92,198	18%
	2010	311,220	0	0%	218	466,207	0	0%
	2011	300,754	0	0%	211	431,791	0	0%
	2012	291,374	0	0%	203	400,896	0	0% 65%
	2013 2014	281,057 275,971	181,894 0	65% 0%	197 195	370,528 348,661	242,145 0	0%
	2014	269,935	0	0%	187	326,850	0	0%
	2016	261,301	0	0%	184	303,271	0	0%
	2017	260,171	0	0%	179	289,373	0	0%
	2018	233,557	0	0%	148	248,951	0	0%
	2019	221,471	206,289	93%	139	226,245	210,850	93%
	2020	313,660	170,071	54%	124	307,038	166,418	54%
	2021	311,283	195,439	63%	120	291,986	183,123	63%
	2022	299,448	228,316	76%	116	269,165	204,856	76%
	2023 2024	287,083 274,168	264,416 302,554	92% 110%	111 106	247,293 226,335	227,200 248,985	92% 110%
	2025	260,678	343,165	132%	100	206,248	270,494	131%
	2026	246,676	385,118	156%	95	187,066	290,784	155%
	2027	232,249	427,508	184%	90	168,823	309,244	183%
	2028	217,430	468,306	215%	84	151,511	324,592	214%
	2029	202,301	507,034	251%	78	135,147	336,804	249%
	2030	186,966	542,261	290%	73	119,756	345,308	288%
D :	2031	171,557	571,579	333%	67	105,368	349,030	331%
Projected Future	2032 2033	156,216	591,761	379% 428%	61 55	92,009	346,572	377%
Experience	2033	141,141 126,517	604,030 610,484	483%	50	79,726 68,543	339,349 329,071	426% 480%
(50 Years)	2035	112,519	609,609	542%	45	58,468	315,370	539%
(55 15)	2036	99,315	603,181	607%	40	49,499	299,476	605%
	2037	87,022	589,612	678%	35	41,599	280,895	675%
	2038	75,711	574,088	758%	31	34,710	262,401	756%
	2039	65,415	558,025	853%	27	28,758	244,668	851%
	2040	56,133	537,479	958%	24	23,659	225,995	955%
	2041	47,843	510,802	1,068%	20	19,328	205,876	1,065%
	2042 2043	40,524	479,288	1,183%	18 15	15,687	185,035	1,180%
	2044	34,133 28,595	449,470 419,831	1,317% 1,468%	13	12,655 10,149	166,092 148,361	1,312% 1,462%
	2045	23,819	386,716	1,624%	11	8,089	130,619	1,615%
	2046	19,730	353,257	1,790%	9	6,408	113,959	1,778%
	2047	16,266	322,355	1,982%	8	5,049	99,235	1,965%
	2048	13,349	291,297	2,182%	6	3,959	85,561	2,161%
	2049	10,894	262,083	2,406%	5	3,085	73,417	2,380%
	2050	8,833	233,145	2,639%	4	2,387	62,288	2,610%
	2051	7,123	208,285	2,924%	3	1,836	53,054	2,889%
	2052	5,709	185,057	3,242%	3	1,404 1,065	44,956 37,116	3,203%
	2053 2054	4,542 3,588	160,060 137,281	3,524% 3,826%	2 2	1,065 802	37,116 30,391	3,485% 3,788%
	2055	2,816	137,281	4,123%	1	601	24,551	3,788% 4,088%
	2056	2,193	96,357	4,394%	1	446	19,463	4,362%
	2057	1,690	77,991	4,615%	1	328	15,054	4,588%
	2058	1,289	60,807	4,717%	1	239	11,219	4,696%
	2059	973	47,072	4,839%	0	172	8,303	4,822%
	2060-2064	2,106	111,224	5,282%	1	335	17,607	5,252%
	2065-2069	323	23,246	7,187%	0	42	2,967	7,148%
His	story	4,804,376	504,099	10%	3,451	7,136,593	643,203	9%
	ture	4,199,826	14,615,783	348%	1,658	2,986,774	7,435,761	249%
Life	time	9,004,201	15,119,882	168%	5,109	10,123,367	8,078,964	80%

Exhibit B-1c MedAmerica, CICA, and CLICNY Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Restated to Assume Implementation of the Originally Requested Rate Increases 780 Series with Auto Inflation Protection

			Without Interest				With Max. Val. Interes	
		A	В	C = B / A	D	E	F	G = F / E
							ll	
	Calendar	Earned	Incurred	Incurred	End of Year	Earned		Incurred
	Year	Premium	Claims	Loss Ratio	Lives	Premium	Claims	Loss Ratio
	1997	0	0	0%	0			0%
	1998 1999	0	0	0% 0%	0		0	0% 0%
	2000	0	0	0%	0		0	0%
	2000	0	0	0%	0	0	0	0%
	2001	0	0	0%	0		0	0%
	2003	26,683	0	0%	61	55,165	0	0%
	2004	223,482	0	0%	262	442,125	0	0%
Historical	2005	449,497	0	0%	407	850,968	0	0%
Experience	2006	786,551	0	0%	718	1,394,107	0	0%
' I	2007	1,124,559	133	0%	802	1,884,317	217	0%
	2008	1,210,537	67,823	6%	775		108,640	6%
	2009	1,118,658	100,932	9%	690	1,720,530	152,362	9%
	2010	1,023,580	20,323	2%	649	1,511,128	30,873	2%
	2011	972,824	32,825	3%	616	1,378,731	47,720	3%
	2012	926,905	82,374	9%	591	1,260,791	114,285	9%
	2013	884,183	204,126	23%	576	1,154,479	266,105	23%
	2014	857,863	374,931	44%	559	1,075,124	468,157	44%
	2015	841,846	141,501	17%	549	1,012,595	168,835	17%
	2016	821,648	323,188	39%	543	948,521	376,556	40%
	2017	805,461	616,302	77%	529	892,404	684,258	77%
	2018	777,140	137,111	18%	507	826,435	146,362	18%
	2019	761,188	500,878	66%	474	776,955	511,629	66%
	2020	892,230	373,580	42%	449	874,133	365,901	42%
	2021	884,953	440,531	50%	436	832,206	413,924	50%
	2022	856,453	519,239	61%	423	773,096	468,041	61%
	2023	826,594	608,358	74%	409	716,230	526,101	73%
	2024	795,403	707,329	89%	395	661,592	586,874	89%
	2025	762,834	813,833	107%	380	609,102		106%
	2026 2027	728,861 693,555	928,295 1,051,846	127% 152%	365 348	558,700 510,398	709,067 770,960	127% 151%
	2028	656,987	1,181,172	180%	332	464,195	830,825	179%
	2029	619,263	1,310,430	212%	315	420,105	884,708	211%
	2030	580,559	1,439,349	248%	297	378,176	932,866	247%
	2030	541,098	1,563,903	289%	279	338,465	973,121	288%
Projected	2032	501,177	1,672,337	334%	260	301,053	999,150	332%
Future	2033	461,247	1,763,685	382%	242	266,088	1,011,832	380%
Experience	2034	421,862	1,837,433	436%	224	233,737	1,012,284	433%
(50 Years)	2035	383,565	1,889,332	493%	206	204,118	999,569	490%
,	2036	346,793	1,921,291	554%	189	177,263	976,098	551%
	2037	311,887	1,946,972	624%	173	153,134	949,890	620%
	2038	279,120	1,966,455	705%	157	131,648	921,337	700%
	2039	248,632	1,972,194	793%	142	112,654	887,330	788%
	2040	220,445	1,968,794	893%	128	95,958	850,713	887%
	2041	194,620	1,960,650	1,007%	115	81,391	813,621	1,000%
	2042	171,153	1,945,152	1,137%	103	68,770	775,233	1,127%
	2043	149,917	1,918,374	1,280%	92	57,877	734,450	1,269%
	2044	130,788	1,882,081	1,439%	82	48,516		1,427%
	2045	113,659	1,835,953	1,615%	72		649,053	1,602%
	2046	98,394	1,775,985	1,805%	64	33,702		1,791%
	2047	84,854	1,707,866	2,013%	56		557,908	1,998%
	2048	72,910	1,637,235	2,246%	49	23,063	514,160	2,229%
	2049	62,430	1,564,242	2,506%	43		472,348	2,489%
	2050	53,273	1,493,189	2,803%	37	15,566	433,696	2,786%
	2051	45,315	1,424,401	3,143%	32		398,042	3,128%
	2052	38,431	1,356,826	3,531%	28 24		364,855	3,516% 3,940%
	2053 2054	32,501 27,408	1,284,338 1,210,478	3,952% 4,417%	20	8,436 6,839	332,388 301,669	3,940% 4,411%
	2055	27,408	1,210,478	4,417%	20 17	5,528	271,409	4,411% 4,910%
	2056	19,305	1,036,989	5,372%	15		239,477	5,378%
	2057	16,108	934,295	5,800%	12			5,809%
	2058	13,380	828,232	6,190%	10			6,197%
	2059	11,059	723,658	6,543%	9		148,255	6,544%
	2060-2064	30,984	2,304,448	7,438%	25		422,508	7,375%
	2065-2069	9,143	870,188	9,518%	9		128,797	9,366%
		5,.70	3.3,.30	5,5.570		.,510	.20,.01	2,00070
His	story	13,612,604	2,602,448	19%	9,308	19,124,891	3,076,001	16%
	-							
Fut	ture	13,412,191	58,701,898	438%	7,063	9,292,506	25,956,348	279%

Exhibit B-2a

MedAmerica, CICA, and CLICNY Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Restated to Reflect Pennsylvania-Specific Rate Increase History and Request 515 Series with Auto Inflation Protection

			Without Interest		With Max. Val. Interest			st
		А	В	C = B / A	D	Е	F	G = F / E
	Calendar	Earned	Incurred	Incurred	End of Year	Earned	Incurred	Incurred
 	Year 1997	Premium 544	Claims 0	Loss Ratio 0%	Lives 10	Premium 1,466	Claims 0	Loss Ratio 0%
	1997	160,240	0	0%	302	412,829	0	0%
	1999	745,926	0	0%	1,148	1,838,992	0	0%
	2000	1,890,494	166,207	9%	1,996	4,460,082	392,118	9%
	2001	3,088,855	145,833	5%	3,163	6,973,470	329,235	5%
	2002	4,396,309	173,328	4%	4,065	9,497,805	374,459	4%
	2003	4,920,879	185,832	4%	4,192	10,173,292	384,183	4%
	2004	4,881,672	546,341	11%	4,010	9,657,642	1,080,853	11%
Historical	2005	4,726,680	1,665,413	35%	3,946	8,948,339	3,152,886	35%
Experience	2006 2007	4,774,621 4,797,776	870,809 805,302	18% 17%	3,970 3,905	8,630,631 8,278,717	1,577,585 1,386,525	18% 17%
	2007	4,658,541	854,361	18%	3,712	7,692,847	1,417,356	18%
	2009	4,424,872	1,578,764	36%	3,502	6,996,702	2,499,144	36%
	2010	4,205,309	1,504,442	36%	3,358	6,366,103	2,285,494	36%
	2011	4,020,008	2,765,000	69%	3,229	5,825,806	4,019,607	69%
	2012	3,864,486	2,253,737	58%	3,118	5,361,255	3,129,971	58%
	2013	3,721,420	2,610,177	70%	3,013	4,942,493	3,474,769	70%
	2014	3,546,875	1,976,488	56%	2,780	4,509,540	2,517,872	56%
	2015	3,583,763	3,263,645	91%	2,598	4,361,718	3,966,108	91%
	2016 2017	3,949,659 3,962,695	4,596,452 4,651,432	116% 117%	2,446 2,350	4,601,439 4,419,249	5,362,036 5,192,510	117% 117%
	2017	3,752,917	4,691,432	125%	2,350 2,211	4,419,249	5,019,753	125%
	2019	3,435,045	5,515,399	161%	2,038	3,510,743	5,637,999	161%
	2020	3,370,366	5,234,823	155%	1,832	3,297,699	5,121,226	155%
	2021	3,682,498	5,660,322	154%	1,741	3,449,460	5,299,836	154%
	2022	4,029,623	6,078,766	151%	1,553	3,613,746	5,447,462	151%
	2023	4,009,983	6,469,694	161%	1,465	3,442,960	5,549,201	161%
	2024	3,740,389	6,957,681	186%	1,377	3,074,792	5,712,021	186%
	2025 2026	3,470,079 3,201,115	7,399,219 7,778,139	213% 243%	1,288 1,199	2,731,261 2,412,502	5,814,356 5,850,575	213% 243%
	2027	2,935,819	8,079,276	275%	1,111	2,118,644	5,817,329	275%
	2028	2,676,376	8,308,608	310%	1,024	1,849,526	5,727,057	310%
	2029	2,425,023	8,466,761	349%	939	1,604,859	5,587,300	348%
	2030	2,183,797	8,582,253	393%	857	1,384,098	5,422,467	392%
	2031	1,954,187	8,652,360	443%	777	1,186,262	5,234,317	441%
Projected	2032	1,737,736	8,651,864	498%	701	1,010,381	5,011,732	496%
Future	2033	1,535,901	8,594,992	560%	629	855,417	4,767,599	557%
Experience (50 Years)	2034 2035	1,349,571 1,179,142	8,489,856	629% 707%	562 499	720,034 602,688	4,509,676	626% 703%
(50 rears)	2036	1,024,623	8,332,966 8,124,922	793%	441	501,751	4,238,897 3,958,119	789%
	2037	885,691	7,869,790	889%	388	415,560	3,671,832	884%
	2038	761,721	7,571,610	994%	339	342,456	3,383,588	988%
	2039	651,882	7,227,940	1,109%	295	280,844	3,093,735	1,102%
	2040	555,180	6,834,457	1,231%	256	229,217	2,802,111	1,222%
	2041	470,588	6,409,169	1,362%	221	186,209	2,517,169	1,352%
	2042	397,003	5,959,856	1,501%	190	150,567	2,242,296	1,489%
	2043	333,327	5,493,621	1,648%	162	121,172	1,980,084	1,634%
	2044 2045	278,523 231,635	5,033,861	1,807% 1,981%	138 117	97,054 77,374	1,738,231	1,791% 1,962%
	2045	191,742	4,588,437 4,164,518	1,981% 2,172%	99	61,398	1,518,015 1,320,044	2,150%
	2047	157,998	3,756,329	2,172%	84	48,501	1,140,802	2,150%
	2048	129,648	3,373,945	2,602%	70	38,153	981,903	2,574%
	2049	105,998	3,017,811	2,847%	59	29,903	841,674	2,815%
	2050	86,413	2,679,247	3,101%	49	23,370	716,215	3,065%
	2051	70,272	2,374,870	3,380%	41	18,219	608,695	3,341%
	2052	57,034	2,096,078	3,675%	34	14,176	515,251	3,635%
	2053	46,249	1,845,068	3,989%	28	11,020	435,047	3,948%
	2054 2055	37,479 30,371	1,620,656	4,324% 4,677%	24 20	8,562 6,652	366,689 308,461	4,283% 4,637%
	2056	24,615	1,420,335 1,239,370	5,035%	16		258,323	4,998%
	2057	19,946	1,075,641	5,393%	13	4,015	215,125	5,358%
	2058	16,160	934,398	5,782%	11	3,119	179,216	5,746%
	2059	13,091	808,304	6,174%	9		148,647	6,137%
	2060-2064	35,984	2,626,678	7,300%	26	5,982	432,128	7,223%
	2065-2069	11,411	1,063,721	9,322%	8	1,538	142,665	9,276%
100		04 500 555	40.007.007	5601	05 000	404 407 777	FC 000 100	,
Histo Futu		81,509,587	40,827,987	50%	65,062 20,697	131,467,726	53,200,462	40%
Lifeti		50,106,188 131,615,776	220,948,214 261,776,200	441% 199%	85,759	36,038,734 167,506,460	120,627,117 173,827,580	335% 104%

Exhibit B-2c

MedAmerica, CICA, and CLICNY Actual and Projected Experience using Current Assumptions by Calendar Year Nationwide Experience Restated to Reflect Pennsylvania-Specific Rate Increase History and No Requested Increase 780 Series with Auto Inflation Protection

Colementary			Without Interest				With Max. Val. Interest		
Permium			А		C = B / A	D			G = F / E
Vest		Colondo		l	lm	Fact -437.	F	lm	I
1997 1998 0		_							Incurred Loss Ratio
1988							0	0	0%
2000									0%
2001			_			· · · · · · · · · · · · · · · · · · ·			0%
2002									0%
2003			-			· · · · · · · · · · · · · · · · · · ·			0%
Historical 2006			_			· · · · · · · · · · · · · · · · · · ·			0% 0%
Historical 2008									0%
Experience 2006 786,551 0 0% 718 1,394,107 0 1,205,59 133 0% 802 1,884,317 217 217 2008 1,121,595 133 0% 802 1,884,317 217 217 2008 1,116,568 10 0,532 9% 600 1,773,503 152,502 2010 1,125,580 10,032 9% 600 1,773,503 152,502 2010 1,125,580 20,035,52 2% 649 1,111,128 30,073 2011 2012 2013 884,183 204,126 23% 514 9% 514 1,202,127 31 144,203 2013 884,183 204,126 23% 576 1,154,479 286,105 2014 877,883 374,931 44% 559 1,775,144 488,157 2015 841,866 141,1501 17% 549 1,101,595 168,835 2016 82,164 83,231,88 39% 543 344,521 376,556 2016 82,164 84 83,231,88 39% 543 344,521 376,556 2016 82,164 84 84,86 141,501 17% 549 1,101,595 168,835 2017 800,481 618,302 77% 529 802,404 644,288 2017 800,481 800,4	Historical						· ·		0%
2007									0%
2008 1.210.537		2007	1,124,559	133	0%	802		217	0%
2010 1,023,860 20,323 2% 649 1,511,128 30,073 2011 972,824 32,825 3% 616 1,378,731 47,720 2012 956,905 82,374 9% 591 1,260,791 114,265 2014 857,863 374,931 44% 559 1,075,124 486,105 2014 857,863 374,931 44% 559 1,075,124 486,105 2016 821,648 323,188 39% 543 948,521 376,566 2017 805,461 616,302 77% 529 802,404 684,258 2017 805,461 616,302 77% 529 802,404 684,258 2019 776,567 500,678 60% 472 741,593 511,629 2019 778,539 388,5183 548,518							1,940,516		6%
2011 972,824 32,825 3% 616 1,378,731 47,720 2013 884,185 204,126 23% 576 1,154,479 268,105 2014 857,863 374,931 44% 559 1,075,124 488,157 2015 841,848 141,501 17% 549 1,102,995 188,355 2016 82,148 323,188 39% 543 948,521 376,556 2017 805,461 616,302 778, 529 802,244 684,259 2018 2019 777,141 137,111 18% 547 2018 2019 2019 777,141 137,111 18% 547 2018 2019 2019 775,356 2019 201									9%
2012 202,000 82,374 9% 591 1,280,791 114,285									2%
2013									3% 9%
2014 857,863 374,831 44% 550 1.075,124 468,157									23%
2015 2016 281,648 323,188 39% 543 484,521 376,556 2017 2016 2017 205,461 616,302 77% 529 892,404 684,258 2018 777,140 137,111 181% 507 262,435 146,362 2019 726,547 500,378 69% 474 741,593 511,629 2020 783,5396 368,519 50% 435 720,486 360,044 2021 798,933 426,703 54% 422 749,448 400,933 446,703 446,703 446,703 447,704,703 445,412 2023 772,031 686,565 500,066 500,066 500,044 422 749,448 400,933 446,703 446,703 446,703 446,412 2023 776,213 686,565 500,066 500									44%
2016									17%
2017									40%
2019 726,647 500,878 69% 474 741,583 511,829 735,396 386,519 50% 435 720,486 380,944 2021 2021 2023 785,398 386,519 50% 436 422 749,486 400,933 426,703 54% 422 749,486 400,933 456,312 2023 792,031 590,509 75% 396 686,302 510,673 2024 2025 731,036 790,005 108% 388 583,742 628,917 620,520 608,537 901,154 129% 355 353,489 688,338 683,742 628,917 620,520 629,782 1146,628 152% 337 489,246 748,442 2029 2030 2031 518,929 1,518,610 293% 270 324,639 945,019 2030 2031 518,929 1,518,610 293% 270 324,639 945,019 270,244 288,821 2034 2034 404,874 1,785,046 41% 217 224,363 983,560 670 2035 368,233 1,835,530 499% 200 196,966 971,470 2035 2036 203		2017	805,461	616,302	77%	529	892,404	684,258	77%
2020									18%
2021 2022 2023 280.883 500.003 54% 422 749.486 400.933 2022 2023 782.031 590.509 75% 396 686.302 510.673 2024 2025 782.031 590.509 75% 396 686.302 510.673 2026 2026 2026 686.567 901.154 129% 383 583.422 628.917 2028 686.567 901.154 129% 353 535.489 688.388 883.742 628.917 2028 664.764 1.021.084 154% 337 489.246 748.442 2028 659.697 1.272.157 214% 344 402.801 868.922 2029 596.697 1.272.157 214% 344 402.801 868.922 2031 518.929 1.156.10 239% 227 322.699 905.808 322 2031 518.929 1.156.10 239% 227 322.699 945.019 2031 518.929 1.156.10 239% 227 228.8821 970.424 514.92 2033 442.561 1.713.032 387% 224 228.8821 970.424 514.92 2033 442.561 1.713.032 387% 224 228.8821 970.424 529.698 2035 368.233 1.889.930 449% 200.235 368.233 1.889.930 449.96 2035 2036 333.042 1.867.462 561% 183 170.269 948.921 2037 228.688 268.246 1.191.2.520 713% 152 126.549 866.272 2039 230.903 1.187.729 2039 230.903 1.187.729 2039 230.903 1.187.729 204.44 1.187.445 1.188.988 1.150% 100 66.205 755.040 1.187.246 1.188.335 1.188.335 1.189.976 622% 1.267.49 866.272 204.44 1.27.45 1.368.168 1.189.976 622% 1.27.45 1.28.549 866.272 204.44 1.27.45 1.368.168 1.189.976 622% 1.27.45 1.28.549 866.272 204.44 1.27.45 1.368.168 1.187.29 803% 1.38 863.044 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.35 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45 2.24.45									69%
2022									50% 53%
2023									53% 61%
2024									74%
2026									90%
Decided Color									108%
2028 629.782 1,146.628 182% 321 445.012 806.567 807.000 80		2026	698,537	901,154	129%	353	535,489	688,358	129%
2029									153%
Projected 2032									181%
Projected 2031 File 929									213%
Projected 2032									250% 291%
Eutine 2033	Projected								291% 336%
Experience (50 Years) 2034 (40 4,874 1,785,046 4411% 217 224,363 983,560 (50 Years) 2035 388,233 1,835,930 499% 200 195,996 971,470 2036 333,042 1,867,462 561% 183 170,269 948,921 32037 299,626 1,892,976 632% 167 147,147 923,735 2038 268,246 1,912,520 713% 152 126,649 896,272 2039 239,035 1,918,729 803% 138 108,333 863,404 2040 212,015 1,915,921 904% 124 92,313 828,094 4 2041 187,245 1,906,511 1,019% 112 78,328 792,220 11, 2042 164,723 1,893,888 1,150% 100 66,205 755,040 1, 2043 144,329 1,866,186 12,244% 89 55,736 715,470 1, 2044 125,945 1,833,114 1,455% 79 46,733 674,541 1, 2045 199,473 1,788,335 1,634% 70 39,033 632,432 11, 2046 94,785 1,730,021 1,825% 62 32,476 580,057 1, 2047 81,752 1,663,758 2,035% 54 26,917 543,679 2, 2048 70,248 1,594,980 2,270% 47 22,228 501,052 2, 2049 60,152 1,523,872 2,533% 41 18,292 460,301 2, 2050 513,330 1,454,629 2,834% 36 15,002 422,622 2, 2051 43,662 1,387,744 3,178% 31 12,266 387,907 3, 2052 37,029 1,322,098 3,570% 27 9,999 355,609 3, 2053 31,315 1,251,741 3,997% 23 8,130 324,031 3, 30,205 12,520,205 143,662 1,387,744 3,178% 31 12,266 387,907 3, 2055 22,200 1,102,676 4,967% 17 5,327 2,64,674 4,1 2,205 2,205 10,653 705,448 6,622% 8 2,182 144,545 6,6 2056 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 206,2064 29,819 2,242,636 7,521% 24 5,514 411,251 7, 2058 2060 8,766 657,114,508 450% 6,838 8,74644 25,248,194 25,248,194									385%
(50 Years) 2035									438%
2036									496%
2038		2036	333,042	1,867,462	561%	183	170,269	948,921	557%
2039 239,035 1,918,729 803% 138 108,333 863,494 2040 221,015 1,915,921 904% 124 92,313 828,094 1			299,626						628%
2040									708%
2041							· ·		797%
2042									897% 1 011%
2043									1,011% 1,140%
2044									1,140%
2045									1,443%
2046									1,620%
2047		2046	94,785	1,730,021	1,825%	62	32,476	588,057	1,811%
2049				1,663,758	2,035%	54			2,020%
2050 51,330 1,454,629 2,834% 36 15,002 422,622 2,4 2,51 43,662 1,387,744 3,178% 31 12,266 387,907 3, 2052 37,029 1,322,098 3,570% 27 9,999 355,609 3, 2053 31,315 1,251,741 3,997% 23 8,130 324,031 3, 2054 26,408 1,179,965 4,468% 20 6,591 294,130 4, 2055 22,200 1,102,676 4,967% 17 5,327 264,674 4, 2056 18,601 1,011,254 5,437% 14 4,291 233,576 5, 2057 15,520 911,123 5,871% 12 3,442 202,374 5, 2058 12,890 807,626 6,266% 10 2,748 172,357 6, 2059 10,653 705,448 6,622% 8 2,182 144,545 6,4 2060-2064 29,819 2,242,636 7,521% 24 5,514 411,251 7,4 2065-2069 8,767 843,729 9,624% 8 1,318 124,893 9,4 2060-2064 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194 25,248,194									2,254%
2051									2,516%
2052 37,029 1,322,098 3,570% 27 9,999 355,609 3,505,009 3,50									2,817% 3 163%
2053 31,315 1,251,741 3,997% 23 8,130 324,031 3,1 254 26,408 1,179,965 4,468% 20 6,591 294,130 4,4 2055 22,200 1,102,676 4,967% 17 5,327 264,674 4,5 2056 18,601 1,011,254 5,437% 14 4,291 233,576 5,5 2057 15,520 911,123 5,871% 12 3,442 202,374 5,4 2058 12,890 807,626 6,266% 10 2,748 172,357 6,2 2059 10,653 705,448 6,622% 8 2,182 144,545 6,1 2065-2069 8,767 843,729 9,624% 8 1,318 124,893 9,4 2065-2069 13,577,962 2,602,448 19% 9,308 19,089,530 3,076,001 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194 25,									3,163% 3,556%
2054 26,408									3,556%
2055 22,200									3,966% 4,463%
2056									4,969%
2057									5,443%
2058		2057	15,520	911,123	5,871%	12	3,442	202,374	5,880%
2060-2064 29,819 2,242,636 7,521% 24 5,514 411,251 7,4 2065-2069 8,767 843,729 9,624% 8 1,318 124,893 9,4 13,577,962 2,602,448 19% 9,308 19,089,530 3,076,001 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194 25,248,1			12,890		6,266%		2,748	172,357	6,273%
2065-2069 8,767 843,729 9,624% 8 1,318 124,893 9,624% 13,577,962 2,602,448 19% 9,308 19,089,530 3,076,001 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194									6,623%
History 13,577,962 2,602,448 19% 9,308 19,089,530 3,076,001 Future 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194									7,459%
Future 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194		∠∪05-2069	8,767	843,729	9,624%	8	1,318	124,893	9,473%
Future 12,695,766 57,114,508 450% 6,838 8,746,440 25,248,194	Hiet	tory	13 577 962	2 602 448	10%	g 308	19 089 530	3 076 001	16%
		-				·			289%
Lifetime 26,273,728 59,716,956 227% 16,146 27,835,969 28,324,195			26,273,728	59,716,956	227%	16,146	27,835,969	28,324,195	102%

Address: 165 Court Street, Rochester, New York 14647

Supplement to the Actuarial Memorandum

July 28, 2021

<u>Product</u>	<u>Number</u>
515 Series	
Tax-Qualified Long-Term Care Policy Form	14515-PA
780 Series	
Tax-Qualified Long-Term Care Policy Form	14785-PA

In 2008, MedAmerica Insurance Company (MedAmerica) acquired the long-term care block of business issued by Combined Insurance Company of America (CICA) from Ace Ltd. and subsequently submitted a certificate of assumption filing. As a result, most of the nationwide policies are now on MedAmerica paper; however, approximately 16% of the in-force policyholders nationwide objected to the assumption filing and remain on CICA paper. In Pennsylvania, all of the in-force policies are on MedAmerica paper. MedAmerica has 100% of the risk on this form(s), including policies on CICA paper, and administers and manages the entire block.

This supplement captures the pooled experience of the policy form(s) listed above as well as similar nationwide policy forms of the 515, 700, and 780 Series. Section 15 of the enclosed actuarial memorandum provides a description as to the appropriateness of pooling the experience of these policy forms. Pennsylvania-specific experience is not considered fully credible but is being provided as required. Pennsylvania-specific actual and projected experience reflects prior rate increases filed for use between May 2014 and August 2020.

A. Purpose of Supplement

This supplement has been prepared for the purpose of demonstrating that the requested rate increase is in compliance with Chapter 18 Section 3803(c) and Reg. 89.83 of the Insurance Regulations for the state of Pennsylvania, as well as provide items generally requested by the Department. It may not be appropriate for other purposes.

B. Demonstration of Compliance with Chapter 18 Section 3803

(c): We believe that we comply with this subsection of the regulation by submitting these rates before they are being used.

C. Demonstration of Compliance with Reg. 89.83

- (a): This subsection requires no action.
- (b): This subsection is not applicable since this filing is not for rates for a new policy form.
- (c): Revision of Current Rates
- (1): For policies issued prior to September 16, 2002, the effective date of rate stability in Pennsylvania, the minimum loss ratio requirement is 60%, as specified in Reg. 89a.117.(b). For policies issued on or after September 16, 2002, the loss ratio requirements are specified in Reg. 89a.118.(c)(2), (i.e., the 58%/85% test). Demonstration of satisfaction of these requirements is discussed in Section 15 of the enclosed actuarial memorandum.

As of December 31, 2019, 4 of the 93 policies that are in force and subject to the requested rate increase in Pennsylvania were issued on or after September 16, 2002 (approximately 4%). However, because the company manages this block of business as a whole, this rate increase filing complies with both sets of requirements for all of the policies, regardless of issue date.

- (2): Section 3 of the actuarial memorandum provides a description of benefits. Copies of the affected policy form(s) may be provided upon request.
- (2)(i): The primary reason why these forms are in need of a premium rate increase is due to emerging experience running more adverse than expected in pricing.

Address: 165 Court Street. Rochester. New York 14647

Supplement to the Actuarial Memorandum

July 28, 2021

Nationwide, the company is requesting a premium rate increase that varies by series and inflation protection option to achieve the cumulative rate increases as shown in Section 2 of the enclosed actuarial memorandum. The company is seeking this current rate increase request to help alleviate the adverse performance on this block of business. The cumulative rate increase levels were determined to vary by series and inflation protection option to better align the rate increase with the adverse experience. The table in Section 2 of the enclosed actuarial memorandum provides the average prior, requested, and cumulative increase by series and inflation protection option based on the nationwide distribution. The enclosed cover letter provides similar information on the Pennsylvania-specific distribution.

The current rate schedules along with the proposed rate schedules are enclosed with this filing. Please note that the actual rates implemented may vary slightly from those shown due to rounding algorithms.

Exhibit I of the actuarial memorandum provides nationwide earned premium and incurred claim actual and projected experience using current assumptions, as described in Section 6 of the actuarial memorandum. Attachment 1 to this supplement provides nationwide written premium and paid claim actual and projected experience using current assumptions. Values in Exhibit I and Attachment 1 are shown both before and after the requested rate increase. The interest rate used in Exhibit I and Attachment 1 to accumulate and discount values is the maximum valuation interest rate for contract reserves applicable for the year of issue (which ranges from 4.0% to 4.5%, and averages 4.4%).

Attachments 2 and 3 to this supplement provide similar information as Exhibit I and Attachment 1 respectively, except using Pennsylvania-specific experience.

(2)(ii)(A): There have been four rate increases approved and implemented on the 515 Series in Pennsylvania. The Department approved increases of 15%, 20%, 20%, and 20% in May 2014, June 2015, August 2019, and August 2020, respectively. The 20% increases approved in August 2019 and August 2020 were on policies with auto inflation only.

There has been one rate increase approved and implemented on the 780 Series in Pennsylvania for auto inflation policies. The Department approved a cumulative 35.0% increase, phased-in over two years, in August 2019. The rate increase was implemented as a 20.0% increase followed by a 12.5% increase to be implemented no sooner than one year after the first increase of 20.0%. The company is not requesting a rate increase on 780 Series policies at this time.

(2)(ii)(B): Commission scales varied by duration to produce an average of 13.6% of premium over each series policies' lifetime. Commissions were assumed to be paid on original premium at issue and not on waived premiums.

The company adjusts renewal commission rates so that total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

(2)(ii)(C)(I): Premiums earned and written since inception for nationwide experience can be found in Exhibit I of the actuarial memorandum and Attachment 1 to this supplement, respectively. Premiums earned and written since inception for Pennsylvania-specific experience can be found in Attachments 2 and 3, respectively. Attachment 4 to this supplement provides reserve balances and the calculation basis for both nationwide and Pennsylvania-specific experience.

(2)(ii)(C)(II): Attachment 4 to this supplement provides a breakdown of historical incurred claims and active life reserve balance, including a description of the calculation basis, for both nationwide and Pennsylvania-specific experience.

Attachment 5 to this supplement provides actual and projected experience on a durational basis using current assumptions. Included are policy year earned premiums, incurred claims, durational loss ratios, end of year lives, and cumulative loss ratios with interest. Values in Attachment 5 are shown both before and after the requested rate increase. The number of durations shown was chosen to capture the majority of the durations underlying Exhibit I. Similar to Exhibit I and Attachments 1 through 3, the values used to calculate the cumulative loss ratios are accumulated and discounted at the maximum valuation interest rate.

Address: 165 Court Street, Rochester, New York 14647

Supplement to the Actuarial Memorandum

July 28, 2021

Attachment 6 to this supplement provides similar information to Attachment 5, except for Pennsylvania-specific experience.

Please note that totals in Attachments 5 and 6 may not tie exactly to Exhibit I and Attachment 2, respectively, because the experience periods captured differ slightly between calendar year and duration.

(2)(ii)(D): We believe that we have provided information sufficient to support the rate increase requested in this filing.

(2)(iii): We understand that data used in this rate increase filing is in agreement with those used in the annual statement filed with the Department.

(d): We believe the proposed rate tables provided with this filing comply with this subsection.

D. Demonstration of Compliance with Generally Requested Information

The table below provides the number of in-force policyholders subject to the requested rate increase split by issue date, series, and inflation protection option. As indicated in the enclosed cover letter for the 780 Series policies, the prior requested rate increase was approved in full. The company is not requesting a rate increase on 780 Series policies at this time.

Pennsylvania-Specific In-Force Life Count^[1]

	Inflatio	Inflation Protection Option							
Series	Non-Auto	Auto	All						
	Issued Prio	r to 9/16/200	2						
515	56	89	145						
780	0	0	0						
	Issued On or	After 9/16/20	002						
515	19	4	23						
780	33	21	54						
	All Issue Dates								
All	108	108 114 222							

[1] As of December 31, 2019.

Attachment 7 to this supplement provides a status of the rate increase filings, along with the current requested increases. The status is shown for each jurisdiction in which there is business in force as of December 31, 2019. Also included in the attachment are the number of policies and annualized premium as of December 31, 2019. Attachment 7 provides the status of (a) the first round and associated follow-up and (b) the current round and the first and second follow-up filings for the current round of the rate increase requests.

As part of this rate increase process, an increase has been or is expected to be requested in most jurisdictions. The company anticipates requesting an actuarially equivalent cumulative rate increase level in all jurisdictions except where limited due to regulatory requirements or the limited amount of inforce business. In jurisdictions where the company has not yet reached a decision regarding the current rate increase or the prior reduced rate increase was phased-in over multiple years, Attachment 7 indicates "TBD" (to be determined).

E. Description of Attachments and Enclosures

An Excel workbook containing the values shown in Exhibits I and II of the actuarial memorandum and Attachments 1 through 7 to this supplement is enclosed with this filing, as required.

Address: 165 Court Street, Rochester, New York 14647

Supplement to the Actuarial Memorandum

July 28, 2021

Attachment 1: Nationwide Actual and Projected Written Premium and Paid Claims Attachment 2: Pennsylvania-Specific Actual and Projected Experience

Attachment 3: Pennsylvania-Specific Actual and Projected Written Premium and Paid Claims Attachment 4: Nationwide and Pennsylvania-Specific Claim Breakdown and Reserve Balances

Attachment 5: Nationwide Actual and Projected Experience by Policy Year

Attachment 6: Pennsylvania-Specific Actual and Projected Experience by Policy Year

Attachment 7: Status Listing

Enclosures: Exhibits and Attachments in Excel

Current and Proposed Premium Rate Schedules

Attachment 1-a MedAmerica, CICA, and CLICNY

Written Premium and Paid Claim Experience and Projections by Calendar Year Nationwide Experience Before Requested Rate Increase 515, 700, and 780 Series

Cale of the Color			Without Interest			With Max. Val. Interest				
Permitted 1997				А	В	C = B / A	D	E	F	G = F / E
Permitted 1997		Calendar		\M/ritton	Paid		End of Vear	Writton	Paid	
1997 8,776 0						Loss Ratio				Loss Ratio
1999										
2000				546,203				1,407,196		
2001 0.244,052 59.391 1% 0.197 14.119.200 134,083 130,013 2002 2003 0.370,180 271,339 3% 8.572 19.371,655 500,568 370,180 271,339 3% 8.572 19.371,655 500,568 370,010 271,339 3% 8.572 19.371,655 500,568 370,010 271,339 3% 8.572 19.371,655 500,568 370,000 370,000 371,000 37										0%
2002 8.411.85										1%
2003 9,370,160 271,339 3% 8,572 19,371,685 560,068 16terical 2005 10,183,677 721,854 7% 9,500 19,278,693 1,306,543 2006 10,183,677 721,854 7% 9,500 10,278,693 1,306,543 2006 12,186,114 1,749,755 14% 10,739 20,086,202 3,033,368 2008 11,136,409 2,149,275 14% 10,739 20,086,202 3,033,368 2016 2010										1% 1%
Milestrical 2006 9,885,450 275,385 3% 8,787 19,161,183 544,786 2006 11,539,866 1,077,814 9% 10,611 20,742,590 1,952,692 2007 21,861,141 1,749,755 14% 10,730 20,866,202 3,033,368 2009 11,904,700 21,207,726 18% 10,220 19,006,439 3,519,376 2009 11,904,700 21,207,726 18% 10,220 19,006,439 3,519,376 2010 10,469,896 22,419,276 22% 8,431 15,742,784 4,602,551 2010 20,863,769 3,405,207 3,448 8,507 141,134,606 2,573,765 2,585 8,531 15,742,784 4,602,551 2012 9,008,202 4,680,155 2,578 4,600,155										3%
instoncial 2006										3%
2007	Historical									7%
2008	Experience	2006		11,539,366	1,077,814	9%	10,611	20,742,509	1,952,602	9%
2009				12,186,114	1,749,755				3,033,368	15%
2010			l l							189
2011										22%
2012 9.481.249 4.159.473 4.4% 8.133 13.086,969 5.770,143 2013 9.099.229 4.680,155 52.9% 7.792 11.912.260 6.220.787 2014 8.516.217 4.716.039 55% 7.710 11.912.260 6.020.787 2016 8.284.471 6.516.618 79% 6.444 12.021.889.376 7.590,790 2016 8.224.471 6.516.618 79% 6.277 9.558.744 7.994.376 7.907.90 2018 7.459,163 8.488.601 11.4% 5.592 7.954.994 9.603.346 1 2019 7.459,163 8.488.601 11.4% 5.592 7.954.994 9.603.346 1 2019 7.113.632 8.617.453 12.1% 5.211 7.267.849 9.603.346 1 2020 6.949.227 6.405.042 92% 4.894 6.2018.70 7.713.201 1 2020 6.949.227 6.405.042 92% 4.894 6.2018.70 7.713.201 1 2020 6.399.831 8.621.007 13.00% 4.001 5.117.100 7.733.201 1 2020 6.399.831 8.621.007 13.00% 4.001 5.117.100 7.733.201 1 2020 6.599.97 1 10.291.983 11.054.555 216% 3.861 4.047.170 8.703.000 2 2020 6.717.334 11.764.990 249% 3.801 3.801 4.047.170 8.703.000 2 2020 6.771.335 11.054.555 216% 3.861 4.047.170 8.703.000 2 2020 7.334.236 11.244.507 287% 3.044 3.140.76 8.893.809 3.300 3.574.554 8.870.400 2 2020 3.394.276 12.244.507 287% 3.044 3.140.76 8.894.88 2 2020 3.3575.800 13.484.732 377% 2.552 2.366.808 8.835.609 3 3.224.610 13.898.323 14.234.764 4.92% 2.005 1.774.198 8.835.809 3 3.224.610 13.898.323 14.234.764 4.92% 2.005 1.774.198 8.835.809 3 3.224.610 13.898.323 14.234.764 4.92% 2.005 1.774.198 8.835.809 3 3.224.610 13.898.323 14.234.764 4.92% 2.005 1.774.198 1.784.509 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.284.509 1.284.764 1.284.701 1.										25%
2013										34% 44%
2014 8.518,217 4.718,039 55% 7.110 10.728,045 6.006,565 12015 8.408,405 6.237,727 74% 6.644 10.20136,000 7.590,790 2016 8.224,471 6.518,618 79% 6.272 9.588,744 7.594,376 2017 7.877,373 7.134,910 91% 5.88 8.770,489,476 7.957,649 12018 7.459,163 8.489,001 114% 5.592 7.954,994 9.063,346 1 12019 7.113,632 8.617,463 121% 5.218 7.267,849 9.063,346 1 12019 7.113,632 8.617,463 121% 5.218 7.267,849 9.063,346 1 1 14% 4.623 6.502,870 7.171,250 1 2020 6.949,227 6.405,042 1 14% 4.623 6.502,870 7.717,1250 1 2022 6.359,631 8.621,007 139% 4.356 5.714,019 7.731,281 1 2023 5,943,776 9.484,952 160% 4.091 5.117,101 7.731,281 1 2023 5,943,776 9.484,952 160% 4.091 5.117,101 8.144,258 1 2024 5.599,497 10.291,983 168% 3.825 4.641,767 8.461,847 1 17.64,990 2.49% 3.802 5.002 8.2026 4.717,334 11,764,990 2.49% 3.802 5.002 8.354,376 8.804,847 1 2.2026 3.942,878 12.2414,507 2.87% 3.044 3.140,764,548 8.804,604 3.2026 3.942,878 12.290,626 3.29% 2.794 2.745,328 8.884,664 3.2020 3.2026 3.942,878 12.900,526 3.29% 2.794 2.745,328 8.884,664 3.2020 3.2030 3.224,610 13,888,323 437% 2.652 2.288,888,684 8.2020 3.002 2.575,588 14,234,754 4.02% 2.095 1.774,191 8.803,300 3 3 224,610 13,888,323 437% 2.522 2.288,888,684 8.2020 3.302 3.224,610 13,888,323 437% 2.525 2.288,888,684 8.203,300 3 3 224,610 13,888,323 437% 2.595 2.288,888,684 8.203,300 3 3 224,610 13,888,323 437% 2.595 2.288,888,684 8.203,300 3 3 224,610 13,888,323 437% 2.652 2.288,888 8.833,800 3 3 224,610 13,888,323 437% 1.000,652 1.774,632 8.803,300 3 3 224,610 13,888,323 437% 1.000,652 1.774,632 8.803,300 3 3 224,610 13,888,323 437% 1.000,652 1.774,632 8.803,300 3 3 224,610 13,888,323 437% 1.000,652 1.774,632 8.803,300 3 3 224,610 13,888,323 437% 1.000,652 1.774,632 8.803,300 3 3 224,610 13,833,323 1.000,652 1.774,652 8.803,300 3 3 224,610 13,833,323 1.000,652 1.774,653 8.603,300 3 3 224,610 13,833,323 1.000,652 1.774,653 8.603,300 3 3 224,610 13,833,323 1.000,652 1.774,653 8.603,300 3 3 224,610 13,833,323 1.000,652 1.784,653 8.603,300 3 3 224,610 13,833,323 1.000,652 1.784,653 8.603,300 3 3 2										52%
2016 8.294,471 6.518.618 79% 6.272 9.556,744 7.594,376 2017 7.677,973 7.134,910 91% 5.963 8.770,488 7.957,649 2018 7.7459,183 8.489,001 114% 5.962 7.949,494 9.063,346 1 7.113,632 8.617,453 121% 5.218 7.267,843 8.07.507 1 2020 6.494,227 6.405,042 92% 4.884 6.81,870 - 0.686,769 2021 6.721,359 7.655,962 114% 4.623 6.302,989 7.171,250 1 6.356,831 8.621,007 139% 4.356 5.714,019 7.731,261 1 2023 5.443,776 9.484,962 160% 4.091 5.117,105 8.446,871 1.2024 5.529,477 10.291,893 186% 3.625 4.561,756 8.461,847 1 2026 5.529,447 10.291,893 186% 3.625 4.561,756 8.461,847 1 2026 5.119,933 11,064,535 216% 3.3691 4.047,910 8.964,438 2 2027 4.324,236 12,414,507 287% 277% 2.552 2.386,898 8.964,438 2 2029 3.575,808 13,484,372 377% 2.552 2.386,898 8.984,684 3 2029 3.575,808 13,484,372 377% 2.552 2.386,898 8.933,809 3 3.224,810 13,889,323 431% 2.319 2.083,826 8.821,396 4 324,326 12,414,507 5.262 14,44,407										56%
2016 8.224,471 6.518,618 79% 6.272 9.558,744 7.594,376 2017 7.677,073 7.134,910 91% 5.063 8.704,88 7.057,649 2018 7.450,163 8.489,001 114% 5.592 7.564,994 9.063,346 1 7.118,632 8.617,453 121% 5.218 7.267,843 8.807,507 1 1 2 2020 6.949,227 6.450,623 121% 5.218 7.267,843 8.807,507 1 1 2 2021 6.594,227 7 9.484,022 192% 4.894 6.801,870 6.268,769 1 2 2022 6.536,631 8.821,007 138% 4.358 5.714,019 7.731,281 1 2 2022 6.536,631 8.821,007 138% 4.358 5.714,019 7.731,281 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2024 5.529,467 1 0.291,983 1 186% 3.825 4.561,756 8.461,847 1 2 2026 4.717,334 1 1.764,999 249% 3.300 3.574,554 8.870,400 2 2 2026 4.717,334 1 1.764,999 249% 3.300 4.314,0761 8.904,438 2 2 2 2 2 2 2 3 3.452,988 1 3.484,372 377% 2.555 2 2.366,988 9.903,809 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2										74%
2018 7,459,163 8,489,001 114% 5,592 7,984,994 9,063,346 1 2019 6,049,227 6,045,050 121% 5,2218 7,267,843 8,075,507 1 2020 6,049,227 6,045,062 114% 4,023 6,029,89 7,717,250 1 2021 6,059,631 8,821,007 130% 4,358 5,714,019 7,731,261 1 2022 6,039,631 8,821,007 130% 4,358 5,714,019 7,731,261 1 2024 5,229,497 10,291,983 180% 3,825 4,561,756 8,461,847 1 2024 5,529,497 10,291,983 180% 3,825 4,561,756 8,461,847 1 2026 5,119,933 11,054,355 2,18% 3,825 4,561,756 8,461,847 1 2026 4,777,334 11,764,999 240% 3,300 3,574,554 8,670,400 2 2027 4,324,236 12,414,507 287% 3,044 3,140,761 8,044,438 2 2028 3,442,978 12,990,526 329% 2,794 2,745,328 8,094,684 3 2029 3,575,808 12,990,526 329% 2,794 2,745,328 8,094,684 3 2029 3,575,808 12,484,372 377% 2,555 2,296,808 8,033,809 3 2030 3,224,610 13,889,323 431% 2,319 2,003,828 8,094,684 3 2031 2,208,208 14,484,701 562% 2,005 1,774,197 8,656,619 4 2032 2,276,226 14,484,701 562% 1,885 1,284,709 8,440,882 5 2,276,226 14,484,701 562% 1,885 1,284,709 1,771,447 8,056,619 4 2,276,226 14,484,701 562% 1,885 1,284,709 1,771,744 8,200 1,281,281,281,281,281,281,281,281,281,28										79%
2019				7,877,973						91%
2020										114%
2021 6 721 359 7 ,7655,962 114% 4,623 6 302,889 7,171,250 1 2 202 2 3 5,843,776 9,484,952 160% 4,091 5,117,105 8,144,258 1 1 2 2023 5,843,776 9,484,952 160% 4,091 5,117,105 8,144,258 1 1 2 2024 5,529,497 10,291,983 186% 3,825 4,561,756 8,481,847 1 1 2 2025 5,119,933 11,094,435 216% 3,561 4,047,910 8,703,300 2 2 2026 4,717,334 11,764,999 249% 3,300 3,574,554 8,870,400 2 2 2 2 2 2 3 3,842,396 12,414,607 287% 3,044 3,140,761 9,964,438 2 2 2 2 2 2 3 3,575,808 13,484,372 377% 2,552 2,368,898 6,933,899 200 3,324,610 13,898,323 431% 2,319 2,063,826 8,821,396 4 2 2 2 2 2 2 2 2 4 1,484,701 562% 13,898,223 2 2 2 2 2 2 4 1,484,701 562% 1,884 1 1,516,315 8,440,882 2 2 2 2 2 2 2 2 4 14,642,736 642% 1,685 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2								· · · · ·		121%
Decided Color Co										92%
Decided Deci										114% 135%
Decided 10,291,983										159%
2025										1859
2027		2025								215%
2028		2026		4,717,334	11,764,999	249%	3,300	3,574,554	8,870,400	248%
2029 2030 3.575.808 13.484.372 377% 2.552 2.386.898 8.933.699 3. 2030 3.224.610 13.898.323 431% 2.319 2.063.826 8.821.396 4. 2031 2.890.835 14.234,754 492% 2.095 1.774.197 8.6566.619 4. 2032 2.576.226 14.484,701 562% 1.884 1.516.315 8.440.682 5. 2.282.440 14.642,736 642% 1.685 1.288.470 8.177.144 6. 2032 2.282.440 14.642,736 642% 1.685 1.288.470 8.177.144 6. 2034 2.2010.652 14.709.304 732% 1.499 1.088.736 7.872.599 7. 2035 1.761.503 14.686.163 834% 1.327 914.999 7.533.744 8. 2036 1.535.104 14.574.959 949% 1.170 764.991 7.166.536 9. 2037 1.331.142 14.380.377 1.080% 1.027 638.446 6.777.874 1.0. 2039 986.843 13.769.512 1.395% 87 527.028 6.375.158 1.2 2040 843.912 13.363.239 1.583% 677 356.517 5.549.390 1.3 2041 718.679 12.895.937 1.795% 584 291.338 5.134.653 1.7 2042 69.287 12.374.181 2.031% 502 2.370.88 4.724.205 1.9 2043 514.494 11.806.413 2.295% 430 192.157 4.322.329 2.2 2044 432.651 11.203.554 2.590% 367 155.104 3.933.492 2.5 2046 302.166 9.933.842 3.288% 264 99.819 3.208.423 3.2 2047 2.510.38 9.285.078 1.295.89% 264 9.819.89 3.005.423 3.2 2048 207.811 8.639.007 4.157% 188 63.271 2.267.661 3.6 2049 171.470 8.003.960 4.668% 158 50.124 2.287.661 3.5 2051 115.785 6.792.816 5.869% 92 2.4544 1.570.633 4.5 2052 9.4834 6.286.68 9.93.842 3.288% 264 99.819 3.208.423 3.2 2055 141.107 7.556 6.792.816 5.869% 132 39.959 2.021.143 5.1 2051 115.785 6.792.816 5.869% 132 39.959 2.021.143 5.1 2051 115.785 6.792.816 5.869% 132 39.959 2.021.143 5.1 2051 115.785 6.792.816 5.869% 132 39.959 2.021.143 5.1 2051 115.785 6.792.816 5.869% 132 39.959 2.021.143 5.1 2051 141.072 7.386.123 5.286% 99 2.4544 1.570.63 6.7 2052 9.8834 6.228.668 9.92.816 5.869% 92 2.4544 1.570.63 6.7 2052 9.8334 6.228.668 9.92.816 5.869% 92 2.4544 1.570.63 6.7 2052 9.8334 6.228.668 9.92.816 5.869% 92 2.4544 1.570.63 6.7 2052 9.8334 6.228.668 9.92.816 5.869% 92 2.4544 1.570.63 6.7 2056 4.2171 4.273.934 10.135% 44 9.290 918.347 9.8 2057 3.4350 3.585.047 11.277% 69 9.127% 53 11.858 1.054.945 9.8 2066-2064 6.265 10.729.266 17.287% 69 10.932 2.1837.346 18.8 2066-2064		2027		4,324,236	12,414,507			3,140,761	8,964,438	285%
2030 224,610 13,888,323 431% 2,319 2,063,826 8,821,396 4										327%
Trojected 2031 2,890,835 14,234,754 492% 2,095 1,774,197 8,656,619 44 2032 (2,576,226 14,484,701 562% 1,884 1,516,315 8,440,882 5 2,282,440 14,642,736 642% 1,685 1,288,470 8,177,144 66 2033 (2,282,440 14,642,736 642% 1,685 1,288,470 8,177,144 66 2034 (2,016,652 14,709,304 732% 1,499 1,088,736 7,872,599 7 1,761,503 14,686,163 834% 1,327 914,993 7,533,744 88 2036 1,535,104 14,574,959 949% 1,170 764,991 7,166,536 9 1,331,142 14,380,377 1,080% 1,027 636,446 6,777,874 1,0 2039 986,843 13,769,512 1,395% 781 4344,30 5,964,251 1,3 2039 986,843 13,769,512 1,395% 781 434,430 5,964,251 1,3 2040 1718,579 12,895,937 1,795% 584 291,338 5,134,653 1,7 2042 609,287 12,374,181 2,031% 502 237,088 4,724,205 1,9 2044 432,651 11,806,413 2,295% 430 192,157 4,322,329 2,2 2044 432,651 11,203,554 2,590% 367 155,104 3,933,492 2,5 2045 362,305 10,576,202 2,919% 312 124,678 3,561,320 2,8 2047 251,038 9,285,078 3,899% 224 99,819 3,208,423 3,2 2047 251,038 9,285,078 3,699% 224 99,819 3,208,423 3,2 2049 171,470 8,003,980 4,688% 158 50,124 2,282,425 4,5 2056 14,072 7,386,123 5,286% 92 4,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2055 11,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2057 2,055 11,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2057 2,059 2,059 2,059 2,069 2,0										374%
rojected 2032										427% 488%
uture 2033	Projected									557%
Experience 2034 2,010,652 14,709,304 732% 1,499 1,088,736 7,872,599 7,2035 1,761,503 14,686,163 834% 1,327 914,993 7,533,744 8,2036 1,535,104 14,674,959 949% 1,170 764,991 7,166,536 9,2036 1,331,142 14,380,377 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 636,446 6,777,874 1,080% 1,027 1,028 1,0	Future									635%
2036	Experience									723%
2037	(50 Years)	2035		1,761,503	14,686,163	834%	1,327	914,993	7,533,744	823%
2038		2036		1,535,104	14,574,959	949%	1,170	764,991	7,166,536	937%
2039 986,843 13,769,512 1,395% 781 434,430 5,964,251 1,3 2040 843,912 13,363,239 1,583% 677 356,517 5,549,390 1,5 2041 718,579 12,895,937 1,795% 584 291,338 5,134,653 1,7 2042 609,287 12,374,181 2,031% 502 237,088 4,724,205 1,9 2043 514,494 11,806,413 2,295% 430 192,157 4,322,329 2,2 2044 432,651 11,203,554 2,590% 367 155,104 3,933,492 2,5 2045 362,305 10,576,202 2,919% 312 124,678 3,661,320 2,8 2046 302,166 9,933,842 3,288% 264 99,819 3,208,423 3,2 2047 251,038 9,285,078 3,699% 223 79,612 2,876,661 3,6 2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867,67 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2059 22,702 3,083,520 13,582% 24 4,433 588,475 13,2 2060-2064 62,065 10,729,266 17,287% 69 10,932 1,837,346 16,8 2065-2069 18,403,013 65,407,808 36% 160,062 294,842,602 83,132,654 Future 78,097,824 422,302,377 541% 56,185 57,234,204 210,742,488 3								· ·		1,065%
2040 843,912 13,363,239 1,583% 677 356,517 5,549,390 1,5 2041 718,579 12,895,937 1,795% 584 291,338 5,134,653 1,7 2042 669,287 12,374,181 2,031% 502 237,088 4,724,205 1,9 2043 514,494 11,806,413 2,295% 430 192,157 4,322,329 2,2 2044 432,651 11,203,554 2,590% 367 155,104 3,933,492 2,5 2045 362,305 10,576,202 2,919% 312 124,678 3,561,320 2,8 2046 302,166 9,933,842 3,288% 264 99,819 3,208,423 3,2 2047 251,038 9,285,078 3,699% 223 79,612 2,876,661 3,6 2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2063 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2069 2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8 2065-2069 18,600 5,153,390 27,647% 21 2,665 720,343 27,0								· ·		1,210%
2041 718,579 12,895,937 1,795% 584 291,338 5,134,653 1,7 2042 609,287 12,374,181 2,031% 502 237,088 4,724,205 1,9 2043 514,494 11,806,413 2,295% 430 192,157 4,322,329 2,2 2044 432,651 11,203,554 2,590% 367 155,104 3,933,492 2,5 2045 362,305 10,576,202 2,919% 312 124,678 3,561,320 2,8 2046 302,166 9,933,842 3,288% 264 99,819 3,208,423 3,2 2047 251,038 9,285,078 3,699% 223 79,612 2,876,661 3,6 2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 1441,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 633,551 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2069 22,702 3,083,520 13,582% 24 4,433 58,475 13,2 2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8 2065-2069 18,640 5,153,390 27,647% 21 2,665 720,343 27,0										1,373%
2042 609,287 12,374,181 2,031% 502 237,088 4,724,205 1,9 2043 514,494 11,806,413 2,295% 430 192,157 4,322,329 2,2 2044 432,651 11,203,554 2,590% 367 155,104 3,933,492 2,5 2045 362,305 10,576,202 2,919% 312 124,678 3,561,320 2,8 2046 302,166 9,933,842 3,288% 264 99,819 3,208,423 3,2 2047 251,038 9,285,078 3,699% 223 79,612 2,876,661 3,6 2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,262,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 666,249 12,0 2059 22,702 3,083,520 13,582% 24 4,433 588,475 13,2 2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8 2065-2069 184,037,013 66,407,808 36% 160,062 294,842,602 83,132,654 Future 78,097,824 422,302,377 541% 56,185 57,234,204 210,742,488 3								· ·		1,557% 1,762%
2043								· ·		1,993%
2044										2,249%
2045 362,305 10,576,202 2,919% 312 124,678 3,561,320 2,8										2,536%
2047 251,038 9,285,078 3,699% 223 79,612 2,876,661 3,6 2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2057 34,350 3,853,047 11,217% 36 7,269		2045						124,678		2,856%
2048 207,811 8,639,007 4,157% 188 63,271 2,567,653 4,0 2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,										3,214%
2049 171,470 8,003,960 4,668% 158 50,124 2,282,425 4,5 2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249						•				3,613%
2050 141,072 7,386,123 5,236% 132 39,595 2,021,143 5,1 2051 115,785 6,792,816 5,867% 110 31,205 1,784,072 5,7 2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2059 22,702 3,083,520 13,582% 24 4,433 588,475 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4,058%</td>										4,058%
2051										4,554% 5,105%
2052 94,834 6,228,668 6,568% 92 24,544 1,570,563 6,3 2053 77,556 5,694,674 7,343% 77 19,278 1,378,966 7,1 2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2059 22,702 3,083,520 13,582% 24 4,433 588,475 13,2 2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8 2065-2069 18,640 5,153,390 27,647% 21 2,665 72										5,105% 5,717%
2053										6,399%
2054 63,351 5,191,652 8,195% 64 15,125 1,207,697 7,9 2055 51,707 4,719,167 9,127% 53 11,858 1,054,945 8,8 2056 42,171 4,273,934 10,135% 44 9,290 918,347 9,8 2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9 2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0 2059 22,702 3,083,520 13,582% 24 4,433 588,475 13,2 2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8 2065-2069 18,640 5,153,390 27,647% 21 2,665 720,343 27,0 History Future 78,097,824 422,302,377 541% 56,185 57,234,204 210,742,488 3										7,153%
2055										7,985%
2057 34,350 3,853,047 11,217% 36 7,269 795,879 10,9				51,707					1,054,945	8,896%
2058 27,945 3,456,119 12,367% 30 5,681 686,249 12,0										9,885%
2059 22,702 3,083,520 13,582% 24 4,433 588,475 13,2										10,948%
2060-2064 62,065 10,729,286 17,287% 69 10,932 1,837,346 16,8										12,080%
2065-2069 18,640 5,153,390 27,647% 21 2,665 720,343 27,0										13,275% 16,808%
History 184,037,013 65,407,808 36% 160,062 294,842,602 83,132,654 Future 78,097,824 422,302,377 541% 56,185 57,234,204 210,742,488 3										27,026%
Future 78,097,824 422,302,377 541% 56,185 57,234,204 210,742,488 3		2000 2000		10,040	0,100,090	21,071/0	21	2,003	7 20,043	21,0207
	His	story	1	84,037,013	65,407,808	36%	160,062	294,842,602	83,132,654	28%
Lifetime 262,134,837 487,710,185 186% 216,247 352,076,806 293,875,142										
	Life	etime	2	62,134,837	487,710,185	186%	216,247	352,076,806	293,875,142	83%

Attachment 1-b MedAmerica, CICA, and CLICNY

Written Premium and Paid Claim Experience and Projections by Calendar Year Nationwide Experience After Requested Rate Increase 515, 700, and 780 Series

			Without Interest				With Max. Val. Intere	est
		Α	В	C = B / A	D	Е	F	G = F / E
	Calendar	Written Premium	Paid Claims	Lasa Datia	End of Year	Written	Paid Claims	Less Detis
	Year 1997	8,976	Ciairis 0	Loss Ratio 0%	Lives 23	Premium 24,166	Oralins 0	Loss Ratio 0%
	1998	546,203	0	0%	789	1,407,196	0	0%
	1999	2,172,401	0	0%	2,811	5,355,795	0	0%
	2000	4,113,275	30,470	1%	4,181	9,704,104	71,884	1%
	2001	6,254,052	59,391	1%	6,197	14,119,290	134,083	1%
	2002	8,411,385	62,957	1%	8,017	18,171,995	136,013	1%
	2003	9,370,180	271,339	3%	8,572	19,371,655	560,958	3%
Historical	2004 2005	9,685,450	275,365	3% 7%	8,787 9,506	19,161,183	544,768	3% 7%
Historical Experience	2005	10,183,367 11,539,366	721,834 1,077,814	9%	10,611	19,278,693 20,742,509	1,366,543 1,952,602	9%
Experience	2007	12,186,114	1,749,755	14%	10,739	20,866,202	3,033,368	15%
	2008	11,904,700	2,126,726	18%	10,226	19,506,439	3,519,976	18%
	2009	11,135,406	2,419,276	22%	9,441	17,482,764	3,836,308	22%
	2010	10,498,999	2,653,705	25%	8,931	15,792,940	4,020,851	25%
	2011	9,936,799	3,403,200	34%	8,507	14,318,462	4,937,108	34%
	2012	9,481,249	4,159,473	44%	8,133	13,086,969	5,779,143	44%
	2013	9,009,229	4,680,155	52%	7,792	11,912,296	6,220,787	52%
	2014 2015	8,516,217 8,408,405	4,718,039 6,237,727	55% 74%	7,110 6,644	10,786,045 10,201,830	6,004,595 7,590,790	56% 74%
	2016	8,224,471	6,518,618	79%	6,272	9,558,744	7,594,376	74%
	2017	7,877,973	7,134,910	91%	5,963	8,770,488	7,957,649	91%
	2018	7,459,163	8,489,601	114%	5,592	7,954,994	9.063.346	114%
	2019	7,113,632	8,617,453	121%	5,218	7,267,843	8,807,507	121%
	2020	6,949,303	6,405,042	92%	4,894	6,801,945	6,266,769	92%
	2021	6,976,391	7,641,289	110%	4,546	6,541,968	7,157,510	109%
	2022	7,360,014	8,500,543	115%	4,198	6,611,788	7,623,307	115%
	2023	6,987,596	9,222,991	132%	3,939	6,014,204	7,919,511	132%
	2024 2025	6,505,547	9,900,013 10,548,559	152%	3,682	5,365,160	8,139,948	152% 174%
	2025	6,027,761 5,557,086	11,159,229	175% 201%	3,427 3,175	4,763,619 4,208,691	8,305,543 8,414,534	200%
	2027	5,096,589	11,722,152	230%	2,927	3,699,461	8,465,646	229%
	2028	4,649,124	12,223,724	263%	2,686	3,234,678	8,455,777	261%
	2029	4,217,500	12,654,243	300%	2,453	2,812,940	8,385,492	298%
	2030	3,804,095	13,014,633	342%	2,228	2,432,469	8,262,597	340%
	2031	3,410,780	13,306,470	390%	2,013	2,091,153	8,094,497	387%
Projected	2032	3,039,745	13,521,014	445%	1,809	1,787,101	7,881,807	441%
Future	2033	2,693,072	13,652,718	507%	1,617	1,518,385	7,627,245	502%
Experience (50 Years)	2034 2035	2,372,254 2,078,098	13,701,454 13,668,593	578% 658%	1,439 1,274	1,282,796 1,077,861	7,336,401 7,015,173	572% 651%
(50 reals)	2036	1,810,762	13,555,459	749%	1,123	900,936	6,668,842	740%
	2037	1,569,918	13,366,318	851%	985	749,343	6,303,646	841%
	2038	1,354,629	13,108,015	968%	860	620,337	5,926,325	955%
	2039	1,163,427	12,786,077	1,099%	748	511,190	5,542,159	1,084%
	2040	994,709	12,404,215	1,247%	648	419,376	5,155,044	1,229%
	2041	846,799	11,967,069	1,413%	560	342,594	4,768,724	1,392%
	2042	717,856	11,480,707	1,599%	481	278,712	4,386,975	1,574%
1	2043	606,054	10,952,839	1,807%	412	225,826	4,013,654	1,777%
1	2044 2045	509,561 426,653	10,393,495 9,812,292	2,040% 2,300%	352 299	182,231 146,450	3,652,813 3,307,697	2,004% 2,259%
1	2045	355,800	9,217,656	2,591%	253	117,227	2,980,570	2,259% 2,543%
1	2040	295,579	8,617,392	2,915%	214	93,482	2,673,087	2,859%
1	2048	244,672	8,019,952	3,278%	180	74,284	2,386,751	3,213%
1	2049	201,883	7,433,033	3,682%	151	58,843	2,122,500	3,607%
1	2050	166,095	6,862,311	4,132%	126	46,479	1,880,474	4,046%
1	2051	136,323	6,314,378	4,632%	106	36,628	1,660,869	4,534%
1	2052	111,654	5,793,391	5,189%	88	28,808	1,463,059	5,079%
1	2053	91,309	5,300,266	5,805%	73	22,624	1,285,518	5,682%
1	2054 2055	74,577 60,856	4,835,665 4,399,022	6,484% 7,229%	61 50	17,747 13,910	1,126,766 985,090	6,349% 7,082%
1	2056	49,610	3,987,144	8,037%	42	10,892	858,279	7,880%
1	2057	40,379	3,597,260	8,909%	34	8,515	744,452	8,742%
1	2058	32,816	3,228,996	9,840%	28	6,647	642,421	9,665%
1	2059	26,625	2,882,722	10,827%	23	5,179	551,292	10,644%
1	2060-2064	72,456	10,044,744	13,863%	66	12,711	1,724,102	13,563%
	2065-2069	21,514	4,836,345	22,480%	20	3,062	677,948	22,143%
		101.00= 0.15	05 105 015		,,,,,,	00101000	00 /22 2= :	22
	story	184,037,013	65,407,808	36%	160,062	294,842,602	83,132,654	28%
	ture etime	89,707,473 273,744,486	396,039,430 461,447,238	441% 169%	54,291 214,353	65,178,250 360,020,852	198,840,816 281,973,469	305% 78%
LIIE	Zui i lC	213,144,400	401,441,230	109%	214,333	500,020,852	201,913,409	10%

Attachment 2-a MedAmerica

Actual and Projected Experience using Current Assumptions by Calendar Year Pennsylvania-Specific Experience Before Requested Rate Increase 515 and 780 Series

			Without Interest	Ī			With Max. Val. Intere	et
		А	B	C = B / A	D	E	F	G = F / E
	Calendar	Earned	Incurred	Incurred	End of Year	Earned	Incurred	Incurred
	Year 1999	Premium 48,447	Claims 0	Loss Ratio 0%	Lives 126	Premium 119,439	Claims 0	Loss Ratio
	2000	254,666	91,218	36%	326	600,813	215,203	36%
	2001	364,003	0 1,2 10	0%	386	821,782	0	0%
	2002	388,780	0	0%	440	839,922	0	0%
	2003	398,558	58,576	15%	451	823,968	121,099	15%
	2004	391,196	0	0%	423	773,921	0	0%
Historical	2005	379,170	0	0%	411	717,827	0	0%
Experience	2006	396,634	183,046	46%	442	715,392	331,612	46%
	2007	452,244	218,956	48% 46%	463	773,690	379,586	49% 46%
	2008 2009	448,838 419,562	204,303 191,388	46%	447 421	735,026 658,448	338,932 303,834	46%
	2010	395,561	281,743	71%	402	594,962	428,014	72%
1	2011	373,398	275,705	74%	380	538,207	400,805	74%
	2012	359,072	105,670	29%	369	495,849	147,002	30%
	2013	341,283	182,971	54%	356	451,575	243,578	54%
	2014	326,490	381,280	117%	320	413,712	485,718	117%
	2015	316,354	44,846	14%	297	384,004	54,669	14%
	2016	325,070	186,513	57%	271	378,027	217,579	58%
	2017	314,964	631,623	201%	259	350,827	705,096	201%
	2018	293,082	111,221	38% 82%	237 222	312,662	118,812	38% 82%
	2019 2020	264,686 254,523	216,616 349,092	137%	204	270,445 249,109	221,415 341,542	137%
	2020	262,945	371,533	141%	193	246,517	347,958	141%
	2022	260,132	399,401	154%	182	233,626	358,085	153%
1	2023	243,372	427,606	176%	171	209,402	367,022	175%
	2024	226,654	454,039	200%	159	186,851	373,114	200%
1	2025	210,032	475,852	227%	148	165,913	374,415	226%
1	2026	193,581	494,557	255%	137	146,544	372,620	254%
	2027	177,470	511,009	288%	126	128,763	368,714	286%
	2028	161,833	525,191	325%	115	112,551	362,932	322%
	2029 2030	146,759 132,371	535,143 542,834	365% 410%	104 94	97,849 84,621	354,217 344,202	362% 407%
	2030	118,764	548,421	462%	85	72,804	333,152	458%
Projected	2032	106,000	551,162	520%	76	62,320	320,790	515%
Future	2033	94,137	551,133	585%	67	53,086	307,336	579%
Experience	2034	83,219	548,731	659%	59	45,019	293,197	651%
(50 Years)	2035	73,262	547,650	748%	52	38,024	280,382	737%
	2036	64,256	542,465	844%	46	32,001	266,161	832%
	2037	56,167	533,076	949%	40	26,845	250,738	934%
	2038	48,939	522,087	1,067%	35	22,452	235,488	1,049%
	2039 2040	42,528 36,858	507,487 490,185	1,193% 1,330%	31 27	18,732 15,589	219,577 203,527	1,172% 1,306%
	2040	31,840	470,061	1,476%	23	12,933	187,384	1,449%
1	2042	27,413	450,014	1,642%	20	10,695	172,291	1,611%
1	2043	23,531	431,884	1,835%	17	8,818	158,837	1,801%
l l	2044	20,131	413,028	2,052%	15	7,246	145,899	2,013%
l l	2045	17,146	392,735	2,291%	13	5,928	133,195	2,247%
l l	2046	14,527	374,580	2,579%	11	4,824	121,916	2,527%
l l	2047	12,241	358,454	2,928%	10	3,903	111,923	2,868%
l l	2048	10,260	340,163	3,315%	8	3,140	101,770	3,241%
	2049 2050	8,546 7,075	317,773 291,425	3,718% 4,119%	7 6	2,509 1,993	91,059 79,959	3,629% 4,013%
	2050	7,075 5,827	266,756	4,119%	5	1,573	79,959	4,453%
	2052	4,770	241,502	5,063%	4	1,234	60,729	4,920%
	2053	3,878	214,260	5,526%	3	961	51,567	5,364%
	2054	3,131	186,436	5,954%	3	744	42,994	5,782%
	2055	2,514	160,408	6,381%	2	572	35,463	6,201%
	2056	2,007	136,990	6,824%	2	438	29,061	6,642%
	2057	1,593	116,536	7,316%	2	333	23,771	7,143%
	2058	1,254	98,362	7,844%	1	251	19,333	7,691%
	2059 2060-2064	983 2,407	81,720 239,154	8,316% 9,935%	1 2	189 422	15,492 41,530	8,191% 9,845%
	2000-2004			13,855%	1	422 78	10,809	9,845% 13,807%
	2065-2069	531	7.3.502					
	2065-2069	531	73,502	13,63376				*
Hist	2065-2069 tory	7,252,060	3,365,675	46%	7,449	11,770,498	4,712,953	40%
Hist Fut Lifet	tory ture							

Attachment 2-b MedAmerica

Actual and Projected Experience using Current Assumptions by Calendar Year Pennsylvania-Specific Experience After Requested Rate Increase 515 and 780 Series

			Without Interest			1	With Max. Val. Intere	st
		Α	В	C = B / A	D	E	F	G = F / E
	Calendar	Earned	Incurred	Incurred	End of Year	Earned	Incurred	Incurred
	Year	Premium	Claims	Loss Ratio	Lives	Premium	Claims	Loss Ratio
	1999 2000	48,447	0 91,218	0%	126 326	119,439	0	0% 36%
	2001	254,666	91,210	36% 0%	386	600,813	215,203 0	0%
	2001	364,003 388,780	0	0%	440	821,782 839,922	0	0%
	2002	398,558	58,576	15%	451	823,968	121,099	15%
	2004	391,196	0	0%	423	773,921	121,099	0%
Historical	2005	379,170	0	0%	411	717,827	0	0%
Experience	2006	396,634	183,046	46%	442	717,327	331,612	46%
Experience	2007	452,244	218,956	48%	463	773,690	379,586	49%
	2008	448,838	204,303	46%	447	735,026	338,932	46%
	2009	419,562	191,388	46%	421	658,448	303,834	46%
	2010	395,561	281,743	71%	402	594,962	428,014	72%
	2011	373,398	275,705	74%	380	538,207	400,805	74%
	2012	359,072	105,670	29%	369	495,849	147,002	30%
	2013	341,283	182,971	54%	356	451,575	243,578	54%
	2014	326,490	381,280	117%	320	413,712	485,718	117%
	2015	316,354	44,846	14%	297	384,004	54,669	14%
	2016	325,070	186,513	57%	271	378,027	217,579	58%
	2017	314,964	631,623	201%	259	350,827	705,096	201%
	2018	293,082	111,221	38%	237	312,662	118,812	38%
	2019	264,686	216,616	82%	222	270,445	221,415	82%
	2020	254,523	349,092	137%	204	249,109	341,542	137%
	2021	262,945	371,533	141%	193	246,517	347,958	141%
	2022	270,322	392,482	145%	177	242,754	351,888	145%
	2023	260,719	415,128	159%	166	224,273	356,326	159%
	2024	242,820	440,542	181%	155	200,112	362,041	181%
	2025	225,007	461,515	205%	144	177,668	363,161	204%
	2026	207,363	479,474	231%	133	156,897	361,291	230%
	2027	190,078	495,221	261%	122	137,826	357,366	259%
	2028	173,300	508,748	294%	112	120,438	351,622	292%
	2029	157,126	518,189	330%	102	104,674	343,057	328%
	2030	141,694	525,463	371%	92	90,493	333,260	368%
	2031	127,107	530,679	418%	82	77,833	322,457	414%
Projected	2032	113,433	533,100	470%	73 65	66,607	310,371	466%
Future	2033 2034	100,729 89,041	532,830 530,274	529% 596%	58	56,724 48,094	297,232 283,447	524% 589%
Experience (50 Years)	2035	78,382	528,987	675%	51	40,612	270,948	667%
(50 rears)	2036	68,740	523,803	762%	45	34,170	257,134	753%
	2037	60,074	514,659	857%	39	28,654	242,214	845%
	2038	52,327	504,066	963%	34	23,953	227,506	950%
	2039	45,452	490,061	1,078%	30	19,971	212,191	1,062%
	2040	39,369	473,533	1,203%	26	16,607	196,772	1.185%
	2041	33,985	454,359	1,337%	22	13,765	181,289	1,317%
	2042	29,235	435,283	1,489%	19	11,372	166,819	1,467%
	2043	25,072	418,053	1,667%	17	9,366	153,921	1,643%
	2044	21,430	400,056	1,867%	15	7,689	141,487	1,840%
	2045	18,238	380,577	2,087%	13		129,238	2,057%
	2046	15,441	363,087	2,351%	11	5,109	118,336	2,316%
	2047	13,005	347,509	2,672%	9	4,130	108,661	2,631%
	2048	10,897	329,694	3,025%	8	3,322	98,784	2,974%
	2049	9,078	307,883	3,392%	7	2,655	88,360	3,329%
	2050	7,519	282,234	3,754%	6	2,108	77,558	3,678%
	2051	6,196	258,222	4,167%	5	1,666	67,929	4,078%
	2052	5,077	233,685	4,603%	4	1,308	58,859	4,501%
	2053	4,131	207,228	5,016%	3	1,019	49,957	4,901%
	2054	3,340	180,294	5,398%	3	789	41,649	5,276%
	2055	2,684	155,127	5,779%	2	608	34,356	5,654%
	2056	2,146	132,515	6,176%	2	465	28,163	6,053%
	2057	1,704	112,818	6,623%	1	354	23,057	6,512%
	2058	1,341	95,347	7,109%	1	267	18,780	7,023%
	2059	1,051	79,332	7,552%	1	201	15,072	7,497%
	2060-2064 2065-2069	2,562	233,293	9,104%	2	446	40,605	9,095%
	2000-2009	556	72,226	12,991%	1	82	10,646	13,054%
Hic	tory	7,252,060	3,365,675	46%	7,449	11,770,498	4,712,953	40%
	ture	3,375,239	15,598,200	462%	2,256	2,436,993	8,143,312	334%
	time	10,627,299	18,963,874	178%	9,705	14,207,491	12,856,265	90%
Liic		10,021,200	.5,555,574	17570	3,700	, 201, -01	.2,000,200	3070

Attachment 3-a

MedAmerica Written Premium and Paid Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience Before Requested Rate Increase 515 and 780 Series

			Without Interest	Ī			With Max. Val. Intere	et
		А	B B	C = B / A	D	E	F	G = F / E
	Calendar	Written	Paid	. 5 "	End of Year	Written	Paid	. 5.
	Year 1999	Premium 76,792	Claims 0	Loss Ratio 0%	Lives 126	Premium 189,322	Claims 0	Loss Ratio
	2000	291,307	0	0%	326	687,256	0	0%
	2001	370,885	644	0%	386	837,319	1,454	0%
	2002	388,969	0	0%	440	840,330	0	0%
	2003	396,064	24,761	6%	451	818,811	51,190	6%
110-4	2004	386,122	43,906	11%	423	763,884	86,861	11%
Historical Experience	2005 2006	374,822 398,224	13,879 21,142	4% 5%	411 442	709,597 717,625	26,275 38,301	4% 5%
Exponence	2007	451,830	106,549	24%	463	772,854	184,715	24%
	2008	445,584	153,270	34%	447	729,783	254,269	35%
	2009	416,357	110,176	26%	421	653,462	174,908	27%
	2010	393,024	235,117	60%	402	591,134	357,181	60%
	2011	370,888	287,307	77%	380	534,611	417,671	78%
	2012 2013	357,607 339,475	284,773 241,872	80% 71%	369 356	493,834 449,169	396,160 321,990	80% 72%
	2014	321,767	288,575	90%	320	407,717	367,619	90%
	2015	317,775	253,908	80%	297	385,737	309,528	80%
	2016	321,313	166,668	52%	271	373,646	194,428	52%
	2017	313,170	283,338	90%	259	348,824	316,297	91%
	2018	289,274	345,793	120%	237	308,594	369,395	120%
	2019 2020	260,147 254,522	242,649 187,705	93% 74%	222 204	265,804 249,108	248,049 183,632	93% 74%
	2021	264,658	243,792	92%	193	248,122	228,291	92%
	2022	257,913	287,626	112%	182	231,638	257,825	111%
	2023	241,178	327,685	136%	171	207,521	281,194	136%
	2024	224,498	365,470	163%	159	185,082	300,245	162%
	2025	207,935	400,387	193%	148	164,266	314,922	192%
	2026 2027	191,563 175,552	432,046 460,459	226% 262%	137 126	145,027 127,383	325,370 332,042	224% 261%
	2028	160,021	485,581	303%	115	111,303	335,316	301%
	2029	145,061	507,167	350%	104	96,730	335,405	347%
	2030	130,793	525,336	402%	94	83,625	332,754	398%
	2031	117,306	540,314	461%	85	71,923	327,825	456%
Projected	2032	104,658	552,224	528%	76	61,543	320,966	522%
Future Experience	2033 2034	92,909 82,105	561,077 566,963	604% 691%	67 59	52,405 44,428	312,424 302,470	596% 681%
(50 Years)	2035	72,256	570,721	790%	52	37,513	291,728	778%
,	2036	63,346	572,262	903%	46	31,559	280,290	888%
	2037	55,349	571,193	1,032%	40	26,464	268,103	1,013%
	2038	48,212	567,605	1,177%	35	22,128	255,354	1,154%
	2039	41,880	561,369	1,340%	31	18,455	242,109	1,312%
	2040 2041	36,282 31,332	552,540 541,105	1,523% 1,727%	27 23	15,353 12,733	228,505 214,640	1,488% 1,686%
	2042	26,967	527,454	1.956%	20	10,527	200,746	1,907%
	2043	23,141	512,434	2,214%	17	8,678	187,185	2,157%
	2044	19,793	496,323	2,508%	15	7,130	174,048	2,441%
	2045	16,854	479,125	2,843%	13	5,831	161,312	2,766%
	2046	14,276	461,359	3,232%	11	4,744	149,130	3,143%
	2047 2048	12,030 10,083	443,597 425,568	3,688% 4,221%	10 8	3,839 3,088	137,651 126,734	3,586% 4,103%
	2049	8,398	406,506	4,840%	7	2,468	116,130	4,705%
	2050	6,952	385,770	5,549%	6	1,960	105,676	5,393%
	2051	5,724	363,803	6,355%	5	1,547	95,524	6,175%
	2052	4,684	340,825	7,277%	4	1,213	85,752	7,069%
	2053	3,804	316,621	8,323%	3	944	76,313	8,083%
,	2054 2055	3,069	291,236 265,166	9,491% 10,777%	3	730 560	67,238 58,642	9,216% 10,464%
,	2055	2,461 1,962	239,106	10,777%	2	428	50,661	10,464%
,	2057	1,553	213,718	13,765%	2	325	43,400	13,358%
,	2058	1,219	189,458	15,539%	1	245	36,897	15,068%
	2059	954	166,530	17,457%	1	184	31,124	16,917%
	2060-2064	2,320	550,286	23,723%	2	408	92,586	22,698%
	2065-2069	504	234,333	46,468%	1	75	32,726	43,706%
Hiet	torv	7,281 396	3.104.326	43%	7 449	11.879.312	4 116 291	35%
Hist Fut	tory ture	7,281,396 3,166,072	3,104,326 17,689,846	43% 559%	7,449 2,307	11,879,312 2,299,232	4,116,291 8,300,887	35% 361%

Attachment 3-b MedAmerica

Written Premium and Paid Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience After Requested Rate Increase 515 and 780 Series

			Without Interest			,	With Max. Val. Interes	st
		Α	В	C = B / A	D	E	F	G = F / E
	Calendar	Written	Paid	. 5.	End of Year	Written	Paid	. 5.
	Year 1999	Premium 76.702	Claims	Loss Ratio 0%	Lives	Premium	Claims 0	Loss Ratio
	2000	76,792 291,307	0	0%	126 326	189,322 687,256	0	0% 0%
	2001	370,885	644	0%	386	837,319	1,454	0%
	2002	388,969	044	0%	440	840,330	1,434	0%
	2003	396,064	24,761	6%	451	818,811	51,190	6%
	2004	386,122	43,906	11%	423	763,884	86,861	11%
Historical	2005	374,822	13,879	4%	411	709,597	26,275	4%
Experience	2006	398,224	21,142	5%	442	717,625	38,301	5%
	2007	451,830	106,549	24%	463	772,854	184,715	24%
	2008	445,584	153,270	34%	447	729,783	254,269	35%
	2009	416,357	110,176	26%	421	653,462	174,908	27%
	2010	393,024	235,117	60%	402	591,134	357,181	60%
	2011	370,888	287,307	77%	380	534,611	417,671	78%
	2012	357,607	284,773	80%	369	493,834	396,160	80%
	2013 2014	339,475 321,767	241,872 288,575	71% 90%	356 320	449,169 407,717	321,990 367,619	72% 90%
	2014	317,775	253,908	80%	297	385,737	309,528	80%
	2016	321,313	166,668	52%	271	373,646	194,428	52%
	2017	313,170	283,338	90%	259	348,824	316,297	91%
	2018	289,274	345,793	120%	237	308,594	369,395	120%
	2019	260,147	242,649	93%	222	265,804	248,049	93%
	2020	254,521	187,705	74%	204	249,107	183,632	74%
	2021	264,658	243,792	92%	193	248,122	228,291	92%
	2022	270,759	286,304	106%	177	243,145	256,641	106%
	2023	258,356	323,810	125%	166	222,246	277,872	125%
	2024	240,491	359,052	149%	155	198,201	294,980	149%
	2025	222,736	391,785	176%	144	175,885	308,169	175%
	2026	205,175	421,576	205%	133	155,252	317,505	205%
	2027 2028	187,995 171,329	448,392 472,146	239% 276%	122 112	136,327 119,081	323,368 326,074	237% 274%
	2029	155,277	492,569	317%	102	103,455	325,796	315%
	2030	139,972	509,758	364%	92	89,407	322,941	361%
	2031	125,513	523,909	417%	82	76,871	317,936	414%
Projected	2032	111,963	535,120	478%	73	65,757	311,100	473%
Future	2033	99,382	543,391	547%	65	55,979	302,661	541%
Experience	2034	87,816	548,802	625%	58	47,445	292,877	617%
(50 Years)	2035	77,275	552,163	715%	51	40,050	282,348	705%
	2036	67,736	553,398	817%	45	33,682	271,165	805%
	2037	59,171	552,148	933%	39	28,234	259,288	918%
	2038	51,524	548,517	1,065%	34	23,595	246,899	1,046%
	2039	44,735	542,390	1,212%	30	19,665	234,064	1,190%
	2040	38,732	533,824	1,378%	26	16,347	220,914	1,351%
	2041	33,421	522,815	1,564%	22	13,544	207,541	1,532%
	2042 2043	28,740	509,732	1,774%	19 17	11,186	194,164	1,736% 1,966%
	2043	24,641 21,057	495,378 479,996	2,010% 2,280%	15	9,211 7,560	181,123 168,495	2,229%
	2044	17,915	463,557	2,588%	13		156,245	2,529%
	2046	15,164	446,545	2,945%	11	5,021	144,516	2,878%
	2047	12,772	429,502	3,363%	9		133,450	3,287%
	2048	10,703	412,142	3,851%	8	3,265	122,905	3,764%
	2049	8,915	393,721	4,416%	7	2,609	112,641	4,317%
	2050	7,383	373,626	5,060%	6	2,072	102,504	4,947%
	2051	6,083	352,304	5,791%	5	1,637	92,650	5,661%
	2052	4,982	329,984	6,624%	4	1,284	83,159	6,474%
	2053	4,051	306,470	7,565%	3		73,990	7,395%
	2054	3,271	281,823	8,615%	3		65,176	8,421%
	2055	2,626	256,535	9,770%	2		56,833	9,551%
	2056	2,095	231,282	11,039%	2	455	49,092	10,792%
	2057	1,659	206,712	12,460%	1	345	42,055	12,178% 13,744%
	2058 2059	1,303 1,019	183,265 161,129	14,068% 15,818%	1	260 195	35,760 30,175	13,744% 15,446%
	2060-2064	2,465	533,321	21,637%	2	431	89,928	20,868%
	2065-2069	527	228,091	43,307%	1	78	31,938	41,076%
		321		, 7 7 7	<u> </u>		2.,200	,2. 070
His	tory	7,281,396	3,104,326	43%	7,449	11,879,312	4,116,291	35%
	ture	3,345,907	17,168,479	513%	2,256	2,419,611	8,078,859	334%
Life	time	10,627,303	20,272,806	191%	9,705	14,298,923	12,195,150	85%

Attachment 4 Breakdown of Historical Incurred Claims and Reserve Balances at December 31, 2019

Nationwide Experience MedAmerica, CICA, and CLICNY 515, 700, and 780 Series

		51	5, 700, and 780 S	eries		
		Discoun	ted to the Year of	Incurral		Year-End
Incurred	Incurred	Paid	Disabled	IBNR		Active Life
Year	Claims ^[1]	Claims	Life Reserve	Reserve	Reserve ^[2]	Reserve ^[3]
1997	0	0	0		0	
1998	0	0	0		0	
1999	43,198	43,198	0		0	
2000	190,025	190,025	0		0	
2001	263,180	263,180	0		0	
2002	587,804	587,804	0		0	
2003	266,048	266,048	0		0	
2004	1,042,726	1,042,726	0		0	
2005	3,021,107	2,753,173	267,934		267,934	
2006	2,720,509	2,670,688	49,821		49,821	
2007	1,713,599	1,713,599	0		0	
2008	2,416,335	2,416,335	0		0	
2009	4,304,209	4,112,946	191,263		191,263	
2010	3,171,158	3,171,158	0		0	
2011	5,732,652	5,512,787	219,865		219,865	
2012	4,077,497	3,793,134	284,364		284,364	
2013	5,684,574	5,213,609	470,966		470,966	
2014	5,600,353	5,381,301	219,051		219,051	
2015	5,775,336	5,254,769	520,567		520,567	
2016	8,185,005	6,172,755	2,012,250		2,012,250	
2017	8,918,678	5,794,045	3,124,633		3,124,633	
2018	9,056,385	2,969,204	6,087,181		6,087,181	
2019	8,884,266	497,630	6,070,290	2,316,346	8,386,636	118,229,828

Pennsylvania-Specific Experience MedAmerica 515 and 780 Series

		Discounted to the Year of Incurral						
Incurred	Incurred		Disabled	IBNR	Total Claim	Active Life		
Year	Claims ^{[1}	Claims	Life Reserve	Reserve	Reserve ^[2]	Reserve ^[3]		
1999	(0	0		0			
2000	91,218	91,218	0		0			
2001	(0	0		0			
2002		0	0		0			
2003	58,576	58,576	0		0			
2004		0	0		0			
2005		0	0		0			
2006	183,046	183,046	0		0			
2007	218,956	218,956	0		0			
2008	204,303	204,303	0		0			
2009	191,388	191,388	0		0			
2010	281,743	281,743	0		0			
2011	275,705	275,705	0		0			
2012	105,670	105,670	0		0			
2013	182,971	182,971	0		0			
2014	381,280	358,924	22,356		22,356			
2015	44,846	44,846	0		0			
2016	186,513	186,513	0		0			
2017	631,623	350,358	281,264		281,264			
2018	111,221	111,221	0		0			
2019	216,616	3,769	119,934	92,912	212,847	4,944,214		

^[1] Incurred claims are the sum of paid claims, disabled life reserve, and incurred but not reported (IBNR) reserve.

^[2] Claim reserve is the sum of disabled life reserve and IBNR reserve.

^[3] Active life reserve is defined as interpolated terminal reserves plus unearned premium reserves.

Attachment 5-a MedAmerica, CICA, and CLICNY Nationwide Experience and Projections by Policy Year - Before Requested Rate Increase 515, 700, and 780 Series

		Actual and Projecte	d Experience using (Current Assumptions	=
		-		·	Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	18,133,511	387,944	2%	14,325	2%
2	15,263,438	778,702	5%	12,706	3%
3	13,860,922	1,593,669	11%	11,708	6%
4	12,970,019	1,913,373	15%	10,970	8%
5	12,282,619	1,260,332	10%	10,366	8%
6	11,704,774	3,263,037	28%	9,900	10%
7	11,186,883	2,815,393	25%	9,435	12%
8	10,631,175	4,020,875	38%	8,990	14%
9	10,149,733	3,214,817	32%	8,580	15%
10	9,743,055	5,227,256	54%	8,192	18%
11	9,327,711	3,657,472	39%	7,831	19%
12	8,942,573	7,281,156	81%	7,420	22%
13	8,551,223	6,423,612	75%	6,990	24%
14	8,224,446	4,936,706	60%	6,550	25%
15	7,958,732	7,198,124	90%	6,183	27%
16	7,709,398	8,338,254	108%	5,820	30%
17	7,415,454	11,440,224	154%	5,444	33%
18	7,074,288	10,250,174	145%	5,102	36%
19	6,779,674	10,180,458	150%	4,781	38%
20	6,436,198	11,288,159	175%	4,467	41%
21	6,075,088	10,989,577	181%	4,166	43%
22	5,691,084	12,339,158	217%	3,884	46%
23	5,278,232	13,146,234	249%	3,604	49%
24	4,853,348	13,857,870	286%	3,327	51%
25	4,431,789	14,400,894	325%	3,053	54%
26	4,020,052	14,785,125	368%	2,785	57%
27	3,622,318	15,028,698	415%	2,525	59%
28	3,242,390	15,101,581	466%	2,276	62%
29	2,882,787	15,032,160	521%	2,040	64%
30	2,546,305	14,826,152	582%	1,818	66%
31	2,235,396	14,546,616	651%	1,611	69%
32	1,950,974	14,218,948	729%	1,421	71%
33	1,693,159	13,839,106	817%	1,248	73%
34	1,461,546	13,400,747	917%	1,090	74%
35	1,255,268	12,909,520	1,028%	948	76%
36	1,072,998	12,379,098	1,154%	821	78%
37	913,071	11,818,412	1,294%	708	79%
38	773,609	11,223,452	1,451%	608	80%
39	652,700	10,596,182	1,623%	520	82%
40	548,475	9,928,278	1,810%	444	83%
41	459,091	9,233,129	2,011%	377	84%
42	382,803	8,542,544	2,232%	319	84%
43	318,028	7,871,215	2,475%	269	85%
44	263,297	7,234,630	2,748%	227	86%
45	217,276	6,616,947	3,045%	190	86%
46	178,734	6,031,861	3,375%	159	87%
47	146,583	5,498,893	3,751%	133	87%
48	119,964	4,998,624	4,167%	111	88%
49	97,976	4,508,672	4,602%	92	88%
50	79,871	4,009,022	5,019%	77	88%
51-55	223,282	13,530,711	6,060%	224	89%
56-60	75,756	6,277,171	8,286%	82	90%
61-65	23,432	2,558,543	10,919%	27	90%
66-70	6,175	780,021	12,633%	7	90%
Total	262,138,682	457,529,530	175%	206,950	90%

Attachment 5-b MedAmerica, CICA, and CLICNY Nationwide Experience and Projections by Policy Year - After Requested Rate Increase 515, 700, and 780 Series

		Actual and Projecte	d Experience using (Current Assumptions	
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	18,133,511	387,944	2%	14,325	2%
2	15,263,438	778,702	5%	12,706	3%
3	13,860,922	1,593,669	11%	11,708	6%
4	12,970,019	1,913,373	15%	10,970	8%
5	12,282,619	1,260,332	10%	10,366	8%
6	11,704,774	3,263,037	28%	9,900	10%
7	11,186,883	2,815,393	25%	9,435	12%
8	10,631,175	4,020,875	38%	8,990	14%
9	10,149,733	3,214,817	32%	8,580	15%
10	9,743,055	5,227,256	54%	8,192	18%
11	9,327,711	3,657,472	39%	7,831	19%
12	8,942,573	7,281,156	81%	7,420	22%
13	8,551,552	6,423,596	75%	6,990	24%
14	8,233,670	4,935,837	60%	6,547	25%
15	8,004,380	7,192,414	90%	6,173	27%
16	7,824,973	8,319,021	106%	5,801	30%
17	7,598,509	11,398,949	150%	5,415	33%
18	7,313,064	10,184,087	139%	5,063	36%
19	7,110,422	10,063,952	142%	4,722	38%
20	6,933,784	11,064,474	160%	4,381	41%
21	6,758,396	10,603,158	157%	4,056	43%
22	6,499,972	11,777,538	181%	3,756	45%
23	6,169,062	12,402,809	201%	3,469	47%
24	5,734,993	12,998,506	227%	3,196	50%
25	5,255,936	13,475,142	256%	2,930	52%
26	4,774,467	13,814,548	289%	2,671	55%
27	4,307,173	14,024,550	326%	2,421	57%
28	3,859,738	14,076,283	365%	2,181	59%
29	3,435,286	13,996,547	407%	1,953	61%
30	3,037,306	13,790,537	454%	1,740	63%
31	2,668,894	13,517,319	506%	1,541	65%
32	2,331,291	13,201,666	566%	1,359	67%
33	2,024,800	12,839,724	634%	1,192	69%
34	1,749,087	12,426,153	710%	1,041	70%
35	1,503,249	11,965,302	710%	905	70%
36	1,285,804	11,468,987	892%	783	73%
37	1,094,846	10,945,179	1,000%	763 675	75% 75%
38	928,196	10,390,029	1,119%	579	76%
39	783,621	9,805,702	1,251%	495	77%
40	658,926		1,251% 1,394%	495 422	77%
41	551,922	9,184,669 8,538,569	1,547%	358	79%
41		8,538,569 7,896,864		303	79% 79%
	460,539		1,715%		
43	382,893	7,275,040	1,900%	256	80%
44	317,233	6,686,995	2,108%	215	81%
45	261,969	6,118,032	2,335%	180	81%
46	215,639	5,580,176	2,588%	151	82%
47	176,943	5,090,278	2,877%	126	82%
48	144,862	4,630,887	3,197%	105	82%
49	118,322	4,181,239	3,534%	87	83%
50	96,439	3,721,934	3,859%	72	83%
51-55	268,967	12,596,843	4,683%	212	84%
56-60	90,417	5,862,395	6,484%	78	84%
61-65	27,659	2,385,195	8,624%	26	84%
66-70	7,219	727,568	10,078%	7	84%
T I	070 740 004	100 000 700	4500/	005.055	2.101
Total	273,748,831	432,992,722	158%	205,057	84%

Attachment 6-a MedAmerica Pennsylvania-Specific Experience and Projections by Policy Year - Before Requested Rate Increase 515 and 780 Series

		Actual and Projecte	d Experience using (Current Assumptions	i i
					Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	689,905	91,218	13%	630	13%
2	585,866	0	0%	570	7%
3	527,771	0	0%	526	5%
4	498,254	58,576	12%	492	7%
5	468,067	0	0%	466	6%
6	443,542	301,405	68%	445	13%
7	420,962	4,369	1%	425	12%
8	403,019	310,557	77%	412	17%
9	385,462	39,299	10%	395	17%
10	370,382	461,396	125%	383	24%
11	355,607	68,080	19%	369	23%
12	338,064	79,135	23%	345	23%
13	324,824	306,736	94%	330	26%
14	309,277	324,484	105%	304	29%
15	303,668	271,647	89%	280	31%
16	310,236	90,427	29%	263	31%
17	307,812	379,331	123%	244	34%
18	287,041	344,667	120%	229	36%
19	265,701	455,472	171%	211	39%
20	249,202	281,560	113%	197	40%
21	245,217	378,428	154%	182	43%
22	241,576	433,216	179%	170	45%
23	229,652	462,738	201%	158	47%
24	213,093	492,550	231%	146	50%
25	195,775	516,725	264%	135	52%
26	178,704	535,809	300%	123	55%
27	162,061	550,743	340%	112	57%
28	146,058	561,429	384%	101	59%
29	130,809	567,799	434%	91	62%
30	116,454	570,276	490%	81	64%
31	103,129	572,701	555%	72	66%
32	90,882	574,523	632%	64	68%
33	79,718	575,006	721%	56	70%
34	69,621	574,572	825%	49	73%
35	60,551	570,865	943%	43	74%
36	52,445	564,981	1,077%	37	76%
37	45,234	556,333	1,230%	32	78%
38	38,855	542,675	1,397%	28	80%
39	33,227	521,690	1,570%	24	81%
40	28,283	495,687	1,753%	21	83%
41	23,966	467,177	1,949%	18	84%
42	20,212	435,197	2,153%	15	85%
43	16,959	402,788	2,375%	13	86%
44	14,167	371,306	2,621%	11	87%
45	11,798	343,861	2,914%	10	88%
46	9,797	319,092	3,257%	8	88%
47	8,114	296,394	3,653%	7	89%
48	6,713	278,273	4,145%	6	90%
49	5,554	261,491	4,708%	5	90%
50	4,597	242,943	5,285%	4	91%
51-55	13,463	933,321	6,932%	13	92%
56-60	4,760	454,730	9,554%	5	93%
61-65	1,230	139,351	11,331%	1	93%
66-70	186	27,283	14,663%	0	93%
Total	10,447,524	10 460 242	186%	0.250	93%
ıolai	10,447,324	19,460,313	100%	9,358	93%

Attachment 6-b MedAmerica Pennsylvania-Specific Experience and Projections by Policy Year - After Requested Rate Increase 515 and 780 Series

		Actual and Projecte	d Experience using (Current Assumptions	<u> </u>
		•		·	Cumulative Loss
Policy	Earned	Incurred	Incurred	End of Year	Ratio w/ Max.
Year	Premium	Claims	Loss Ratio	Lives	Val. Interest
1	689,905	91,218	13%	630	13%
2	585,866	0	0%	570	7%
3	527,771	0	0%	526	5%
4	498,254	58,576	12%	492	7%
5	468,067	0	0%	466	6%
6	443,542	301,405	68%	445	13%
7	420,962	4,369	1%	425	12%
8	403,019	310,557	77%	412	17%
9	385,462	39,299	10%	395	17%
10	370,382	461,396	125%	383	24%
11	355,607	68,080	19%	369	23%
12	338,064	79,135	23%	345	23%
13	324,824	306,736	94%	330	26%
14	309,277	324,484	105%	304	29%
15	303,668	271,647	89%	280	31%
16	310,236	90,427	29%	263	31%
17	307,812	379,331	123%	244	34%
18	287,041	344,667	120%	229	36%
19	265,815	455,449	171%	211	39%
20 21	249,886	281,352 377,599	113% 153%	196 182	40% 42%
21	247,228 248,095	429,933	173%		45%
23	243,068	453,840	187%	168 154	45%
24	229,100	479,852	209%	142	49%
25	211,255	502,478	238%	131	52%
26	192,980	520,735	270%	120	54%
27	175,143	534,897	305%	108	56%
28	157,976	544,892	345%	98	59%
29	141,601	550,677	389%	88	61%
30	126,168	552,704	438%	78	63%
31	111,826	554,689	496%	69	65%
32	98,628	556,104	564%	61	67%
33	86,581	556,251	642%	54	69%
34	75,671	555,562	734%	47	71%
35	65,858	551,799	838%	41	73%
36	57,077	546,015	957%	36	75%
37	49,257	537,608	1,091%	31	76%
38	42,331	524,376	1,239%	27	78%
39	36,217	504,095	1,392%	23	79%
40	30,843	478,999	1,553%	20	81%
41	26,148	451,508	1,727%	17	82%
42	22,064	420,564	1,906%	15	83%
43	18,525	389,137	2,101%	13	84%
44	15,487	358,557	2,315%	11	85%
45	12,909	331,858	2,571%	9	86%
46	10,729	307,756	2,868%	8	86%
47	8,896	285,613	3,210%	7	87%
48	7,369	267,908	3,635%	6	87%
49	6,105	251,542	4,120%	5	88%
50	5,060	233,557	4,616%	4	88%
51-55	14,863	896,969	6,035%	12	90%
56-60	5,270	437,541	8,303%	5	90%
61-65	1,364	134,161	9,836%	1	91%
66-70	207	26,189	12,640%	0	91%
Total	10,627,358	18,974,091	179%	9,307	91%
าบเลเ	10,021,338	10,974,091	179%	9,307	91%

Attachment 7-a MedAmerica, CICA, and CLICNY Status of Fillings as of July 20, 2021 All Jurisdictions in Which These Forms are In Force 515, 700, and 780 Series

Nevada	raties pries	Policies In Force In	Annualized Premlum" \$149.667 \$13.034 \$4.186 \$4.186 \$4.856 \$4.856 \$4.856 \$5.1090 \$5.100	Requested Requested Increases 38% N/A	Disapproved Disapproved Disapproved 4/2/2014 8/22/2014 4/4/2014 11/12/2014 6/6/2014 11/13/2014 2/27/2015	Filed Increase ¹⁰ 0% 0% 0% 0% 38% 15% 20% 22% 38%	Requested lorreases 38% Ni/A Nor Filed No Follow-Up Ni/A Ni/A Nor Follow-Up Ni/A Ni/A Ni/A Nor Follow-Up Ni/A Ni/A Nor Follow-Up Ni/A Ni/A Ni/A Ni/A Ni/A Ni/A Ni/A Ni/A	Disposition Date 6/19/2015 3/30/2015 7/28/2015 7/28/2015 Disapproved 4/18/2016 Disapproved	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Arkansas Ark	raties pries	119 119 14 4 4 3 3 4 5 5 9 6 4 8 8 8 2 4 4 4 3 3 6 6 6 8 1 5 6 4 6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	\$140,667 \$130,034 \$41,865 \$4,856 \$122,142 \$51,090 \$124,227 \$1,761 \$132,71 \$1,761 \$132,71 \$1,761 \$132,71 \$1,761 \$132,038 \$145,245 \$150,315 \$145,245 \$132,038	38% NA N	Disapproved Disapproved 4/22014 8/22/2014 4/4/2014 11/12/2014 8/15/2014 11/13/2014 11/13/2014 2/27/2015	0% 0% 0% 08 38% 15% 20% 38% 20% 22%	38% Not Filed Ni/A Not Filed Ni/A Not Filed Ni/A Not Filed No Follow-Up Ni/A	3/30/2015 3/30/2015 7/28/2015 9/10/2015 Disapproved 8/7/2015	11
Arkansas 780 Se Arizona 780 Se California 515 Se Delaware 780 Se Florida 700 Se Florida 700 Se Georgia 515 Se Idaho 780 Se Illinois 780 Se Indiana 515 Se Indiana 515 Se Indiana 515 Se Indiana 515 Se Indiana 516 Se Kansas 516 Se Kansas 517 Se Kentucky 517 Se Kentucky 518 Se Kentucky 518 Se Kentucky 519 Se Maryland 780 Se Minesota 515 Se Illinois 780 Se Minesota 780 Se North Carolina 780 Se North Carolina 515 Se North Carolina	rates	4 4 3 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	\$4,186 \$12,142 \$132,142 \$51,099 \$242,274 \$51,327 \$13,277 \$13,277 \$145,245 \$13,277 \$145,245 \$13,202 \$13,203 \$13	Not Filed Not Filed Not Filed NiA NiA NiA NiA Not Filed NiA Not Filed NiA Not Filed NiA	Disapproved 4/2/2014 8/2/2014 4/4/2014 11/12/2014 8/15/2014 4/7/2014 11/13/2014 2/27/2015	0% 38% 15% 20% 38% 38% 20% 20%	Not Filed Not Fi	3/30/2015 7/28/2015 9/10/2015 Disapproved 4/18/2016	
Anzona 780 SE California 515 SE California	rates	3 3 92 3 6 6 6 4 4 4 4 3 3 2 2 4 4 4 3 3 2 2 3 3 2 3 6 5 6 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	\$4,650 \$122,142 \$51,099 \$1,099	NIAN NOT Filed NIAN NOT Filed NIAN NOT Filed NIAN NIAN NIAN NIAN NIAN NIAN NIAN NIAN	8/22/2014 4/4/2014 11/12/2014 8/15/2014 6/6/2014 11/13/2014 11/13/2014 2/27/2015	38% 15% 20% 38% 38% 20% 22%	NIA Not Filed Not Follow-Up NIA Not Filed No Follow-Up NIA	7/28/2015 9/10/2015 Disapproved 8/7/2015	1
California	eries	151 300 6 6 6 4 147 84 3 3 65 97 117 124 4 4 59 50 5 5 2 2 2 3 3 3 3 5 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 6 5 6	\$242.274 \$13.271 \$13.271 \$13.271 \$13.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.272 \$1.3.27	N/A	8/22/2014 4/4/2014 11/12/2014 8/15/2014 6/6/2014 11/13/2014 11/13/2014 2/27/2015	38% 15% 20% 38% 38% 20% 22%	N/A 38% Not Filed No Follow-Up N/A N/A N/A N/A 15% N/A	7/28/2015 9/10/2015 Disapproved 8/7/2015	1
Colorado	eries	151 300 6 6 6 4 147 84 3 3 65 97 117 124 4 4 59 50 5 5 2 2 2 3 3 3 3 5 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 5 6 5 6 5 6	\$242.274 \$13.271 \$13.271 \$13.271 \$13.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.271 \$1.3.272 \$1.3.27	Not Filed (Not Filed (8/22/2014 4/4/2014 11/12/2014 8/15/2014 6/6/2014 11/13/2014 11/13/2014 2/27/2015	38% 15% 20% 38% 38% 20% 22%	38% Not Filed No Follow-Up No F	7/28/2015 9/10/2015 Disapproved 8/7/2015	1
Delaware Delaware Delaware Delaware Delaware Fire 57 Florida Fire 700 Se Flillinois Fire 700 Se Flill	raties	6 6 2 2 2 6 4 4 4 4 3 3 5 2 3 3 6 5 5 6 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	\$13.271 \$17.67 \$103.870 \$103.870 \$15.65 \$145.244 \$15.2085 \$150.315 \$3.292 \$132.085 \$132.085 \$132.085 \$132.085 \$132.085 \$132.085 \$132.085 \$313.856 \$331.856 \$	38% N/A	8/22/2014 4/4/2014 11/12/2014 8/15/2014 6/6/2014 11/13/2014 11/13/2014 2/27/2015	38% 15% 20% 38% 38% 20% 22%	No Follow-Up	9/10/2015 Disapproved 8/7/2015 4/18/2016	1
Delaware 780 Se Florida 760 Se Georgia 515 Se Georgia 515 Se Georgia 515 Se Georgia 780 Se Georgia 780 Se Georgia 780 Se Idaho 515 Se Illinois 760 Se Illinois 76	eries	2 9 44 147 147 147 147 147 147 147 147 147	\$1,761 \$103,870 \$145,245 \$150,315 \$3,282 \$99,529 \$132,088 \$134,367 \$22,246 \$311,859 \$311,859 \$311,859 \$311,859 \$311,859 \$311,859 \$313,200 \$30,562 \$56,652 \$56,652 \$56,652 \$57,000 \$30,349 \$47,249 \$47,	N/A	8/22/2014 4/4/2014 11/1/2/2014 8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015	15% 17% 20% 38% 38% 15% 20%	N/A	9/10/2015 Disapproved 8/7/2015 4/18/2016	1
Florida	rries	147 844 33 977 117 244 182 44 88 599 500 5 5 2 2 33 33 6 8 8 8 8 24 4 24 23 3 3 3 3 3 3 3 6 8 8 8 8 8 8 8 8 9 7 7 8 8 8 8 8 8 9 9 9 9	\$145,2445 \$150,3151 \$3,2925 \$99,529 \$132,085 \$13	N/A\ 38%	4/4/2014 11/1/2/2014 8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015	17% 20% 38% 38% 15% 20%	N/A 20% N/A 18% N/A 18% N/A 15% N/A No Follow-Up N/A No Follow-Up N/A 18% N/A No Follow-Up N/A 18% N/A No Follow-Up N/A	9/10/2015 Disapproved 8/7/2015 4/18/2016	1
Georgia	pries	84 3 3 65 97 1177 24 4 4 888 59 55 57 57 57 22 87 57 26 6 6 6 4 4 4 4 33 23 33 23 33 4 4 4 4 4 5 9 9 9 9 9 9 9 9 9 9 9 9 9 9	\$150,316,316,316,316,316,316,316,316,316,316	38% NAA 38% NAA 38% NAA 38% NAA NAA NAA NOT Filed NAA NAA NOT Filed NAA NAA NOT Filed NAA NAA NOT Filed NAA NAA NOT Filed NAA NAA NAA NAA NAA NAA NOT Filed NAA NAA NAA NAA NAA NAA NOT Filed	4/4/2014 11/1/2/2014 8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015	17% 20% 38% 38% 15% 20%	20% NAA 18% 18% N/A 15% N/A 15% N/A NO Follow-Up N/A NO Follow-Up N/A NO Follow-Up N/A NO Follow-Up N/A N/A NO Follow-Up N/A N/A NO Follow-Up N/A N/A NO Follow-Up N/A N/A N/A NO Follow-Up N/A N/A N/A NO Follow-Up N/A	9/10/2015 Disapproved 8/7/2015 4/18/2016	1
15, 58	raties	3 65 97 117 124 182 182 182 182 182 182 182 182 182 182	\$99,529 \$132,089,529 \$132,089,529 \$28,246 \$28,246 \$311,859 \$311,859 \$313,200 \$90,562 \$5,838 \$32,131 \$33,210 \$30,349,93 \$43,122 \$5,27,52 \$12,299 \$24,607 \$29,796 \$32,432 \$31,434 \$44,438 \$44,43	38% NAA NAA NAA NAA NAA NAA NAA NAA NAA NA	11/12/2014 8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015	20% 38% 38% 15% 20%	18% N/A 15% N/A 15% N/A 15% N/A	8/7/2015 4/18/2016	
Jova	eries	97 117 124 4 4 888 59 50 5 2 2 87 57 26 33 33 6 8 8 24 4 4 4 3 3 3 3 3 3 6 8 8 8 8 8 8 8 8 8 8 8 8 8	\$132.085 \$134.367 \$28.246 \$134.367 \$311.855 \$6.058 \$130.200 \$60.652 \$66.652 \$66.652 \$68.353 \$3.213 \$43.122 \$12.299 \$12.299 \$14.203 \$14.203 \$15.303 \$15	NIAI NIAI NIAI NIAI NIAI NIAI NIAI NIAI	11/12/2014 8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015	20% 38% 38% 15% 20%	NIA 15% No Follow-Up NiA No Follow-Up NiA NiA No Follow-Up NiA NiA No Follow-Up NiA NiA No Follow-Up NiA NiA NiA No Follow-Up NiA	8/7/2015 4/18/2016	
Idaho	eries	24 4 4 4 4 3 3 2 2 3 3 6 6 4 4 4 4 5 5 6 6 1 5 6 1 5 6 1 5 6 1 5 6 6 1 5 6 1 5 6 1 6 1	\$28,244 \$311,859 \$310,200 \$90,552 \$66,652 \$68,652 \$7,009 \$30,349 \$7,009 \$30,349 \$43,122 \$29,752 \$29,752 \$32,433 \$32,733 \$34,438 \$34,43	N/A\ N/A\ N/A\ N/A\ N/A\ N/A\ N/A\ N/A\	8/15/2014 6/6/2014 4/7/2014 11/13/2014 2/27/2015 2/3/2014	38% 38% 15% 20%	N/A No Follow-Up N/A N/A N/A N/A N/A NO FOIlow-Up N/A 15% N/A 15% N/A Not Filed N/A N/A	8/7/2015 4/18/2016	1
Illinois	eries	1822 4 888 599 500 5 5 22 87 575 575 233 6 6 8 8 244 245 253 644 4 4 4 352 645 646 647 647 648 649 649 649 649 649 649 649 649 649 649	\$311,859 \$3.059 \$3.0595 \$3.0595 \$40,562 \$5.838 \$3.213 \$3.243 \$3.348 \$41,229 \$41,229 \$2.752 \$3.243 \$3	38% N/A	6/6/2014 4/7/2014 11/13/2014 2/27/2015 2/3/2014	38% 15% 20% 22%	No Follow-Up N/A N/A N/A No Follow-Up N/A N/A NO Follow-Up N/A Not Filed N/A No Follow-Up N/A N/A N/A N/A N/A	4/18/2016	
Illinois	eries	88 59 50 5 2 87 97 97 97 96 88 8 24 25 64 4 4 3 3 3 3 3 3 3 3 3 3 3 6 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	\$130,200 \$90,562 \$66,682 \$5,838 \$32,131 \$32,131 \$33,343 \$43,122 \$43,122 \$12,299 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$22,799 \$24,607 \$24,60	N/A Not Filed Ni/A 38% N/A 38% N/A Not Filed Ni/A 38% N/A Not Filed N/A N/A Not Filed N/A Not Filed N/A Not Filed	4/7/2014 11/13/2014 2/27/2015 2/3/2014	15% 20% 22%	N/A 38% N/A No Follow-Up N/A 22% N/A N/A Not Filed N/A	4/18/2016	
ndlana 515 Se ndlana 515 Se ndlana 700 Se Cansas 515 Se Cansas 780 Se Centucky 715 Se	eries	59 50 50 2 877 26 333 23 6 6 8 24 24 24 33 23 33 23 6 8 8 24 4 33 5 5 5 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	\$90,562 \$66,652 \$5,838 \$3,213 \$83,544 \$67,000 \$43,122 \$29,752 \$22,752 \$21,299 \$24,607 \$32,432 \$33,444,607 \$32,432 \$43,122 \$43,	Not Filed	4/7/2014 11/13/2014 2/27/2015 2/3/2014	15% 20% 22%	38% N/A No Follow-Up N/A 22% N/A 15% N/A 15% N/A Not Filed N/A Not Filed N/A Not Filed N/A N/A Not Follow-Up N/A	4/18/2016	
ndlana 700 Se Kansas Kansas 515 Se Kansas Kansas 750 Se Kansas Kansas 750 Se Kansas Kentucky 750 Se Kentucky Kentucky 750 Se Kentucky Kansasachusetts 515 Se Kentucky Kansasachusetts 515 Se Kentucky Massachusetts 515 Se Kentucky Maring Mana 780 Se Maring Maline 780 Se Minel Maline 780 Se Michigan Michigan 700 Se Michigan Michigan 760 Se Minesota Minnesota 515 Se Minesota Minsouri 515 Se Minesota Missouri 515 Se Minesota Morth Carolina 780 Se Velvaria North Carolina 780 Se Velvaria North Carolina 780 Se Velvaria New Hampshire 780 Se Velvaria New Hawa 780 Se Velvaria <	eries	5 2 87 57 26 33 23 6 8 8 24 25 23 6 4 352 366 155 81	\$5,838 \$3,213 \$33,214 \$67,009 \$43,122 \$29,752 \$12,299 \$24,607 \$29,796 \$21,299 \$32,432 \$33,432 \$33,656 \$44,033 \$42,443 \$42,443 \$42,443 \$43,122 \$22,888 \$45,455 \$17,545 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$23,432 \$24,432 \$24,432 \$24,432 \$25,452 \$25,452 \$26,452	38% N/A 38% N/A 38% N/A Not Filed N/A	4/7/2014 11/13/2014 2/27/2015 2/3/2014	15% 20% 22%	No Follow-Up N/A 22% N/A 15% N/A No Filed N/A Not Filed N/A No Follow-Up N/A N/A No Follow-Up N/A		
Aansas 780 Se Kansas 780 Se Kantucky 515 Se Kentucky 780 Se Centucky 780 Se Centucky 780 Se Coulsiana 515 Se Coulsiana 515 Se Maryland 780 Se Minnesota 780 Se Missouri 515 Se Montana 780 Se Missouri 780 Se North Carolina 515 Se North Carolina 780 Se North Carolina 515 Se Se North Caro	eries	2 87 57 26 33 23 6 8 24 25 23 64 4 352 366 155	\$3,213 \$83,548 \$67,000 \$30,349 \$43,122 \$12,299 \$24,607 \$32,759 \$32,432 \$53,656 \$114,203 \$444,033 \$422,443 \$282,889 \$282,889 \$45,455 \$1,754 \$21	N/A 38% N/A 38% N/A Not Filed N/A 38% N/A Not Filed N/A	4/7/2014 11/13/2014 2/27/2015 2/3/2014	15% 20% 22%	N/A 22% N/A 15% N/A Not Filed N/A Not Filed N/A Not Filed N/A		
Kentucky 780 Se Coulsiana 515 Se Coulsiana 515 Se Coulsiana 515 Se Maryland 780 Se Maline 515 Se Michigan 700 Se Mississippi 515 Se Mississippi 515 Se Montana 780 Se Mississippi 515 Se Montana 780 Se Morth Carolina 780 Se Morth Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 S	eries	57 26 333 23 6 8 24 25 23 64 4 4 352 366 155 81	\$67,009 \$43,122 \$29,752 \$12,299 \$24,607 \$29,796 \$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754	N/A 38% N/A Not Filed N/A 38% N/A N/A N/A N/A N/A Not Filed N/A 38%	2/27/2014	20%	N/A 15% N/A Not Filed N/A Not Filed N/A N/A No Follow-Up N/A N/A		
oulsialana 515 Se oulsialana 780 Se Massachusetts 515 Se Massachusetts 780 Se Maline 700 Se Maline 700 Se Maline 700 Se Michigan 515 Se Michigan 760 Se Michigan 760 Se Michigan 780 Se Minnesota 780 Se Missouri 780 Se Missouri 780 Se Missouri 780 Se Mississippi 515 Se Montana 780 Se Montana 780 Se North Carolina 515 Se North Carolina 780 Se North Carolina 780 Se North Dakota 780 Se New Hampshire 780 Se New Hampshire 780 Se New Hampshire 780 Se New Ada 515 Se New John 515 Se New John 515 Se New John 515 Se <td>eries eries eries</td> <td>26 33 23 6 8 8 24 25 23 64 4 352 366 155 81</td> <td>\$30.349 \$43.122 \$29.752 \$12,299 \$24,607 \$29,796 \$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754</td> <td>38% N/A Not Filed N/A 38% N/A 38% N/A 38% N/A 38% N/A A 38% N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A</td> <td>2/27/2015</td> <td>22%</td> <td>15% N/A Not Filed N/A Not Filed N/A Not Filed N/A N/A N/A N/A N/A N/A N/A N/A N/A</td> <td>Disapproved</td> <td></td>	eries	26 33 23 6 8 8 24 25 23 64 4 352 366 155 81	\$30.349 \$43.122 \$29.752 \$12,299 \$24,607 \$29,796 \$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754	38% N/A Not Filed N/A 38% N/A 38% N/A 38% N/A 38% N/A A 38% N/A	2/27/2015	22%	15% N/A Not Filed N/A Not Filed N/A Not Filed N/A N/A N/A N/A N/A N/A N/A N/A N/A	Disapproved	
Massachusetts 515 Se Many Amy Amy Amy Amy Amy Amy Amy Amy Amy Am	eries	6 8 24 25 23 64 4 352 366 155 81	\$29,752 \$12,299 \$24,607 \$29,796 \$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$17,54	Not Filed N/A 38% N/A N/A 38% N/A N/A N/A N/A N/A N/A N/A Not Filed N/A 38%	2/3/2014		Not Filed N/A Not Filed N/A N/A No Follow-Up N/A N/A		
Maryland 780 Se Maine 515 Se Maine 750 Se Maine 750 Se Maine 750 Se Maine 750 Se Milchigan 750 Se Milchigan 750 Se Milchigan 750 Se Minesota 515 Se Minnesota 515 Se Missouri 515 Se Missouri 515 Se Missouri 780 Se Montana 515 Se Morth Carolina 515 Se Morth Carolina 780 Se North Carolina 780 Se North Carolina 780 Se New Hampshire 780 Se New Hampshire 780 Se New Hampshire 780 Se New Mexico 780 Se New Ada 515 Se New York 515 Se Dilio 780 Se Dilo 780 Se Dilo 780 Se Dregon 750 Se Dennsyl	eries	6 8 24 25 23 64 4 352 366 155 81	\$12,299 \$24,607 \$29,796 \$332,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754	N/A 38% N/A N/A 38% N/A N/A Not Filed N/A 38%	2/3/2014		N/A Not Filed N/A N/A No Follow-Up N/A N/A		
Maine 700 Se Maine Maine 700 Se Mines Mines Michigan Michigan 515 Se Michigan 700 Se Minesota 700 Se Minesota Michigan 780 Se Minesota Minnesota 780 Se Minesota Minsouri 515 Se Missouri 515 Se Missouri 515 Se Missouri Missouri 515 Se Mississippi Montana 515 Se Mississippi Morth Carolina 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se New Hampshire 780 Se North Carolina 780 Se New Hampshire 780 Se North Carolina 780 Se North Carolina 780 Se North Carolina 780 Se Orlio 780 Se Orlio	eries	24 25 23 64 4 352 366 155 81	\$29,796 \$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754	N/A N/A 38% N/A N/A Not Filed N/A 38%	2/3/2014		N/A N/A No Follow-Up N/A N/A		
Maine 780 Se Michigan Michigan 515 Se Michigan 700 Se Michigan 700 Se Michigan Michigan 700 Se Michigan Michigan 700 Se Michigan Mischael 515 Se Missouri Missouri 515 Se Missouri Missouri 780 Se Missouri Missouri 780 Se Montana Morth Garollina 515 Se Morth Carollina North Carollina 780 Se North Carollina North Carollina 780 Se North Carollina North Dakota 780 Se North Carollina North Dakota 780 Se North Carollina New Hampshire 780 Se North Carollina New Hampshire 780 Se North Carollina New Mexico 515 Se North Carollina New York 515 Se North Carollina Ohlo 700 Se Ohlo Oregon 515 Se North Carollina South Carollina 780 Se North Carollina South Dakota 780 Se North Carollina South Dakota 780 Se North Carollina South Dakota 780 Se North Carollina	eries eries eries eries eries eries eries eries	25 23 64 4 352 366 155 81	\$32,432 \$53,656 \$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$5,455 \$1,754	N/A 38% N/A N/A Not Filed N/A 38%		38%	N/A No Follow-Up N/A N/A		
Michigan 700 Se Michigan 700 Se Michigan 780 Se Minnesota 780 Se Minnesota 780 Se Minnesota 780 Se Minnesota 780 Se Missouri 780 Se Missouri 780 Se Missouri 780 Se Montana 780 Se Morth Carolina 780 Se Mor	eries eries eries eries eries eries eries	64 4 352 366 155 81	\$114,203 \$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754 \$52,358	N/A N/A Not Filed N/A 38%		38%	N/A N/A		
Wilnesota	eries eries eries eries eries eries	4 352 366 155 81	\$4,438 \$494,033 \$422,443 \$282,889 \$85,455 \$1,754 \$52,358	N/A Not Filed N/A 38%			N/A		
Minnesota 780 Se Missouri 780 Se Missouri 780 Se Missouri 780 Se Missouri 780 Se Mississippi 515 Se Mississippi 515 Se Montana 780 Se Morth Carolina 780 Se Morth Carolina 780 Se Morth Dakota 780 Se Morth Carolina 780 Se Morth Caro	eries eries eries eries	155 81 2	\$282,889 \$85,455 \$1,754 \$52,358	N/A 38%					
Missouri 515.5 km Missouri 515.5 km Missouri 780.5 km Mississippi 515.5 km Mississippi 515.5 km Montana 515.5 km North Carollina 780.5 km North Carollina 780.5 km North Dakota 780.5 km Nebraska 751.5 km Nebraska 750.5 km New Hampshire 780.5 km New Hampshire 780.5 km New Hampshire 780.5 km New Mexico 750.5 km New Mexico 750.5 km Nevada 750.5 km Nevada 750.5 km Nevada 750.5 km Ohlio 750	eries eries eries	155 81 2	\$282,889 \$85,455 \$1,754 \$52,358	38%			38% N/A	2/5/2016	
Mississippi 515 Se Montana 515 Se Se Montana 515 Se Se Se Se Se Se Se Se	eries	2	\$1,754 \$52,358	N/A	3/25/2014	20%	15%	5/4/2015	
Montana		_	\$52,358	Not Filed			N/A Not Filed		
North Carolina 515 Se North Carolina 780 Se North Dakota 780 Se Dakahoma 780 Se Dakahoma 780 Se Dakahoma 780 Se Dregon 780 Se Dregon 780 Se Dregon 780 Se Dregon 780 Se Dakahoma 780 Se Dregon 780 Se Dregon 780 Se Dakahoma 780 Se Fensese 780 Se Fenses 780 Se F		1		38%	7/3/2014	15%	20%	Withdrawn	
North Carolina 780 Se North Dakota 780 Se Nebraska 780 Se New Hampshire 780 Se Dhio 780 Se Nouth Carolina 780 Se Nouth Carolina		235	\$2,711 \$340,181	N/A 38%	9/26/2014	20%	N/A Not Filed		
Nebraska	eries	84	\$95,559	N/A	3/20/2014	2070	N/A		
Nebraska 700 Se New Hampshire 515 Se New Hampshire 700 Se New Hampshire 780 Se New Mexico 515 Se New Mexico 780 Se Newada 515 Se Newada 700 Se Newada 700 Se New York 515 Se Dhio 700 Se Dhio 700 Se Dklahoma 515 Se Dklahoma 515 Se Oregon 515 Se Pennsylvania 750 Se Pennsylvania 750 Se South Carolina 515 Se South Carolina 515 Se South Dakota 515 Se South Dakota 760 Se Se Cennessee 750 Se Fennessee 780 Se		26 15	\$26,111 \$18,305	N/A 38%	8/11/2014	38%	N/A No Follow-Up		
New Hampshire New York New Yo	eries	9	\$14,852	N/A			N/A		
New Hampshire 780 Se New Mexico 515 Se New Mexico 780 Se New Mexico 780 Se New Mexico 780 Se New York 515 Se Ohio 515 Se Ohio 700 Se Ohio 700 Se Ohio 700 Se Oklahoma 515 Se Oklahoma 515 Se Oregon 515 Se Oregon 515 Se Pennsylvania 515 Se Shode Island 515 Se South Carolina 515 Se South Dakota 515 Se South Dakota 780 Se Fennessee 515 Se Fennessee 780 Se Fennessee 780 Se	eries eries	22 7	\$31,761 \$6,567	38% N/A	3/23/2015	30%	Not Filed N/A		
New Mexico 780 Se	eries	10	\$10,955	N/A			N/A		
Nevada 515 Se Nevada 515 Se Nevada 515 Se Nevada 700 Se Nevada 700 Se Dhio 700 Se Nevada 515 Se Nevada 515 Se Nevada 515 Se South Carolina 700 Se Nevada 515 Se South Carolina 700 Se South Carolina 700 Se South Dakota 750 Se South Dakota 750 Se South Dakota 750 Se South Dakota 750 Se Se South Dakota 750 Se Se South Se	eries eries	5 1	\$3,821 \$2,799	N/A N/A			N/A N/A		
New York 515 Se Dhio 515 Se Dhio 700 Se Dh	eries	10	\$14,790	38%	10/15/2014	38%	No Follow-Up		
Ohio 515 Se Ohio 760 Se Ohio 780 Se Ohio 780 Se Ohio 780 Se Oklahoma 780 Se Oregon 515 Se Oregon 515 Se Pennsylvania 780 Se Rhode Island 515 Se South Carolina 515 Se South Carolina 780 Se South Dakota 515 Se South Dakota 780 Se Tennessee 515 Se		1 68	\$817 \$117,879	N/A Not Filed			N/A 15%	7/20/2015	
Ohio 780 Se Nel Nel Nel Nel Nel Nel Nel Nel Nel Ne	eries	27	\$41,701	38%	4/24/2015	25%	Not Filed		
Dklahoma 515 Se Dklahoma 780 Se Dregon 515 Se Dregon 515 Se Dregon 780 Se Pennsylvania 515 Se Pennsylvania 780 Se Rhode Island 515 Se South Carolina 515 Se South Carolina 780 Se South Dakota 780 Se Fennessee 515 Se South Dakota 780 Se Fennessee 780 Se Fennessee 780 Se Fenses 515 Se		6 27	\$6,565 \$41,980	N/A N/A			N/A N/A		
Dregon 515.58 Dregon 750.58 Pennsylvania 515.58 Pennsylvania 780.58 Rhode Island 515.58 South Carolina 515.58 South Carolina 780.58 South Dakota 515.58 South Dakota 780.58 Fennessee 515.58 Fennessee 780.58 Fennessee 780.58 Fenas 515.58	eries	35	\$65,910	38%	6/4/2014	25%	10%	1/25/2016	
Oregon 780 Se Pennsylvania 515 Se Pennsylvania 780 Se Pennsylvania 780 Se Rhode Island 515 Se South Carolina 515 Se South Carolina 780 Se South Dakota 780 Se Fennessee 515 Se Tennessee 780 Se Fexas 515 Se		7 119	\$9,522 \$186 299	N/A 38%	5/13/2014	38%	N/A No Follow-Up		
Pennsylvania 780 Se Rhode Island 515 Se South Carolina 515 Se South Carolina 780 Se South Dakota 515 Se South Dakota 780 Se South Dakota 780 Se Fennessee 515 Se Tennessee 780 Se Tennessee 780 Se	eries	27	\$186,299 \$50,790	N/A			N/A		
Rhode Island		168 54	\$212,925 \$76,466	38% N/A	5/13/2014	15%	20% N/A	6/24/2015	
South Carolina 780 Se South Dakota 515 Se South Dakota 780 Se Tennessee 515 Se Tennessee 780 Se Tennessee 780 Se Texas 515 Se	eries	11	\$18,158	38%	2/26/2019	38%	No Follow-Up		
South Dakota 515 Se South Dakota 780 Se Tennessee 515 Se Tennessee 780 Se Tennessee 780 Se Texas 515 Se		113 1	\$140,272 \$6,795	38% N/A	3/17/2014	20%	Not Filed N/A		
Tennessee 515 Se Tennessee 780 Se Texas 515 Se	eries	21	\$52,970	38%	1/6/2014	38%	No Follow-Up		
Tennessee 780 Se Texas 515 Se	eries eries	7	\$7,784 \$458,754	N/A 38%	3/24/2014	38%	N/A No Follow-Up		
	eries	292 17	\$16,141	N/A			N/A		
		193 97	\$346,018 \$117,392	38% N/A	9/10/2014	19%	Not Filed N/A		
Utah 780 Se	eries	9	\$9,050	N/A			N/A	Disease	
Virginia 515 Se Virginia 780 Se	eries	139 13	\$143,126 \$20,535	Not Filed N/A	L		38% N/A	Disapproved	
Vermont 515 Se	ries	79	\$122,887	38%	Disapproved	0%	38%	Disapproved	
Vermont 515 Se Vermont 700 Se Vermont 780 Se	eries	79 25 2	\$36,825 \$2,542	N/A N/A	L		N/A N/A		
Washington 515 Se		199	\$458,666	38%	4/15/2014	38%	No Follow-Up		
Wisconsin 515 Se Wisconsin 780 Se	eries	111 8	\$176,653 \$12,218	38% N/A	3/6/2014	38%	No Follow-Up N/A		
West Virginia 515 Se	eries eries	17	\$33,526	38%	8/6/2014	15%	20%	8/5/2015	
Wyoming 515 Se Wyoming 780 Se	eries eries eries eries	61 18	\$130,595 \$38,653	Not Filed N/A	L		38% N/A	5/19/2015	
1] Annualized premium reflects all ra 2] "Filed" is used in a generic sense	eries eries eries eries eries	ases filed for use b	etween January			a jurisdiction.	·	a U	
ncrease percentages are based off ti	eries eries eries eries eries eries	ness in force as of D	December 31, 20	19.					
3] The requested rate increase level 4] The company is "Not Filing" in juri	eries eries eries eries eries eries eries eries ate increa	y inflation option; a						ecember 31, 2019.	

Attachment 7-b MedAmerica, CICA, and CLICNY Status of Filings as of July 20, 2021 All Jurisdictions in Which These Forms are In Force 515, 700, and 780 Series

		12/31/2019	12/31/2019		Current Rou	ind Nationwid	e request	Average	-	Current	Round Follow	w-∪p	Average		Current R	ound 2nd Fol	iow-Up	Average	Aver Cumula
		Policies	Annualized	Requested	0 [2][4][5]	Date	Disposition	Filed	Requested	0 [2][4][5]	Date	Disposition	Filed	Requested	0 [2][4][5]	Date	Disposition	Filed	Incre
	Rate Series 515 Series	In Force 119	Premium ^[1] \$149,667		Status ^{[2][4][5]} Filed	Submitted 6/8/2018	Date 6/18/2018	Increase ^[2]	Increase ^[3] 36%	Status ^{[2][4][5]} Filed	Submitted 3/9/2020	Date 3/30/2020	Increase ^[2]		Status ^{[2][4][5]} Filed	Submitted 12/3/2020	Date 1/11/2021	Increase ^[2]	File 5
	780 Series	15	\$13,034		Filed	6/8/2018	6/18/2018	3%	30 /0	Not Filing	3/3/2020	3/30/2020	12 /0	2070	Not Filing	12/3/2020	1/11/2021	13 /0	
	515 Series 780 Series	4	\$4,186 \$4,650		Not Filing Not Filing					Not Filing					Not Filing Not Filing				
		92	\$122,142		Not Filina					Not Filing Not Filing					Not Filing				
	515 Series 780 Series	36	\$51,090		Not Filing	014010000				Not Filing					Not Filing				
	515 Series 515 Series	151 30	\$242,274 \$51,947		Pending Filed	3/18/2020 4/25/2018	5/23/2018	11%	78%	Filed	2/10/2020	4/28/2020	15%	64%	Pending	6/10/2021			
lelaware	515 Series	6	\$13,271		Not Filing					Not Filina					Not Filing				
	780 Series 700 Series	64	\$1,761 \$103.870		Not Filing Filed	3/2/2017	10/3/2017	35%		Not Filing TBD					Not Filing				
lorida	780 Series	147	\$145,245	42%	Filed	3/2/2017	10/3/2017	37%		TBD									
	515 Series	84	\$150,315		Filed	2/6/2018	5/29/2018	7%	46%	Filed	11/13/2019	2/19/2020	8%	33%	Filed	10/19/2020	11/24/2020	8%	
eorgia wa	780 Series 515 Series	65	\$3,292 \$99,529	51%	Not Filing Filed	4/17/2019	6/24/2019	14%	37%	Not Filing Filed	6/8/2020	7/13/2020	24%		Not Filing TBD				
wa	780 Series	97	\$132,085	20%	Filed	4/17/2019	6/24/2019	10%	11%	Filed	6/8/2020	7/13/2020	11%		No Follow-Up				
aho aho	515 Series 780 Series	117 24	\$134,367 \$28,246	66% 26%	Filed	2/2/2018 2/2/2018	1/13/2021 1/13/2021	24% 11%								 	ļ		ļ
inois	515 Series 700 Series	182	\$311,859	41%	Filed	12/21/2017	1/15/2019	41%		No Follow-Up No Follow-Up					No Follow-Up				
inois inois	700 Series 780 Series	4 88	\$8,058 \$130,200	46% 18%	Filed Filed	12/21/2017 12/21/2017	1/15/2019 1/15/2019	46% 18%		No Follow-Up No Follow-Up					No Follow-Up No Follow-Up	ļ			
	515 Series	59	\$90,562			12/4/2018	4/17/2019	0%		TBD					No Follow-Up				
diana	700 Series	50	\$66,652	62%	Disapproved Disapproved	12/4/2018	4/17/2019	0%		TBD									
ansas ansas	515 Series 780 Series	5 2	\$5,838 \$3,213		Not Filing Not Filing					Not Filing Not Filing					Not Filing Not Filing		 		
entucky	515 Series	87	\$83,548	7%	Disapproved	3/27/2019	5/21/2019	0%	6%	Not Yet Filed									
	780 Series 515 Series	57 26	\$67,009 \$30,349	3% 67%	Filed Disapproved	3/27/2019 7/9/2018	5/21/2019 7/30/2018	3%		No Follow-Up Not Filing					No Follow-Up Not Filing				
ouisiana	780 Series	33	\$43,122	22%	Disapproved	7/9/2018	7/30/2018			Not Filing					Not Filing				
	515 Series 780 Series	23	\$29,752 \$12,299	40%	Filed Not Filing	8/4/2017	10/17/2018	20%		TBD Not Filing					Not Filing				\vdash
	515 Series	8	\$12,299	78%		8/10/2018	10/19/2018	24%	46%	Not Yet Filed					NOT FIIIIG				
aine	700 Series	24	\$29,796	73%	Filed	8/10/2018	10/19/2018	29%	36%	Not Yet Filed		[N. 6.0				
	780 Series 515 Series	25 23	\$32,432 \$53,656		Filed Filed	8/10/2018 1/26/2018	10/19/2018 2/27/2018	17% 60%		No Follow-Up No Follow-Up					No Follow-Up No Follow-Up				
lichigan	515 Series 700 Series	64	\$114,203	74%	Filed	1/26/2018	2/27/2018	74%		No Follow-Up					No Follow-Up	l			<u> </u>
lichigan	780 Series	4	\$4,438	500/	Not Filing	0/45/0000		E40/		Not Filing					Not Filing				
innesota innesota	515 Series 780 Series	352 366	\$494,033 \$422,443	52% 20%	Filed Filed	6/15/2020 6/15/2020	2/2/2021 2/2/2021	54% 20%								 -			
issouri	515 Series	155	\$282,889	70%	Filed	3/13/2018	5/29/2018	29%	16%	Filed	6/29/2020	7/31/2020	16%		No Follow-Up				
issouri ississippi	780 Series 515 Series	81	\$85,455 \$1,754		Filed Not Filing	3/13/2018	5/25/2018	4%	4%	Filed Not Filing	6/29/2020	7/29/2020	4%		No Follow-Up Not Filing				<u> </u>
ontana	515 Series	36	\$52,358	83%	Filed	3/22/2019	6/19/2019	32%		TBD					rvocrining				
	780 Series 515 Series	1	\$2,711 \$340,181		Filed Filed	3/22/2019 3/13/2018	6/19/2019 8/5/2019	35% 24%		No Follow-Up TBD					No Follow-Up				
	780 Series	235 84	\$95,559	14%	Filed	3/13/2018	8/5/2019	8%		TBD						 -			
lorth Dakota	780 Series	26	\$26,111	2001	Not Filing					Not Filing					Not Filing				
lebraska lebraska	515 Series 700 Series	15 9	\$18,305 \$14,852	63% 96%	Not Yet Filed Not Yet Filed			 											
lew Hampshire	515 Series	22	\$31,761	50%	Not Yet Filed														
lew Hampshire lew Hampshire	700 Series 780 Series	7	\$6,567 \$10,955		Not Yet Filed Not Yet Filed				 								ļ		
lew Mexico	515 Series	5	\$3,821	2570	Not Filing					Not Filing					Not Filing				
	780 Series	1	\$2,799 \$14,790		Not Filing					Not Filing					Not Filing Not Filing				
levada levada	515 Series 700 Series	10	\$14,790		Not Filing Not Filing					Not Filing Not Filing					Not Filing				l
lew York	515 Series	68	\$117,879	77%		4/12/2018	11/29/2018	10%	66%	Pending	2/2/2021				Ž				
Ohio Ohio	515 Series 700 Series	27 6	\$41,701 \$6,565	62% 85%	Filed Filed	6/15/2018 6/15/2018	10/11/2018 10/11/2018	11% 13%	12% 13%	Pending Pending	6/24/2020 6/24/2020						 		
)hio	780 Series	27	\$41,980	14%	Filed	6/15/2018	10/11/2018	6%	6%	Pending	6/24/2020								
klahoma klahoma	515 Series 780 Series	35	\$65,910 \$9,522	35% 23%	Filed Filed	3/21/2019 3/21/2019	4/5/2019 4/5/2019	8% 10%	29% 14%	Filed Filed	2/28/2020 2/28/2020	3/13/2020 3/13/2020	9% 10%	17% 2%	Filed Filed	2/24/2021 2/24/2021	3/9/2021 3/9/2021	8%	ļ
	515 Series	119	\$186,299	58%	Pending	12/21/2018	4/3/2019	1070	14 /0	riieu	2/20/2020	3/13/2020	10 /6	2.70	riieu	2/24/2021	3/3/2021	270	
regon	780 Series	27	\$50,790	32%	Pending	12/21/2018	014010040	400/	000/		7/0/0000	0/04/0000	4.404	400/					
ennsylvania ennsylvania	515 Series 780 Series	168 54	\$212,925 \$76,466	41% 18%	Filed Filed	3/21/2019 3/21/2019	8/12/2019 8/12/2019	12% 18%	32%	Filed No Follow-Up	7/6/2020	8/21/2020	14%	12%	Not Yet Filed No Follow-Up	 -	 -		
hode Island	515 Series	11	\$18,158		TBD										THO T OHOW OF				
outh Carolina outh Carolina	515 Series 780 Series	113	\$140,272 \$6,795	35% 35%	Filed Filed	6/1/2018 6/1/2018	9/10/2018 9/10/2018	8% 20%	26% 14%	Filed Filed	1/22/2021 1/22/2021	4/13/2021 4/13/2021	5% 12%		L	ļ	ļ	-	ļ
outh Dakota	515 Series	21	\$52,970	52%	Filed	6/12/2019	9/5/2019	52%	14%	No Follow-Up	1/22/2021	4/13/2021	12%		No Follow-Up	 	-	 	
	780 Series	7	\$7,784	13%	Filed	6/12/2019	9/5/2019	13%		No Follow-Up	4/44/0001	3101000	401		No Follow-Up	[[Ε
ennessee ennessee	515 Series 780 Series	292 17	\$458,754 \$16,141	18% 6%	Filed Filed	3/4/2019 3/4/2019	9/20/2019 9/20/2019	11% 3%	7% 2%	Filed Filed	1/11/2021 1/11/2021	3/8/2021 3/8/2021	4% 2%			 -	 		ļ
exas	515 Series	193	\$346,018	46%	Filed	8/13/2018	12/21/2018	46%		TBD									Ĺ
	780 Series 780 Series	97 q	\$117,392 \$9,050		Filed Not Filing	8/13/2018	12/21/2018	18%	 	No Follow-Up Not Filing	ļ	ļ			No Follow-Up Not Filing	ļ	ļ	ļ	
irginia	780 Series 780 Series	139	\$143,126		Filed	5/2/2018	9/4/2020	75%	 	TBD									
		13	\$20,535		Not Filing			Γ		Not Filing	[Not Filing		[
ermont ermont	515 Series 700 Series	79 25	\$122,887 \$36,825	108% 100%	Filed Filed	2/9/2018 2/9/2018	8/21/2019 8/21/2019	32% 22%	 	TBD TBD				L	L	 	 		
ermont	780 Series	2	\$2,542	35%	Filed	2/9/2018	8/21/2019	14%	[TBD	 								
/ashington /isconsin	515 Series 515 Series	199 111	\$458,666 \$176,653	53% 70%		6/13/2018 6/24/2019	3/25/2020 9/12/2019	30% 70%	10%	Pending No Follow-Up	3/24/2021				No Follow-Up			1	
/isconsin	780 Series	8	\$12,218	3%	Filed	6/24/2019	9/12/2019	3%	<u> </u>	No Follow-Up	L	<u> </u>			No Follow-Up	<u> </u>	<u> </u>	<u> </u>	<u> </u>
/est Virginia	515 Series	17	\$33,526		Filed	7/9/2018	10/26/2018	20%		TBD					No Follow-Up				
	515 Series 780 Series	61 18	\$130,595 \$38,653	52% 33%	Filed Filed	2/27/2018 2/27/2018	4/17/2018 4/17/2018	52% 33%	 	No Follow-Up No Follow-Up	 	 			No Follow-Up No Follow-Up	 -	 		ļ
Annualized premium refle																			
"Filed" is used in a gener					filed for use, etc., b	y a jurisdiction. Av	erage rate												
crease percentages are ba] The requested rate increa					are based on the dis	tribution of in-forc	e business as of [December 31, 2	019.										
	ng" in jurisdictions	where limited by	regulatory require		mited amount of in-			,-											
indicated for jurisdictions t "TBD" (to be determined)																			



MedAmerica Insurance Company

Home Office: Pittsburgh, PA

MedAmerica Insurance Company of New York

Home Office: Rochester, NY

MedAmerica Insurance Company of Florida

Home Office: Orlando, FL

Letter of Authorization

To: Department of Insurance

MedAmerica Insurance Company ("MedAmerica") has entered into a service agreement with Milliman, Inc. ("Milliman") effective October 3, 2016, that includes long-term care rate filing services on our behalf. The agreement provides, in part, that Milliman is responsible for preparing and filing for approval with state insurance departments MedAmerica's long-term care rate increase filings as directed by MedAmerica. Milliman is also authorized to receive, on MedAmerica's behalf, written and oral communication from each state department of insurance for the purpose of completing the rate increase filing process.

Please accept this letter of authorization for the purpose stated above. Should you have any questions regarding the above, please forward your comments to:

MedAmerica Insurance Company 165 Court Street Rochester, NY 14647

William J. Naylon

Bill Naylon, President

MedAmerica Insurance Company



Time-Sensitive! Action Needed - Review Options and Make Your Decision RE: Your Long Term Care Insurance Notice of Premium Increase — Please Read & Retain for Your Records

<<FIRST_NAME>> <<LAST_NAME>> <<STREET_ADDRESS1>> <<STREET_ADDRESS2>> <<CITY>> <<STATE>> <<ZIP>>

<<DATE>>
Billing Account ID: <<POLICY NUMBER>>

Dear << SALUTATION LAST NAME>>:

We are writing to notify you that we have filed a premium increase of <<INC_AMT>> with the Department of Insurance. This premium change is based on the overall experience of all contracts in your class and has nothing to do with your current age, health status, claims history or any other personal factors. This increase applies to all insureds having the same policy form as you, regardless of the effective date of coverage. Please be advised that premiums are subject to future rate increases.

The premium rate increase for your long term care insurance coverage will change on <<NEXT_BILL_DATE>>. Your <<MODAL>> premium payment will change from <<CURRENT_RATE>> to <<FUTURE RATE>>.

We understand this premium increase may affect your ability to afford your current level of benefits. Please review the options regarding your coverage that are outlined below and make the decision that best meets your needs.

- Option #1: Continue your coverage at your current level of benefits. You may keep your current level of benefits by paying the increased premium when it is due on <<NEXT_BILL_DATE>>. If you choose this option, no additional action, other than your premium payment, is required. Please understand that paying the increased premium for coverage through 120 days from the date of the rate increase constitutes your acceptance of the rate increase and voids the offer of the Contingent Non-Forfeiture Benefit outlined in Option #3 below.
- Option #2: Offset the increased premium by reducing your level of benefits. You <u>may</u> be able to adjust your benefits to reduce your premium. Please understand that this option is not always available as you may have selected the state-mandated minimum benefits allowable for long term care insurance. Please call Customer Service toll free at 1-800-240-1675 to discuss your options.
- Option #3: Elect the reduced Contingent Non-Forfeiture Benefit.

If you elect the Contingent Non-Forfeiture Benefit Option, no further premium is due. This option becomes effective as of your current paid through date. As of the date of this letter, your Contingent Non-Forfeiture Benefit would be <<RESULT OF CNF FORMULA>>.

There are two ways to elect the Contingent Non-Forfeiture Benefit:

- Choose this option today by signing and dating the enclosed Contingent Non-Forfeiture Benefit Election Form and returning it in the enclosed postage-paid envelope; OR
- If you do not pay the increased premium <u>within 120 days of the due date</u>, which is <<NEXT_BILL_DATE>>, you will be entitled to the Contingent Non-Forfeiture Benefit. We will automatically change your coverage to the Contingent Non-Forfeiture Benefit in lieu of your policy lapsing for non-payment of premium.

<u>IMPORTANT:</u> Paying the increased premium for coverage through 120 days from <<NEXT_BILL_DATE>>, constitutes your acceptance of the rate increase and voids the Contingent Non-Forfeiture Benefit offer.

What is the Contingent Non-Forfeiture Benefit?

The Contingent Non-Forfeiture Benefit Option allows you to retain reduced long term care insurance benefits in the event you can no longer afford your premium due to a substantial premium increase. Under this option, the same **Daily Benefit Amount** in effect at the time of the lapse will be payable, but the **Lifetime Benefit Amount** will be equal to the greater of the items a) or b) below:

- a) The total amount of premiums paid and applied to Your Policy; **OR**
- b) Thirty (30) times the Daily Benefit Amount

The total of all benefits paid under your policy will not exceed the **Lifetime Benefit Amount** that would have been payable if your policy did not lapse.

Important facts to know about this reduced benefit are:

- No future premium is due.
- The Lifetime Benefit Amount is significantly less than the benefit provided if you choose to continue paying your premium.
- All riders and inflation options will be terminated.
- All other terms, conditions, limitations and exclusions in your current coverage apply to the Contingent Non-Forfeiture Benefit.

<u>IMPORTANT NOTE:</u> If your policy includes a Spousal Benefit Transfer Rider, both you and your spouse must continue to maintain identical coverage. You must both select the same option regarding this rate increase.

If you have questions on the above options, please call Customer Service toll free at **1-800-240-1675** between the hours of 8:30 a.m. and 5 p.m. EST, Monday through Friday.

If you are currently on claim and your premium is being waived, the increase will be applied when your premium is no longer being waived. Please be assured that your benefits are not affected and that your claims will continue to be paid.

As always, thank you for your business with the company.

Sincerely,

Cheryl Bush, RN

They Bushen

Senior Vice President, Long Term Care Operations



Contingent Non-Forfeiture Benefit Election Form

< <first name="">> <<last name="">></last></first>	< <date>></date>
< <street_address1>></street_address1>	Billing Account ID: < <policy_number>></policy_number>
< <street_address2>></street_address2>	_
< <city>> <<stδtf>> <<7IP>></stδtf></city>	

I have decided to stop future premium payments and accept the reduced Contingent Non-Forfeiture Benefit.

I understand the following:

- · No future premium is due; and
- I will have a reduced lifetime benefit equal to the sum of all premiums paid and applied to date, OR thirty (30) times the Daily Benefit Amount, whichever is greater; and
- The Contingent Non-Forfeiture Benefit is significantly less than the benefit provided if I chose to keep paying my premium; and
- The Contingent Non-Forfeiture Benefit is only available if I satisfy the requirements for Benefit Eligibility as defined in my policy or certificate; and
- The Contingent Non-Forfeiture Benefit will be payable up to my Daily Benefit Amount in effect on the date of this change; and
- All riders and inflation options will be terminated; and
- All other terms, conditions, limitations and exclusions in my current coverage apply to the Contingent Non-Forfeiture Benefit.

Signature:

I request my current long term care insurance coverage be reduced to the Contingent Non-Forfeiture Benefit offered by the company. This option becomes effective as of my current paid through date. This option is not a cash refund. A summary of Contingent Non-Forfeiture Benefits will be sent to me when this request is processed.

Signature	Date

Mailing Instructions: Sign and date this form and return in the enclosed postage-paid envelope.